<p>9000,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9001,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9002,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9003,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9004,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9005,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9006,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9007,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9008,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9009,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9010,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9011,"In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ), platelet_inhibitors ( acetylsalicylic_acid ), NSAIDs ( piroxicam ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux_sodium ."</p>
<p>9012,"In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin , acetylsalicylic_acid , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state."</p>
<p>9013,"In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin , acetylsalicylic_acid , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state."</p>
<p>9014,"In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin , acetylsalicylic_acid , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state."</p>
<p>9015,"In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin , acetylsalicylic_acid , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state."</p>
<p>9016,"In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin , acetylsalicylic_acid , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state."</p>
<p>9017,"In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin , acetylsalicylic_acid , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state."</p>
<p>9018,"In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin , acetylsalicylic_acid , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state."</p>
<p>9019,"In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin , acetylsalicylic_acid , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state."</p>
<p>9020,"In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i,e,, # mg/L) was 17-28%."</p>
<p>9021,Short-Acting_beta2-agonists : Aerosol bronchodilators of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using formoterol .</p>
<p>9022,Concomitant administration of other sympathomimetic_agents may potentiate the undesirable effects of FORADIL .</p>
<p>9023,Monoamine_Oxidase_Inhibitors and Tricyclic_Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine_oxidase_inhibitors or tricyclic_antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.</p>
<p>9024,Monoamine_Oxidase_Inhibitors and Tricyclic_Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine_oxidase_inhibitors or tricyclic_antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.</p>
<p>9025,Monoamine_Oxidase_Inhibitors and Tricyclic_Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine_oxidase_inhibitors or tricyclic_antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.</p>
<p>9026,Monoamine_Oxidase_Inhibitors and Tricyclic_Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine_oxidase_inhibitors or tricyclic_antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.</p>
<p>9027,Monoamine_Oxidase_Inhibitors and Tricyclic_Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine_oxidase_inhibitors or tricyclic_antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.</p>
<p>9028,Monoamine_Oxidase_Inhibitors and Tricyclic_Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine_oxidase_inhibitors or tricyclic_antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.</p>
<p>9029,Monoamine_Oxidase_Inhibitors and Tricyclic_Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine_oxidase_inhibitors or tricyclic_antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.</p>
<p>9030,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9031,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9032,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9033,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9034,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9035,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9036,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9037,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9038,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9039,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9040,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9041,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9042,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9043,"Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists,"</p>
<p>9044,"Acute symptoms should be treated with a short-acting, inhaled  beta2-agonist such as salbutamol (the physician should provide the patient with such medication and instruct the patient in how it should be used)."</p>
<p>9045,FORADIL should not be used as a substitute for oral or inhaled corticosteroids .</p>
<p>9046,"Guardians of children who have been prescribed FORADIL should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of short-acting__beta2-agonists ."</p>
<p>9047,A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.</p>
<p>9048,Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;</p>
<p>9049,"Because of foscarnet s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides , amphotericin_B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient."</p>
<p>9050,"Because of foscarnet s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides , amphotericin_B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient."</p>
<p>9051,"Because of foscarnet s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides , amphotericin_B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient."</p>
<p>9052,"Because of foscarnet s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides , amphotericin_B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient."</p>
<p>9053,"Because of foscarnet s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides , amphotericin_B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient."</p>
<p>9054,"Because of foscarnet s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides , amphotericin_B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient."</p>
<p>9055,"Because of foscarnet s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides , amphotericin_B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient."</p>
<p>9056,Ganciclovir : The pharmacokinetics of foscarnet and ganciclovir were not altered in # patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.</p>
<p>9057,"Metoclopramide : When coadministered with MONUROL , metoclopramide , a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin ."</p>
<p>9058,"Metoclopramide : When coadministered with MONUROL , metoclopramide , a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin ."</p>
<p>9059,"Metoclopramide : When coadministered with MONUROL , metoclopramide , a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin ."</p>
<p>9060,"Metoclopramide : When coadministered with MONUROL , metoclopramide , a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin ."</p>
<p>9061,"Metoclopramide : When coadministered with MONUROL , metoclopramide , a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin ."</p>
<p>9062,Cimetidine : Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL .</p>
<p>9063,Cimetidine : Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL .</p>
<p>9064,Cimetidine : Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL .</p>
<p>9065,"Diuretics : Patients on diuretics , especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril_sodium ."</p>
<p>9066,"Diuretics : Patients on diuretics , especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril_sodium ."</p>
<p>9067,The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril_sodium .</p>
<p>9068,Potassium Supplements and Potassium-Sparing_Diuretics : Fosinopril_sodium can attenuate potassium loss caused by thiazide_diuretics .</p>
<p>9069,"Potassium-sparing_diuretics ( spironolactone , amiloride , triamterene , and others) or potassium supplements can increase the risk of hyperkalemia."</p>
<p>9070,"Potassium-sparing_diuretics ( spironolactone , amiloride , triamterene , and others) or potassium supplements can increase the risk of hyperkalemia."</p>
<p>9071,"Potassium-sparing_diuretics ( spironolactone , amiloride , triamterene , and others) or potassium supplements can increase the risk of hyperkalemia."</p>
<p>9072,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE_inhibitors during therapy with lithium .</p>
<p>9073,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE_inhibitors during therapy with lithium .</p>
<p>9074,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE_inhibitors during therapy with lithium .</p>
<p>9075,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE_inhibitors during therapy with lithium .</p>
<p>9076,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9077,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9078,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9079,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9080,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9081,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9082,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9083,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9084,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9085,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9086,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9087,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9088,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9089,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9090,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9091,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9092,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9093,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9094,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9095,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9096,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9097,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9098,"Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum_hydroxide , magnesium_hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril ."</p>
<p>9099,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9100,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9101,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9102,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9103,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9104,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9105,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9106,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9107,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9108,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9109,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9110,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9111,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9112,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9113,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9114,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9115,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9116,"In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs."</p>
<p>9117,"In a study with concomitant administration of aspirin and fosinopril_sodium , the bioavailability of unbound fosinoprilat was not altered."</p>
<p>9118,"In a study with concomitant administration of aspirin and fosinopril_sodium , the bioavailability of unbound fosinoprilat was not altered."</p>
<p>9119,"In a study with concomitant administration of aspirin and fosinopril_sodium , the bioavailability of unbound fosinoprilat was not altered."</p>
<p>9120,Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab RIA Kit for Digoxin .</p>
<p>9121,Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab RIA Kit for Digoxin .</p>
<p>9122,"The pharmacokinetics and protein binding of fosphenytoin , phenytoin , and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses."</p>
<p>9123,"The pharmacokinetics and protein binding of fosphenytoin , phenytoin , and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses."</p>
<p>9124,"The pharmacokinetics and protein binding of fosphenytoin , phenytoin , and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses."</p>
<p>9125,"The pharmacokinetics and protein binding of fosphenytoin , phenytoin , and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses."</p>
<p>9126,"The pharmacokinetics and protein binding of fosphenytoin , phenytoin , and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses."</p>
<p>9127,"The pharmacokinetics and protein binding of fosphenytoin , phenytoin , and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses."</p>
<p>9128,The most significant drug interactions following administration of Cerebyx are expected to occur with drugs that interact with phenytoin .</p>
<p>9129,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9130,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9131,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9132,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9133,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9134,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9135,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9136,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9137,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9138,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9139,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9140,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9141,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9142,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9143,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9144,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9145,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9146,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9147,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9148,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9149,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9150,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9151,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9152,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9153,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9154,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9155,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9156,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9157,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9158,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9159,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9160,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9161,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9162,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9163,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9164,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9165,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9166,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9167,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9168,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9169,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone"</p>
<p>9170,"- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine , chronic alcohol abuse, reserpine"</p>
<p>9171,"- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine , chronic alcohol abuse, reserpine"</p>
<p>9172,"- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine , chronic alcohol abuse, reserpine"</p>
<p>9173,"- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine , chronic alcohol abuse, reserpine"</p>
<p>9174,"- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine , chronic alcohol abuse, reserpine"</p>
<p>9175,"- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine , chronic alcohol abuse, reserpine"</p>
<p>9176,"- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital , vaiproic acid, and sodium_valproate ."</p>
<p>9177,"- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital , vaiproic acid, and sodium_valproate ."</p>
<p>9178,"Similarly, the effects of phenytoin on phenobarbital , valproic_acid and sodium plasma valproate concentrations are unpredictable"</p>
<p>9179,"Similarly, the effects of phenytoin on phenobarbital , valproic_acid and sodium plasma valproate concentrations are unpredictable"</p>
<p>9180,"Similarly, the effects of phenytoin on phenobarbital , valproic_acid and sodium plasma valproate concentrations are unpredictable"</p>
<p>9181,"Similarly, the effects of phenytoin on phenobarbital , valproic_acid and sodium plasma valproate concentrations are unpredictable"</p>
<p>9182,"Similarly, the effects of phenytoin on phenobarbital , valproic_acid and sodium plasma valproate concentrations are unpredictable"</p>
<p>9183,"- Although not a true drug interaction, tricyclic_antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted"</p>
<p>9184,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9185,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9186,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9187,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9188,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9189,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9190,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9191,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9192,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9193,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9194,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9195,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9196,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9197,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9198,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9199,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9200,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9201,"- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D ."</p>
<p>9202,Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations following Cerebyx administration.</p>
<p>9203,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and FROVA within # hours of each other should be avoided (see a href= frova_od,htm#CI CONTRAINDICATIONS)."</p>
<p>9204,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and FROVA within # hours of each other should be avoided (see a href= frova_od,htm#CI CONTRAINDICATIONS)."</p>
<p>9205,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and FROVA within # hours of each other should be avoided (see a href= frova_od,htm#CI CONTRAINDICATIONS)."</p>
<p>9206,"Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."</p>
<p>9207,"Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."</p>
<p>9208,"Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."</p>
<p>9209,"Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."</p>
<p>9210,"Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."</p>
<p>9211,"Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."</p>
<p>9212,"If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised."</p>
<p>9213,"Furosemide may increase the ototoxic potential of aminoglycoside_antibiotics , especially in the presence of impaired renal function."</p>
<p>9214,Furosemide should not be used concomitantly with ethacrynic_acid because of the possibility of ototoxicity.</p>
<p>9215,"Patients receiving high doses of salicylates concomitantly with furosemide , as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites."</p>
<p>9216,"Patients receiving high doses of salicylates concomitantly with furosemide , as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites."</p>
<p>9217,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine .</p>
<p>9218,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine .</p>
<p>9219,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine .</p>
<p>9220,Lithium generally should not be given with diuretics because they reduce lithium s renal clearance and add a high risk of lithium toxicity.</p>
<p>9221,Lithium generally should not be given with diuretics because they reduce lithium s renal clearance and add a high risk of lithium toxicity.</p>
<p>9222,Lithium generally should not be given with diuretics because they reduce lithium s renal clearance and add a high risk of lithium toxicity.</p>
<p>9223,Furosemide may add to or potentiate the therapeutic effect of other antihypertensive_drugs .</p>
<p>9224,Potentiation occurs with ganglionic_adrenergic_blocking_drugs or peripheral_adrenergic_blocking_drugs .</p>
<p>9225,Furosemide may decrease arterial responsiveness to norepinephrine .</p>
<p>9226,Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide .</p>
<p>9227,Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide .</p>
<p>9228,The intake of furosemide and sucralfate should be separated by at least two hours.</p>
<p>9229,"Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic_acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency."</p>
<p>9230,"There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs ."</p>
<p>9231,Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.</p>
<p>9232,Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.</p>
<p>9233,Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.</p>
<p>9234,Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic_drugs .</p>
<p>9235,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9236,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9237,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9238,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9239,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9240,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9241,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9242,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9243,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9244,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9245,"Phenytoin : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least # months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics."</p>
<p>9246,"Carbamazepine : Steady-state trough plasma carbamazepine and carbamazepine_10,_11_epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;"</p>
<p>9247,"Carbamazepine : Steady-state trough plasma carbamazepine and carbamazepine_10,_11_epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;"</p>
<p>9248,"Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration."</p>
<p>9249,Valproic_Acid : The mean steady-state trough serum valproic_acid concentrations prior to and during concomitant gabapentin administration (400 mg TID;</p>
<p>9250,N=17) were not different and neither were gabapentin pharmacokinetic parameters affected by valproic_acid .</p>
<p>9251,Phenobarbital : Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg TID;</p>
<p>9252,Naproxen : Coadministration (N=18) of naproxen_sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.</p>
<p>9253,Naproxen : Coadministration (N=18) of naproxen_sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.</p>
<p>9254,Naproxen : Coadministration (N=18) of naproxen_sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.</p>
<p>9255,Naproxen : Coadministration (N=18) of naproxen_sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.</p>
<p>9256,Naproxen : Coadministration (N=18) of naproxen_sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.</p>
<p>9257,Gabapentin had no effect on naproxen pharmacokinetic parameters.</p>
<p>9258,Hydrocodone : Coadministration of Neurontin  (125 to # mg;</p>
<p>9259,Hydrocodone increases gabapentin AUC values by 14%.</p>
<p>9260,"Morphine : A literature article reported that when a 60-mg controlled-release morphine capsule was administered # hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine ."</p>
<p>9261,"Morphine : A literature article reported that when a 60-mg controlled-release morphine capsule was administered # hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine ."</p>
<p>9262,"Morphine : A literature article reported that when a 60-mg controlled-release morphine capsule was administered # hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine ."</p>
<p>9263,"Morphine : A literature article reported that when a 60-mg controlled-release morphine capsule was administered # hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine ."</p>
<p>9264,"Morphine : A literature article reported that when a 60-mg controlled-release morphine capsule was administered # hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine ."</p>
<p>9265,"Morphine : A literature article reported that when a 60-mg controlled-release morphine capsule was administered # hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine ."</p>
<p>9266,"Morphine : A literature article reported that when a 60-mg controlled-release morphine capsule was administered # hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine ."</p>
<p>9267,"Morphine : A literature article reported that when a 60-mg controlled-release morphine capsule was administered # hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine ."</p>
<p>9268,Morphine pharmacokinetic parameter values were not affected by administration of Neurontin  # hours after morphine .</p>
<p>9269,Morphine pharmacokinetic parameter values were not affected by administration of Neurontin  # hours after morphine .</p>
<p>9270,Cimetidine : In the presence of cimetidine at # mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.</p>
<p>9271,"Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function."</p>
<p>9272,This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.</p>
<p>9273,The effect of gabapentin on cimetidine was not evaluated.</p>
<p>9274,"Oral Contraceptive : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of tablets containing # mg of norethindrone_acetate and # mcg of ethinyl_estradiol were similar with and without coadministration of gabapentin (400 mg TID;"</p>
<p>9275,"Oral Contraceptive : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of tablets containing # mg of norethindrone_acetate and # mcg of ethinyl_estradiol were similar with and without coadministration of gabapentin (400 mg TID;"</p>
<p>9276,"Oral Contraceptive : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of tablets containing # mg of norethindrone_acetate and # mcg of ethinyl_estradiol were similar with and without coadministration of gabapentin (400 mg TID;"</p>
<p>9277,"Oral Contraceptive : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of tablets containing # mg of norethindrone_acetate and # mcg of ethinyl_estradiol were similar with and without coadministration of gabapentin (400 mg TID;"</p>
<p>9278,"Oral Contraceptive : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of tablets containing # mg of norethindrone_acetate and # mcg of ethinyl_estradiol were similar with and without coadministration of gabapentin (400 mg TID;"</p>
<p>9279,"Oral Contraceptive : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of tablets containing # mg of norethindrone_acetate and # mcg of ethinyl_estradiol were similar with and without coadministration of gabapentin (400 mg TID;"</p>
<p>9280,"Oral Contraceptive : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of tablets containing # mg of norethindrone_acetate and # mcg of ethinyl_estradiol were similar with and without coadministration of gabapentin (400 mg TID;"</p>
<p>9281,"Oral Contraceptive : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of tablets containing # mg of norethindrone_acetate and # mcg of ethinyl_estradiol were similar with and without coadministration of gabapentin (400 mg TID;"</p>
<p>9282,The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin ;</p>
<p>9283,Antacid ( Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.</p>
<p>9284,This decrease in bioavailability was about 5% when gabapentin was administered # hours after Maalox .</p>
<p>9285,It is recommended that gabapentin be taken at least # hours following Maalox administration.</p>
<p>9286,Gabapentin pharmacokinetic parameters without and with probenecid were comparable.</p>
<p>9287,This indicates that gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid .</p>
<p>9288,"Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when gabapentin was added to other antiepileptic_drugs , the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein"</p>
<p>9289,"In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin , a dose increase to # mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections)."</p>
<p>9290,International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.</p>
<p>9291,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole ) decrease gefitinib metabolism and increase gefitinib plasma concentrations."</p>
<p>9292,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole ) decrease gefitinib metabolism and increase gefitinib plasma concentrations."</p>
<p>9293,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole ) decrease gefitinib metabolism and increase gefitinib plasma concentrations."</p>
<p>9294,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole ) decrease gefitinib metabolism and increase gefitinib plasma concentrations."</p>
<p>9295,Drugs that cause significant sustained elevation in gastric pH ( histamine_H2-receptor_antagonists such as ranitidine or cimetidine ) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.</p>
<p>9296,Drugs that cause significant sustained elevation in gastric pH ( histamine_H2-receptor_antagonists such as ranitidine or cimetidine ) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.</p>
<p>9297,Drugs that cause significant sustained elevation in gastric pH ( histamine_H2-receptor_antagonists such as ranitidine or cimetidine ) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.</p>
<p>9298,"Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine ."</p>
<p>9299,"Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine ."</p>
<p>9300,"Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine ."</p>
<p>9301,"Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine ."</p>
<p>9302,"For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section."</p>
<p>9303,"Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive_product in healthy subjects."</p>
<p>9304,"Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive_product in healthy subjects."</p>
<p>9305,"Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive_product in healthy subjects."</p>
<p>9306,"Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive_product in healthy subjects."</p>
<p>9307,"Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive_product in healthy subjects."</p>
<p>9308,"Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive_product in healthy subjects."</p>
<p>9309,"Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive_product in healthy subjects."</p>
<p>9310,"Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive_product in healthy subjects."</p>
<p>9311,"Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive_product in healthy subjects."</p>
<p>9312,"Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol /levonorgestrol oral contraceptive_product in healthy subjects."</p>
<p>9313,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9314,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9315,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9316,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9317,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9318,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9319,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9320,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9321,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9322,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9323,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9324,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9325,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9326,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9327,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9328,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9329,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9330,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9331,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9332,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9333,"Concomitant administration of FACTIVE and calcium_carbonate , cimetidine , omeprazole , or an estrogen / progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin , which were considered to be without clinical significance."</p>
<p>9334,Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin .</p>
<p>9335,Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin .</p>
<p>9336,Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin .</p>
<p>9337,FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy.</p>
<p>9338,FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy.</p>
<p>9339,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone_antimicrobial is administered concomitantly with warfarin or its derivatives."</p>
<p>9340,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone_antimicrobial is administered concomitantly with warfarin or its derivatives."</p>
<p>9341,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone_antimicrobial is administered concomitantly with warfarin or its derivatives."</p>
<p>9342,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone_antimicrobial is administered concomitantly with warfarin or its derivatives."</p>
<p>9343,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone_antimicrobial is administered concomitantly with warfarin or its derivatives."</p>
<p>9344,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium .</p>
<p>9345,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium .</p>
<p>9346,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium .</p>
<p>9347,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium .</p>
<p>9348,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium .</p>
<p>9349,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium .</p>
<p>9350,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9351,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9352,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9353,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9354,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9355,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9356,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9357,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9358,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9359,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9360,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9361,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9362,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9363,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9364,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9365,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9366,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9367,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9368,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9369,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9370,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9371,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9372,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9373,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9374,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9375,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9376,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9377,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9378,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9379,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9380,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9381,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9382,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9383,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9384,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9385,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9386,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9387,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9388,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9389,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9390,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9391,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9392,"Magnesium - and/or aluminum -containing antacids , products containing ferrous_sulfate ( iron ), multivitamin_preparations containing zinc or other metal cations, or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after FACTIVE ."</p>
<p>9393,Sucralfate should not be taken within # hours of FACTIVE .</p>
<p>9394,"Results from existing clinical trials suggest no significant interactions between COPAXONE  and other therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to # days."</p>
<p>9395,COPAXONE  has not been formally evaluated in combination with Interferon_beta .</p>
<p>9396,"However, # patients who switched from therapy with Interferon_beta to COPAXONE  did not report any serious and unexpected adverse reactions thought to be related to treatment."</p>
<p>9397,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9398,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9399,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9400,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9401,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9402,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9403,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9404,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9405,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9406,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9407,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9408,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9409,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9410,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9411,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9412,"These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines, thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimet-ics, calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9413,"These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines, thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimet-ics, calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9414,"These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines, thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimet-ics, calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9415,"These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines, thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimet-ics, calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9416,"These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines, thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimet-ics, calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9417,"A possible interaction between glyburide and ciprofloxacin , a fluoroquinolone_antibiotic , has been reported, resulting in a potentiation of the hypoglycemic action of glyburide ."</p>
<p>9418,"A possible interaction between glyburide and ciprofloxacin , a fluoroquinolone_antibiotic , has been reported, resulting in a potentiation of the hypoglycemic action of glyburide ."</p>
<p>9419,"A possible interaction between glyburide and ciprofloxacin , a fluoroquinolone_antibiotic , has been reported, resulting in a potentiation of the hypoglycemic action of glyburide ."</p>
<p>9420,"A possible interaction between glyburide and ciprofloxacin , a fluoroquinolone_antibiotic , has been reported, resulting in a potentiation of the hypoglycemic action of glyburide ."</p>
<p>9421,"A possible interaction between glyburide and ciprofloxacin , a fluoroquinolone_antibiotic , has been reported, resulting in a potentiation of the hypoglycemic action of glyburide ."</p>
<p>9422,A potential interaction between oral miconazole and oral hypoglycemic_agents leading to severe hypoglycemia has been reported.</p>
<p>9423,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9424,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9425,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9426,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9427,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9428,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9429,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9430,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9431,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9432,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9433,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9434,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9435,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9436,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9437,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9438,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9439,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9440,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9441,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9442,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9443,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9444,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9445,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9446,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9447,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9448,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9449,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9450,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9451,"Before taking glimepiride , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline_salicylate ( Trilisate ), salsalate ( Disalcid , others), choline_salicylate ( Arthropan ), magnesium_salicylate ( Magan ), or bismuth_subsalicylate ( Pepto-Bismol );"</p>
<p>9452,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9453,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9454,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9455,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9456,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9457,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9458,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9459,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9460,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9461,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9462,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9463,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9464,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9465,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9466,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9467,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9468,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9469,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9470,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9471,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9472,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9473,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9474,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9475,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9476,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9477,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9478,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9479,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9480,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9481,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9482,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9483,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9484,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9485,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9486,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9487,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9488,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9489,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9490,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9491,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9492,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9493,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9494,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9495,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9496,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9497,"- a nonsteroidal_anti-inflammatory_drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis_KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve );"</p>
<p>9498,"- a sulfa-based drug such as sulfamethoxazole - trimethoprim ( Bactrim , Septra ), sulfisoxazole ( Gantrisin ), or sulfasalazine ( Azulfidine );"</p>
<p>9499,"- a sulfa-based drug such as sulfamethoxazole - trimethoprim ( Bactrim , Septra ), sulfisoxazole ( Gantrisin ), or sulfasalazine ( Azulfidine );"</p>
<p>9500,"- a sulfa-based drug such as sulfamethoxazole - trimethoprim ( Bactrim , Septra ), sulfisoxazole ( Gantrisin ), or sulfasalazine ( Azulfidine );"</p>
<p>9501,"- a sulfa-based drug such as sulfamethoxazole - trimethoprim ( Bactrim , Septra ), sulfisoxazole ( Gantrisin ), or sulfasalazine ( Azulfidine );"</p>
<p>9502,"- a sulfa-based drug such as sulfamethoxazole - trimethoprim ( Bactrim , Septra ), sulfisoxazole ( Gantrisin ), or sulfasalazine ( Azulfidine );"</p>
<p>9503,"- a sulfa-based drug such as sulfamethoxazole - trimethoprim ( Bactrim , Septra ), sulfisoxazole ( Gantrisin ), or sulfasalazine ( Azulfidine );"</p>
<p>9504,"- a sulfa-based drug such as sulfamethoxazole - trimethoprim ( Bactrim , Septra ), sulfisoxazole ( Gantrisin ), or sulfasalazine ( Azulfidine );"</p>
<p>9505,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9506,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9507,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9508,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9509,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9510,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9511,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9512,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9513,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9514,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9515,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9516,"- a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil );"</p>
<p>9517,"- a beta-blocker such as propranolol ( Inderal ), atenolol ( Tenormin ), acebutolol ( Sectral ), metoprolol ( Lopressor ), and others;"</p>
<p>9518,"- a beta-blocker such as propranolol ( Inderal ), atenolol ( Tenormin ), acebutolol ( Sectral ), metoprolol ( Lopressor ), and others;"</p>
<p>9519,"- a beta-blocker such as propranolol ( Inderal ), atenolol ( Tenormin ), acebutolol ( Sectral ), metoprolol ( Lopressor ), and others;"</p>
<p>9520,"- a beta-blocker such as propranolol ( Inderal ), atenolol ( Tenormin ), acebutolol ( Sectral ), metoprolol ( Lopressor ), and others;"</p>
<p>9521,"- a beta-blocker such as propranolol ( Inderal ), atenolol ( Tenormin ), acebutolol ( Sectral ), metoprolol ( Lopressor ), and others;"</p>
<p>9522,"- a beta-blocker such as propranolol ( Inderal ), atenolol ( Tenormin ), acebutolol ( Sectral ), metoprolol ( Lopressor ), and others;"</p>
<p>9523,"- a beta-blocker such as propranolol ( Inderal ), atenolol ( Tenormin ), acebutolol ( Sectral ), metoprolol ( Lopressor ), and others;"</p>
<p>9524,"- a beta-blocker such as propranolol ( Inderal ), atenolol ( Tenormin ), acebutolol ( Sectral ), metoprolol ( Lopressor ), and others;"</p>
<p>9525,"- a diuretic (water pill) such as hydrochlorothiazide ( HCTZ , Hydrodiuril ), chlorothiazide ( Diuril ), and others;"</p>
<p>9526,"- a diuretic (water pill) such as hydrochlorothiazide ( HCTZ , Hydrodiuril ), chlorothiazide ( Diuril ), and others;"</p>
<p>9527,"- a diuretic (water pill) such as hydrochlorothiazide ( HCTZ , Hydrodiuril ), chlorothiazide ( Diuril ), and others;"</p>
<p>9528,"- a diuretic (water pill) such as hydrochlorothiazide ( HCTZ , Hydrodiuril ), chlorothiazide ( Diuril ), and others;"</p>
<p>9529,"- a diuretic (water pill) such as hydrochlorothiazide ( HCTZ , Hydrodiuril ), chlorothiazide ( Diuril ), and others;"</p>
<p>9530,"- a steroid_medicine such as prednisone ( Deltasone , Orasone , others), methylprednisolone ( Medrol , others), prednisolone ( Prelone , Pediapred , others), and others;"</p>
<p>9531,"- a steroid_medicine such as prednisone ( Deltasone , Orasone , others), methylprednisolone ( Medrol , others), prednisolone ( Prelone , Pediapred , others), and others;"</p>
<p>9532,"- a steroid_medicine such as prednisone ( Deltasone , Orasone , others), methylprednisolone ( Medrol , others), prednisolone ( Prelone , Pediapred , others), and others;"</p>
<p>9533,"- a steroid_medicine such as prednisone ( Deltasone , Orasone , others), methylprednisolone ( Medrol , others), prednisolone ( Prelone , Pediapred , others), and others;"</p>
<p>9534,"- a steroid_medicine such as prednisone ( Deltasone , Orasone , others), methylprednisolone ( Medrol , others), prednisolone ( Prelone , Pediapred , others), and others;"</p>
<p>9535,"- a steroid_medicine such as prednisone ( Deltasone , Orasone , others), methylprednisolone ( Medrol , others), prednisolone ( Prelone , Pediapred , others), and others;"</p>
<p>9536,"- a steroid_medicine such as prednisone ( Deltasone , Orasone , others), methylprednisolone ( Medrol , others), prednisolone ( Prelone , Pediapred , others), and others;"</p>
<p>9537,"- a steroid_medicine such as prednisone ( Deltasone , Orasone , others), methylprednisolone ( Medrol , others), prednisolone ( Prelone , Pediapred , others), and others;"</p>
<p>9538,"- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others;"</p>
<p>9539,"- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others;"</p>
<p>9540,"- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others;"</p>
<p>9541,"- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others;"</p>
<p>9542,"- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others;"</p>
<p>9543,"- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others;"</p>
<p>9544,"- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others;"</p>
<p>9545,"- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others;"</p>
<p>9546,"- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others;"</p>
<p>9547,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9548,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9549,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9550,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9551,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9552,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9553,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9554,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9555,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9556,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9557,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9558,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9559,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9560,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9561,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9562,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9563,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9564,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9565,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9566,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9567,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9568,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9569,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9570,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9571,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>9572,In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol .</p>
<p>9573,In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol .</p>
<p>9574,In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol .</p>
<p>9575,In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol .</p>
<p>9576,In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol .</p>
<p>9577,In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol .</p>
<p>9578,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9579,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9580,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9581,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9582,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9583,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>9584,A potential interaction between oral miconazole and oral hypoglycemic_agents leading to severe hypoglycemia has been reported.</p>
<p>9585,The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.</p>
<p>9586,All subjects received glipizide alone and following treatment with # mg of fluconazole as a single daily oral dose for seven days.</p>
<p>9587,The mean percentage increase in the glipizide AUC after fluconazole administration was #% (range: # to 81).</p>
<p>9588,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines , antiparkinson_drugs , or tricyclic_antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."</p>
<p>9589,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines , antiparkinson_drugs , or tricyclic_antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."</p>
<p>9590,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines , antiparkinson_drugs , or tricyclic_antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."</p>
<p>9591,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines , antiparkinson_drugs , or tricyclic_antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."</p>
<p>9592,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines , antiparkinson_drugs , or tricyclic_antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."</p>
<p>9593,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines , antiparkinson_drugs , or tricyclic_antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."</p>
<p>9594,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines , antiparkinson_drugs , or tricyclic_antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects."</p>
<p>9595,Concomitant administration of Robinul Injection and potassium_chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.</p>
<p>9596,"The gonadotropin levels may be transiently elevated by spironolactone , minimally elevated by levodopa , and suppressed by oral contraceptives and digoxin ."</p>
<p>9597,"The gonadotropin levels may be transiently elevated by spironolactone , minimally elevated by levodopa , and suppressed by oral contraceptives and digoxin ."</p>
<p>9598,"The gonadotropin levels may be transiently elevated by spironolactone , minimally elevated by levodopa , and suppressed by oral contraceptives and digoxin ."</p>
<p>9599,"The gonadotropin levels may be transiently elevated by spironolactone , minimally elevated by levodopa , and suppressed by oral contraceptives and digoxin ."</p>
<p>9600,"The gonadotropin levels may be transiently elevated by spironolactone , minimally elevated by levodopa , and suppressed by oral contraceptives and digoxin ."</p>
<p>9601,"The gonadotropin levels may be transiently elevated by spironolactone , minimally elevated by levodopa , and suppressed by oral contraceptives and digoxin ."</p>
<p>9602,The response to Factrel may be blunted by phenothiazines and dopamine_antagonists which cause a rise in prolactin.</p>
<p>9603,The response to Factrel may be blunted by phenothiazines and dopamine_antagonists which cause a rise in prolactin.</p>
<p>9604,The response to Factrel may be blunted by phenothiazines and dopamine_antagonists which cause a rise in prolactin.</p>
<p>9605,"Antacids , Sucralfate , Metal Cations, Multivitamins  Quinolones form chelates with alkaline earth and transition metal cations."</p>
<p>9606,"Antacids , Sucralfate , Metal Cations, Multivitamins  Quinolones form chelates with alkaline earth and transition metal cations."</p>
<p>9607,"Antacids , Sucralfate , Metal Cations, Multivitamins  Quinolones form chelates with alkaline earth and transition metal cations."</p>
<p>9608,"Antacids , Sucralfate , Metal Cations, Multivitamins  Quinolones form chelates with alkaline earth and transition metal cations."</p>
<p>9609,"Antacids , Sucralfate , Metal Cations, Multivitamins  Quinolones form chelates with alkaline earth and transition metal cations."</p>
<p>9610,"Antacids , Sucralfate , Metal Cations, Multivitamins  Quinolones form chelates with alkaline earth and transition metal cations."</p>
<p>9611,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9612,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9613,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9614,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9615,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9616,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9617,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9618,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9619,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9620,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9621,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9622,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9623,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9624,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9625,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9626,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9627,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9628,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9629,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9630,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9631,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9632,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9633,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9634,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9635,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9636,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9637,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9638,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9639,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9640,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9641,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9642,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9643,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9644,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9645,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9646,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9647,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9648,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9649,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9650,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9651,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9652,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9653,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9654,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9655,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9656,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9657,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9658,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9659,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9660,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9661,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9662,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9663,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9664,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9665,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9666,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9667,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9668,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9669,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9670,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9671,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9672,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9673,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9674,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9675,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9676,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9677,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9678,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9679,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9680,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9681,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9682,"Administration of quinolones with antacids containing aluminum , magnesium , or calcium , with sucralfate , with metal cations such as iron , or with multivitamins containing iron or zinc , or with formulations containing divalent and trivalent cations such as VIDEX ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones , resulting in systemic concentrations considerably lower than desired."</p>
<p>9683,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9684,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9685,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9686,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9687,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9688,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9689,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9690,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9691,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9692,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9693,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9694,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9695,"Caffeine  Theobromine  Grepafloxacin , like other quinolones , may inhibit the metabolism of caffeine and theobromine ."</p>
<p>9696,"In some patients, this may lead to reduced clearance, prolongation of plasma half-life, and enhanced effects of caffeine and theobromine ."</p>
<p>9697,Theophylline : Grepafloxacin is a competitive inhibitor of the metabolism of theophylline .</p>
<p>9698,Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline .</p>
<p>9699,Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline .</p>
<p>9700,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline , the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments."</p>
<p>9701,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline , the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments."</p>
<p>9702,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline , the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments."</p>
<p>9703,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline , the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments."</p>
<p>9704,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline , the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments."</p>
<p>9705,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline , the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments."</p>
<p>9706,"Warfarin : In subjects receiving warfarin , no significant change in clotting time was observed when grepafloxacin was coadministered."</p>
<p>9707,"Warfarin : In subjects receiving warfarin , no significant change in clotting time was observed when grepafloxacin was coadministered."</p>
<p>9708,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone_antimicrobial is administered with warfarin or its derivatives."</p>
<p>9709,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone_antimicrobial is administered with warfarin or its derivatives."</p>
<p>9710,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone_antimicrobial is administered with warfarin or its derivatives."</p>
<p>9711,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone_antimicrobial is administered with warfarin or its derivatives."</p>
<p>9712,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone_antimicrobial is administered with warfarin or its derivatives."</p>
<p>9713,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2."</p>
<p>9714,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2."</p>
<p>9715,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2."</p>
<p>9716,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2."</p>
<p>9717,"substrates, in vitro data suggest similar effects of grepafloxacin in CYP3A4 mediated metabolism and theophylline metabolism."</p>
<p>9718,"In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine ."</p>
<p>9719,Nonsteroidal_Anti-inflammatory_Drugs ( NSAIDs ): The concomitant administration of a nonsteroidal_anti_inflammatory_drug with a quinolone may increase the risks of CNS stimulation and convulsions.</p>
<p>9720,"Antidiabetic_Agents : Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic_agent ."</p>
<p>9721,"Antidiabetic_Agents : Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic_agent ."</p>
<p>9722,Patients on warfarin-type_anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.</p>
<p>9723,Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.</p>
<p>9724,The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.</p>
<p>9725,"The use of codeine may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , psychotropics or other drugs that produce CNS depression."</p>
<p>9726,"The use of codeine may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , psychotropics or other drugs that produce CNS depression."</p>
<p>9727,"The use of codeine may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , psychotropics or other drugs that produce CNS depression."</p>
<p>9728,Serious toxicity may result if dextromethorphan is coadministered with monoamine_oxidase_inhibitors ( MAOIs ).</p>
<p>9729,Serious toxicity may result if dextromethorphan is coadministered with monoamine_oxidase_inhibitors ( MAOIs ).</p>
<p>9730,"The use of dextromethorphan_hydrobromide may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , psychotropics or other drugs that produce CNS depression."</p>
<p>9731,"The use of dextromethorphan_hydrobromide may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , psychotropics or other drugs that produce CNS depression."</p>
<p>9732,"The use of dextromethorphan_hydrobromide may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , psychotropics or other drugs that produce CNS depression."</p>
<p>9733,The potential for increased sedation when guanfacine is given with other CNS-depressant_drug should be appreciated.</p>
<p>9734,The administration of guanfacine concomitantly with known microsomal enzyme inducer ( phenobarbital or phenytoin ) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.</p>
<p>9735,The administration of guanfacine concomitantly with known microsomal enzyme inducer ( phenobarbital or phenytoin ) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.</p>
<p>9736,TCAs decrease the hypotensive effect of guanfacine .</p>
<p>9737,"Noncardioselective_beta-blockers ( nadolol ,porpranolol, timolol ) may exacerbate rebound hypertension when guanfacine is withdrawn."</p>
<p>9738,"Noncardioselective_beta-blockers ( nadolol ,porpranolol, timolol ) may exacerbate rebound hypertension when guanfacine is withdrawn."</p>
<p>9739,"Noncardioselective_beta-blockers ( nadolol ,porpranolol, timolol ) may exacerbate rebound hypertension when guanfacine is withdrawn."</p>
<p>9740,The gradual withdrawal of guafacine or a cardioselective_beta-blocker could be substituted.</p>
<p>9741,"Anticoagulants : Ten patients who were stabilized on oral anticoagulants were given guanfacine , 1-2 mg/day, for # weeks."</p>
<p>9742,"In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported."</p>
<p>9743,"The principal drugs given (number of patients in parentheses) were: cardiac_glycosides (115), sedatives and hypnotics (103), coronary_vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout_drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta_blockers (10)."</p>
<p>9744,"The principal drugs given (number of patients in parentheses) were: cardiac_glycosides (115), sedatives and hypnotics (103), coronary_vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout_drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta_blockers (10)."</p>
<p>9745,"The principal drugs given (number of patients in parentheses) were: cardiac_glycosides (115), sedatives and hypnotics (103), coronary_vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout_drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta_blockers (10)."</p>
<p>9746,"The principal drugs given (number of patients in parentheses) were: cardiac_glycosides (115), sedatives and hypnotics (103), coronary_vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout_drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta_blockers (10)."</p>
<p>9747,"The principal drugs given (number of patients in parentheses) were: cardiac_glycosides (115), sedatives and hypnotics (103), coronary_vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout_drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta_blockers (10)."</p>
<p>9748,"An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL ."</p>
<p>9749,A causal relationship between these events and the concomitant administration of lithium and HALDOL has not been established;</p>
<p>9750,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9751,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9752,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9753,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9754,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9755,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9756,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9757,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9758,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9759,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9760,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9761,"As with other antipsychotic_agents , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and alcohol ."</p>
<p>9762,"In a study of # schizophrenic patients coadministered oral haloperidol and rifampin , plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline."</p>
<p>9763,"In a study of # schizophrenic patients coadministered oral haloperidol and rifampin , plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline."</p>
<p>9764,"In # other schizophrenic patients treated with oral haloperidol and rifampin , discontinuation of rifampin produced a mean #-fold increase in haloperidol concentrations."</p>
<p>9765,"In # other schizophrenic patients treated with oral haloperidol and rifampin , discontinuation of rifampin produced a mean #-fold increase in haloperidol concentrations."</p>
<p>9766,"In # other schizophrenic patients treated with oral haloperidol and rifampin , discontinuation of rifampin produced a mean #-fold increase in haloperidol concentrations."</p>
<p>9767,"In # other schizophrenic patients treated with oral haloperidol and rifampin , discontinuation of rifampin produced a mean #-fold increase in haloperidol concentrations."</p>
<p>9768,"Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol -treated patients."</p>
<p>9769,FLUOTHANE augments the action of non-depolarising_muscle_relaxant s and the muscle relaxant effects of aminoglycosides .</p>
<p>9770,FLUOTHANE augments the action of non-depolarising_muscle_relaxant s and the muscle relaxant effects of aminoglycosides .</p>
<p>9771,FLUOTHANE augments the action of non-depolarising_muscle_relaxant s and the muscle relaxant effects of aminoglycosides .</p>
<p>9772,FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine .</p>
<p>9773,Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.</p>
<p>9774,For this reason the dose of adrenaline should be restricted and an antiarrhythmic_agent administered as appropriate.</p>
<p>9775,"Caution should also be applied for other sympathomimetics , and for aminophylline and theophylline and tricyclic_antidepressants , which may also precipitate arrhythmias."</p>
<p>9776,"Caution should also be applied for other sympathomimetics , and for aminophylline and theophylline and tricyclic_antidepressants , which may also precipitate arrhythmias."</p>
<p>9777,"Caution should also be applied for other sympathomimetics , and for aminophylline and theophylline and tricyclic_antidepressants , which may also precipitate arrhythmias."</p>
<p>9778,"Drug Interactions: a, Drugs Enhancing Heparin Effect: Oral anticoagulants : Heparin_sodium may prolong the one-stage prothrombin time."</p>
<p>9779,"Therefore, when heparin_sodium is given with dicumarol or warfarin_sodium , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained."</p>
<p>9780,"Therefore, when heparin_sodium is given with dicumarol or warfarin_sodium , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained."</p>
<p>9781,"Therefore, when heparin_sodium is given with dicumarol or warfarin_sodium , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained."</p>
<p>9782,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9783,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9784,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9785,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9786,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9787,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9788,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9789,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9790,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9791,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9792,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9793,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9794,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9795,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9796,"Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin_sodium ."</p>
<p>9797,The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin_III (human) in patients with hereditary antithrombin III deficiency.</p>
<p>9798,"Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin_III (human)."</p>
<p>9799,"Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of heparin_sodium ."</p>
<p>9800,"Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of heparin_sodium ."</p>
<p>9801,"Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of heparin_sodium ."</p>
<p>9802,"Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of heparin_sodium ."</p>
<p>9803,"Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of heparin_sodium ."</p>
<p>9804,"Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of heparin_sodium ."</p>
<p>9805,"Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of heparin_sodium ."</p>
<p>9806,"Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of heparin_sodium ."</p>
<p>9807,"Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of heparin_sodium ."</p>
<p>9808,"Heparin_Sodium Injection should not be mixed with doxorubicin , droperidol , ciprofloxacin , or mitoxantrone , since it has been reported that these drugs are incompatible with heparin and a precipitate may form."</p>
<p>9809,"Heparin_Sodium Injection should not be mixed with doxorubicin , droperidol , ciprofloxacin , or mitoxantrone , since it has been reported that these drugs are incompatible with heparin and a precipitate may form."</p>
<p>9810,"Heparin_Sodium Injection should not be mixed with doxorubicin , droperidol , ciprofloxacin , or mitoxantrone , since it has been reported that these drugs are incompatible with heparin and a precipitate may form."</p>
<p>9811,"Heparin_Sodium Injection should not be mixed with doxorubicin , droperidol , ciprofloxacin , or mitoxantrone , since it has been reported that these drugs are incompatible with heparin and a precipitate may form."</p>
<p>9812,"Heparin_Sodium Injection should not be mixed with doxorubicin , droperidol , ciprofloxacin , or mitoxantrone , since it has been reported that these drugs are incompatible with heparin and a precipitate may form."</p>
<p>9813,"Heparin_Sodium Injection should not be mixed with doxorubicin , droperidol , ciprofloxacin , or mitoxantrone , since it has been reported that these drugs are incompatible with heparin and a precipitate may form."</p>
<p>9814,"Heparin_Sodium Injection should not be mixed with doxorubicin , droperidol , ciprofloxacin , or mitoxantrone , since it has been reported that these drugs are incompatible with heparin and a precipitate may form."</p>
<p>9815,"Heparin_Sodium Injection should not be mixed with doxorubicin , droperidol , ciprofloxacin , or mitoxantrone , since it has been reported that these drugs are incompatible with heparin and a precipitate may form."</p>
<p>9816,"Opioids are strong central_nervous_system_depressants , but regular users develop physiological tolerance allowing gradually increased dosages."</p>
<p>9817,"In combination with other central_nervous_system_depressants , heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased."</p>
<p>9818,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9819,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9820,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9821,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9822,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9823,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9824,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9825,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9826,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9827,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9828,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9829,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9830,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9831,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9832,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9833,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9834,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9835,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9836,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9837,"Toxicology studies of heroin -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone ."</p>
<p>9838,"Ironically, benzodiazepines are often used in the treatment of heroin addiction while they cause much more severe withdrawal symptoms."</p>
<p>9839,Cocaine sometimes proves to be fatal when used in combination with heroin .</p>
<p>9840,"Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers ."</p>
<p>9841,"Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers ."</p>
<p>9842,"Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers ."</p>
<p>9843,"Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers ."</p>
<p>9844,"Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers ."</p>
<p>9845,"Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers ."</p>
<p>9846,"Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers ."</p>
<p>9847,MAO_inhibitors should be used with caution in patients receiving hydralazine .</p>
<p>9848,"When other potent parental antihypertensive_drugs , such as diazoxide , are used in combination with hydralazine , patients should be continuously observed for several hours for any excessive fall in blood pressure."</p>
<p>9849,"When other potent parental antihypertensive_drugs , such as diazoxide , are used in combination with hydralazine , patients should be continuously observed for several hours for any excessive fall in blood pressure."</p>
<p>9850,"When other potent parental antihypertensive_drugs , such as diazoxide , are used in combination with hydralazine , patients should be continuously observed for several hours for any excessive fall in blood pressure."</p>
<p>9851,Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.</p>
<p>9852,Propranolol increases hydralazine s serum concentrations.</p>
<p>9853,NSAIDs may decrease the hemodynamic effects of hydralazine ;</p>
<p>9854,"Alcohol , barbiturates , or narcotics : potentiation of orthostatic hypotension may occur."</p>
<p>9855,Antidiabetic_drugs : (oral agents and insulin ) - dosage adjustment of the antidiabetic_drug may be required.</p>
<p>9856,Antidiabetic_drugs : (oral agents and insulin ) - dosage adjustment of the antidiabetic_drug may be required.</p>
<p>9857,Cholestyramine and colestipol  resins : Absorption of hydrochlorothiazide is impaired in the presence of anionic_exchange_resins .</p>
<p>9858,Cholestyramine and colestipol  resins : Absorption of hydrochlorothiazide is impaired in the presence of anionic_exchange_resins .</p>
<p>9859,Cholestyramine and colestipol  resins : Absorption of hydrochlorothiazide is impaired in the presence of anionic_exchange_resins .</p>
<p>9860,Cholestyramine and colestipol  resins : Absorption of hydrochlorothiazide is impaired in the presence of anionic_exchange_resins .</p>
<p>9861,Cholestyramine and colestipol  resins : Absorption of hydrochlorothiazide is impaired in the presence of anionic_exchange_resins .</p>
<p>9862,Cholestyramine and colestipol  resins : Absorption of hydrochlorothiazide is impaired in the presence of anionic_exchange_resins .</p>
<p>9863,Cholestyramine and colestipol  resins : Absorption of hydrochlorothiazide is impaired in the presence of anionic_exchange_resins .</p>
<p>9864,Cholestyramine and colestipol  resins : Absorption of hydrochlorothiazide is impaired in the presence of anionic_exchange_resins .</p>
<p>9865,Cholestyramine and colestipol  resins : Absorption of hydrochlorothiazide is impaired in the presence of anionic_exchange_resins .</p>
<p>9866,"Single doses of either cholestyramine or colestipol  resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to # and # percent, respectively."</p>
<p>9867,"Single doses of either cholestyramine or colestipol  resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to # and # percent, respectively."</p>
<p>9868,"Single doses of either cholestyramine or colestipol  resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to # and # percent, respectively."</p>
<p>9869,"Single doses of either cholestyramine or colestipol  resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to # and # percent, respectively."</p>
<p>9870,"Single doses of either cholestyramine or colestipol  resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to # and # percent, respectively."</p>
<p>9871,"Single doses of either cholestyramine or colestipol  resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to # and # percent, respectively."</p>
<p>9872,"Corticosteroids , ACTH : intensified electrolyte depletion, particularly hypokalemia."</p>
<p>9873,"Skeletal_muscle_relaxants , nondepolarizing (e,g,, tubocurarine ): possible increased responsiveness to the muscle_relaxant ."</p>
<p>9874,"Skeletal_muscle_relaxants , nondepolarizing (e,g,, tubocurarine ): possible increased responsiveness to the muscle_relaxant ."</p>
<p>9875,Lithium : generally should not be given with diuretics .</p>
<p>9876,Diuretic_agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.</p>
<p>9877,Diuretic_agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.</p>
<p>9878,Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide .</p>
<p>9879,"Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>9880,"Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>9881,"Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>9882,"Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>9883,"Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>9884,"Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>9885,"Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>9886,"Therefore, when Hydrochlorothiazide and non-steroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."</p>
<p>9887,"Therefore, when Hydrochlorothiazide and non-steroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."</p>
<p>9888,"Therefore, when Hydrochlorothiazide and non-steroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."</p>
<p>9889,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9890,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9891,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9892,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9893,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9894,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9895,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9896,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9897,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9898,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9899,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9900,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9901,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9902,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9903,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9904,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9905,"Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression."</p>
<p>9906,The use of MAO_inhibitors or tricyclic_antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone .</p>
<p>9907,The use of MAO_inhibitors or tricyclic_antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone .</p>
<p>9908,The use of MAO_inhibitors or tricyclic_antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone .</p>
<p>9909,The use of MAO_inhibitors or tricyclic_antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone .</p>
<p>9910,The use of MAO_inhibitors or tricyclic_antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone .</p>
<p>9911,The use of MAO_inhibitors or tricyclic_antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone .</p>
<p>9912,The use of MAO_inhibitors or tricyclic_antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone .</p>
<p>9913,The use of MAO_inhibitors or tricyclic_antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone .</p>
<p>9914,The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.</p>
<p>9915,"Antihypertensive_medications , other, especially diazoxide , or pre anesthetic and anesthetic agents used in surgery or skeletal-muscle_relaxants , nondepolarizing, used in surgery"</p>
<p>9916,"Antihypertensive_medications , other, especially diazoxide , or pre anesthetic and anesthetic agents used in surgery or skeletal-muscle_relaxants , nondepolarizing, used in surgery"</p>
<p>9917,"Antihypertensive_medications , other, especially diazoxide , or pre anesthetic and anesthetic agents used in surgery or skeletal-muscle_relaxants , nondepolarizing, used in surgery"</p>
<p>9918,"Antihypertensive_medications , other, especially diazoxide , or pre anesthetic and anesthetic agents used in surgery or skeletal-muscle_relaxants , nondepolarizing, used in surgery"</p>
<p>9919,"Antihypertensive_medications , other, especially diazoxide , or pre anesthetic and anesthetic agents used in surgery or skeletal-muscle_relaxants , nondepolarizing, used in surgery"</p>
<p>9920,"Antihypertensive_medications , other, especially diazoxide , or pre anesthetic and anesthetic agents used in surgery or skeletal-muscle_relaxants , nondepolarizing, used in surgery"</p>
<p>9921,(Concurrent use with thiazide_diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.</p>
<p>9922,"for adult-onset diabetics, dosage adjustment of hypoglycemic_medications may be necessary during and after thiazide_diuretic therapy;"</p>
<p>9923,"(Concurrent use with thiazide_diuretics is not recommended, as they may provoke lithium toxicity because of reduced renal clearance."</p>
<p>9924,"(In some patients, the steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium_sparing_diuretics , and thiazide_diuretics ."</p>
<p>9925,"(In some patients, the steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium_sparing_diuretics , and thiazide_diuretics ."</p>
<p>9926,"(In some patients, the steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium_sparing_diuretics , and thiazide_diuretics ."</p>
<p>9927,"(In some patients, the steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium_sparing_diuretics , and thiazide_diuretics ."</p>
<p>9928,"(In some patients, the steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium_sparing_diuretics , and thiazide_diuretics ."</p>
<p>9929,"Therefore, when hydroflumethiazide and nonsteroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."</p>
<p>9930,"Therefore, when hydroflumethiazide and nonsteroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."</p>
<p>9931,"Therefore, when hydroflumethiazide and nonsteroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."</p>
<p>9932,( Thiazides may decrease arterial responsiveness to norepinephrine .</p>
<p>9933,( Thiazide_drugs may increase the responsiveness to tubocurarine .</p>
<p>9934,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9935,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9936,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9937,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9938,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9939,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9940,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9941,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9942,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9943,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9944,"Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression."</p>
<p>9945,"Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric_medication may be necessary"</p>
<p>9946,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES ."</p>
<p>9947,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES ."</p>
<p>9948,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES ."</p>
<p>9949,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES ."</p>
<p>9950,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES ."</p>
<p>9951,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES ."</p>
<p>9952,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES ."</p>
<p>9953,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES ."</p>
<p>9954,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES ."</p>
<p>9955,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES ."</p>
<p>9956,Therefore when central_nervous_system_depressants are administered concomitantly with hydroxyzine their dosage should be reduced.</p>
<p>9957,"Patients should be advised against the simultaneous use of other CNS_depressant_drugs , and cautioned that the effect of alcohol may be increased."</p>
<p>9958,"Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines ."</p>
<p>9959,"Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines ."</p>
<p>9960,"Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines ."</p>
<p>9961,"Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines ."</p>
<p>9962,"Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines ."</p>
<p>9963,"Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines ."</p>
<p>9964,"Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines ."</p>
<p>9965,"Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines ."</p>
<p>9966,Antacids may interfere with the absorption of LEVSIN .</p>
<p>9967,Calcium Supplements/ Antacids</p>
<p>9968,"Products containing calcium and other multivalent cations (such as aluminum , magnesium , iron ) are likely to interfere with absorption of Ibandronate ."</p>
<p>9969,"Products containing calcium and other multivalent cations (such as aluminum , magnesium , iron ) are likely to interfere with absorption of Ibandronate ."</p>
<p>9970,"Products containing calcium and other multivalent cations (such as aluminum , magnesium , iron ) are likely to interfere with absorption of Ibandronate ."</p>
<p>9971,"Products containing calcium and other multivalent cations (such as aluminum , magnesium , iron ) are likely to interfere with absorption of Ibandronate ."</p>
<p>9972,"Products containing calcium and other multivalent cations (such as aluminum , magnesium , iron ) are likely to interfere with absorption of Ibandronate ."</p>
<p>9973,"Products containing calcium and other multivalent cations (such as aluminum , magnesium , iron ) are likely to interfere with absorption of Ibandronate ."</p>
<p>9974,"Products containing calcium and other multivalent cations (such as aluminum , magnesium , iron ) are likely to interfere with absorption of Ibandronate ."</p>
<p>9975,"Ibandronate should be taken at least # minutes before any oral medications containing multivalent cations (including antacids , supplements or vitamins )."</p>
<p>9976,"Ibandronate should be taken at least # minutes before any oral medications containing multivalent cations (including antacids , supplements or vitamins )."</p>
<p>9977,H2_Blockers and Proton_Pump_Inhibitors ( PPIs )</p>
<p>9978,H2_Blockers and Proton_Pump_Inhibitors ( PPIs )</p>
<p>9979,"Of over # patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2_blockers and PPIs )."</p>
<p>9980,"Of over # patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2_blockers and PPIs )."</p>
<p>9981,Aspirin / Nonsteroidal_Antiinflammatory_Drug s ( NSAIDs )</p>
<p>9982,Aspirin / Nonsteroidal_Antiinflammatory_Drug s ( NSAIDs )</p>
<p>9983,Aspirin / Nonsteroidal_Antiinflammatory_Drug s ( NSAIDs )</p>
<p>9984,"In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal_anti-inflammatory_drugs were taken by 62% of the # patients."</p>
<p>9985,"Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate # mg daily (#%) was similar to that in placebo-treated patients (#%)."</p>
<p>9986,"Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate # mg daily (#%) was similar to that in placebo-treated patients (#%)."</p>
<p>9987,"Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate # mg daily (#%) was similar to that in placebo-treated patients (#%)."</p>
<p>9988,"Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal_anti-inflammatory_drugs were taken by 39% of the # patients."</p>
<p>9989,The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate # mg daily (#%) and # mg once monthly (#%).</p>
<p>9990,The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate # mg daily (#%) and # mg once monthly (#%).</p>
<p>9991,The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate # mg daily (#%) and # mg once monthly (#%).</p>
<p>9992,"However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate ."</p>
<p>9993,"However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate ."</p>
<p>9994,"However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate ."</p>
<p>9995,"However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate ."</p>
<p>9996,"However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate ."</p>
<p>9997,"However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate ."</p>
<p>9998,"However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate ."</p>
<p>9999,"However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate ."</p>
<p>10000,"However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate ."</p>
<p>10001,"However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate ."</p>
<p>10002,Coumarin-Type_Anticoagulants : Several short-term controlled studies failed to show that ibuprofen significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on coumarin-type_anticoagulants .</p>
<p>10003,"However, because bleeding has been reported when ibuprofen and other nonsteroidal_anti-inflammatory_agents have been administered to patients on coumarin-type_anticoagulants , the physician should be cautious when administering ibuprofen to patients on anticoagulants ."</p>
<p>10004,"However, because bleeding has been reported when ibuprofen and other nonsteroidal_anti-inflammatory_agents have been administered to patients on coumarin-type_anticoagulants , the physician should be cautious when administering ibuprofen to patients on anticoagulants ."</p>
<p>10005,"However, because bleeding has been reported when ibuprofen and other nonsteroidal_anti-inflammatory_agents have been administered to patients on coumarin-type_anticoagulants , the physician should be cautious when administering ibuprofen to patients on anticoagulants ."</p>
<p>10006,"However, because bleeding has been reported when ibuprofen and other nonsteroidal_anti-inflammatory_agents have been administered to patients on coumarin-type_anticoagulants , the physician should be cautious when administering ibuprofen to patients on anticoagulants ."</p>
<p>10007,"However, because bleeding has been reported when ibuprofen and other nonsteroidal_anti-inflammatory_agents have been administered to patients on coumarin-type_anticoagulants , the physician should be cautious when administering ibuprofen to patients on anticoagulants ."</p>
<p>10008,"However, because bleeding has been reported when ibuprofen and other nonsteroidal_anti-inflammatory_agents have been administered to patients on coumarin-type_anticoagulants , the physician should be cautious when administering ibuprofen to patients on anticoagulants ."</p>
<p>10009,"However, because bleeding has been reported when ibuprofen and other nonsteroidal_anti-inflammatory_agents have been administered to patients on coumarin-type_anticoagulants , the physician should be cautious when administering ibuprofen to patients on anticoagulants ."</p>
<p>10010,"However, because bleeding has been reported when ibuprofen and other nonsteroidal_anti-inflammatory_agents have been administered to patients on coumarin-type_anticoagulants , the physician should be cautious when administering ibuprofen to patients on anticoagulants ."</p>
<p>10011,"Aspirin : Animal studies show that aspirin given with nonsteroidal_anti-inflammatory_agents , including ibuprofen , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug."</p>
<p>10012,"Aspirin : Animal studies show that aspirin given with nonsteroidal_anti-inflammatory_agents , including ibuprofen , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug."</p>
<p>10013,"Aspirin : Animal studies show that aspirin given with nonsteroidal_anti-inflammatory_agents , including ibuprofen , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug."</p>
<p>10014,Single dose bioavailability studies in normal volunteers have failed to show an effect of aspirin on ibuprofen blood levels.</p>
<p>10015,"Methotrexate : Ibuprofen , as well as other nonsteroidal_anti-inflammatory_drugs , probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices."</p>
<p>10016,"Methotrexate : Ibuprofen , as well as other nonsteroidal_anti-inflammatory_drugs , probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices."</p>
<p>10017,"Methotrexate : Ibuprofen , as well as other nonsteroidal_anti-inflammatory_drugs , probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices."</p>
<p>10018,"Methotrexate : Ibuprofen , as well as other nonsteroidal_anti-inflammatory_drugs , probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices."</p>
<p>10019,"Methotrexate : Ibuprofen , as well as other nonsteroidal_anti-inflammatory_drugs , probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices."</p>
<p>10020,This may indicate that ibuprofen could enhance the toxicity of methotrexate .</p>
<p>10021,Caution should be used if ibuprofen is administered concomitantly with methotrexate .</p>
<p>10022,"H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations."</p>
<p>10023,"H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations."</p>
<p>10024,"H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations."</p>
<p>10025,"H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations."</p>
<p>10026,"H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations."</p>
<p>10027,"Furosemide : Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>10028,"Furosemide : Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>10029,"Furosemide : Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>10030,"Furosemide : Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>10031,"Furosemide : Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>10032,"During concomitant therapy with ibuprofen , the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy."</p>
<p>10033,Lithium : Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.</p>
<p>10034,Lithium : Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.</p>
<p>10035,"Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."</p>
<p>10036,"Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."</p>
<p>10037,Coadministration of digoxin did not have effects on either the safety or efficacy of ibutilide in the clinical trials.</p>
<p>10038,Calcium_channel_blocking_agents : Coadministration of calcium_channel_blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.</p>
<p>10039,Calcium_channel_blocking_agents : Coadministration of calcium_channel_blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.</p>
<p>10040,Calcium_channel_blocking_agents : Coadministration of calcium_channel_blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.</p>
<p>10041,Beta-adrenergic_blocking_agents : Coadministration of beta-adrenergic_blocking_agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.</p>
<p>10042,Beta-adrenergic_blocking_agents : Coadministration of beta-adrenergic_blocking_agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.</p>
<p>10043,Insulin : A clinical study in # insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulin s ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL .</p>
<p>10044,Insulin : A clinical study in # insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulin s ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL .</p>
<p>10045,Insulin : A clinical study in # insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulin s ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL .</p>
<p>10046,Insulin : A clinical study in # insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulin s ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL .</p>
<p>10047,Insulin : A clinical study in # insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulin s ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL .</p>
<p>10048,Insulin : A clinical study in # insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulin s ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL .</p>
<p>10049,"However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed."</p>
<p>10050,In vitro studies demonstrated no evidence of incompatibility of heparin with EXTRANEAL .</p>
<p>10051,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10052,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10053,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10054,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10055,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10056,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10057,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10058,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10059,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10060,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10061,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10062,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10063,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10064,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10065,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL ."</p>
<p>10066,Interactions may occur between EPA supplements and aspirin and other non-steroidal_anti-inflammatory_drugs and herbs such as garlic (Allium sativum) and ginkgo ( Ginkgo_biloba ).</p>
<p>10067,Interactions may occur between EPA supplements and aspirin and other non-steroidal_anti-inflammatory_drugs and herbs such as garlic (Allium sativum) and ginkgo ( Ginkgo_biloba ).</p>
<p>10068,Interactions may occur between EPA supplements and aspirin and other non-steroidal_anti-inflammatory_drugs and herbs such as garlic (Allium sativum) and ginkgo ( Ginkgo_biloba ).</p>
<p>10069,Interactions may occur between EPA supplements and aspirin and other non-steroidal_anti-inflammatory_drugs and herbs such as garlic (Allium sativum) and ginkgo ( Ginkgo_biloba ).</p>
<p>10070,Interactions may occur between EPA supplements and aspirin and other non-steroidal_anti-inflammatory_drugs and herbs such as garlic (Allium sativum) and ginkgo ( Ginkgo_biloba ).</p>
<p>10071,Interactions may occur between EPA supplements and aspirin and other non-steroidal_anti-inflammatory_drugs and herbs such as garlic (Allium sativum) and ginkgo ( Ginkgo_biloba ).</p>
<p>10072,Interactions may occur between EPA supplements and aspirin and other non-steroidal_anti-inflammatory_drugs and herbs such as garlic (Allium sativum) and ginkgo ( Ginkgo_biloba ).</p>
<p>10073,Interactions may occur between EPA supplements and aspirin and other non-steroidal_anti-inflammatory_drugs and herbs such as garlic (Allium sativum) and ginkgo ( Ginkgo_biloba ).</p>
<p>10074,"When you are using idoxuridine , it is especially important that your health care professional know if you are using the following: Eye product containing boric_acid ."</p>
<p>10075,Boric_acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.</p>
<p>10076,Boric_acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.</p>
<p>10077,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive_agents ."</p>
<p>10078,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive_agents ."</p>
<p>10079,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive_agents ."</p>
<p>10080,"Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants ."</p>
<p>10081,"During clinical trials, iloprost was used concurrently with anticoagulants , diuretics , cardiac_glycosides , calcium_channel_blockers , analgesics , antipyretics , nonsteroidal_antiinflammatories , corticosteroids , and other medications."</p>
<p>10082,"During clinical trials, iloprost was used concurrently with anticoagulants , diuretics , cardiac_glycosides , calcium_channel_blockers , analgesics , antipyretics , nonsteroidal_antiinflammatories , corticosteroids , and other medications."</p>
<p>10083,"During clinical trials, iloprost was used concurrently with anticoagulants , diuretics , cardiac_glycosides , calcium_channel_blockers , analgesics , antipyretics , nonsteroidal_antiinflammatories , corticosteroids , and other medications."</p>
<p>10084,"During clinical trials, iloprost was used concurrently with anticoagulants , diuretics , cardiac_glycosides , calcium_channel_blockers , analgesics , antipyretics , nonsteroidal_antiinflammatories , corticosteroids , and other medications."</p>
<p>10085,"During clinical trials, iloprost was used concurrently with anticoagulants , diuretics , cardiac_glycosides , calcium_channel_blockers , analgesics , antipyretics , nonsteroidal_antiinflammatories , corticosteroids , and other medications."</p>
<p>10086,"During clinical trials, iloprost was used concurrently with anticoagulants , diuretics , cardiac_glycosides , calcium_channel_blockers , analgesics , antipyretics , nonsteroidal_antiinflammatories , corticosteroids , and other medications."</p>
<p>10087,"During clinical trials, iloprost was used concurrently with anticoagulants , diuretics , cardiac_glycosides , calcium_channel_blockers , analgesics , antipyretics , nonsteroidal_antiinflammatories , corticosteroids , and other medications."</p>
<p>10088,"During clinical trials, iloprost was used concurrently with anticoagulants , diuretics , cardiac_glycosides , calcium_channel_blockers , analgesics , antipyretics , nonsteroidal_antiinflammatories , corticosteroids , and other medications."</p>
<p>10089,Intravenous infusion of iloprost had no effect on the pharmacokinetics of digoxin .</p>
<p>10090,Acetylsalicylic_acid did not alter the clearance (pharmacokinetics) of iloprost .</p>
<p>10091,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10092,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10093,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10094,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10095,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10096,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10097,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10098,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10099,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10100,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10101,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10102,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10103,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10104,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , erythromycin , clarithromycin )."</p>
<p>10105,There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).</p>
<p>10106,There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).</p>
<p>10107,There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).</p>
<p>10108,"Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec , increased Gleevec oral-dose clearance by #-fold, which significantly (p #) decreased mean cmax and AUC(0-8)."</p>
<p>10109,"Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec , increased Gleevec oral-dose clearance by #-fold, which significantly (p #) decreased mean cmax and AUC(0-8)."</p>
<p>10110,"Drugs that may have their plasma concentration altered by Gleevec  Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and #-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec ."</p>
<p>10111,"Drugs that may have their plasma concentration altered by Gleevec  Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and #-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec ."</p>
<p>10112,"Drugs that may have their plasma concentration altered by Gleevec  Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and #-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec ."</p>
<p>10113,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e,g,, cyclosporine or pimozide )."</p>
<p>10114,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e,g,, cyclosporine or pimozide )."</p>
<p>10115,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e,g,, triazolo- benzodiazepines , dihydropyridine_calcium_channel_blockers , certain HMG-CoA_reductase_inhibitors , etc,)."</p>
<p>10116,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e,g,, triazolo- benzodiazepines , dihydropyridine_calcium_channel_blockers , certain HMG-CoA_reductase_inhibitors , etc,)."</p>
<p>10117,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e,g,, triazolo- benzodiazepines , dihydropyridine_calcium_channel_blockers , certain HMG-CoA_reductase_inhibitors , etc,)."</p>
<p>10118,"Because warfarin is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard heparin ."</p>
<p>10119,Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec .</p>
<p>10120,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10121,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10122,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10123,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10124,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10125,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10126,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10127,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10128,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10129,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10130,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10131,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic_amine (e,g,, epinephrine , norepinephrine ), since it has been reported that tricyclic_antidepressants can potentiate the effects of catecholamines."</p>
<p>10132,Imipramine_hydrochloride may potentiate the effects of CNS_depressant_drugs .</p>
<p>10133,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10134,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10135,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10136,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10137,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10138,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10139,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10140,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10141,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10142,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10143,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10144,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary."</p>
<p>10145,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."</p>
<p>10146,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."</p>
<p>10147,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."</p>
<p>10148,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."</p>
<p>10149,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."</p>
<p>10150,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e, g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>10151,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e, g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>10152,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e, g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>10153,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e, g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>10154,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e, g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>10155,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e, g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>10156,"The extent to which SSRI - TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved."</p>
<p>10157,"The extent to which SSRI - TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved."</p>
<p>10158,Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir .</p>
<p>10159,Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir .</p>
<p>10160,Antiarrhythmics : amiodarone</p>
<p>10161,"Ergot derivatives: dihydroergotamine , ergonovine , ergotamine , methylergonovine"</p>
<p>10162,"Ergot derivatives: dihydroergotamine , ergonovine , ergotamine , methylergonovine"</p>
<p>10163,"Sedative / hypnotics : midazolam , triazolam"</p>
<p>10164,"Sedative / hypnotics : midazolam , triazolam"</p>
<p>10165,"Sedative / hypnotics : midazolam , triazolam"</p>
<p>10166,"Sedative / hypnotics : midazolam , triazolam"</p>
<p>10167,"Sedative / hypnotics : midazolam , triazolam"</p>
<p>10168,"Sedative / hypnotics : midazolam , triazolam"</p>
<p>10169,Neuroleptic : pimozide</p>
<p>10170,May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease_inhibitors .</p>
<p>10171,Antimycobacterial : rifampin</p>
<p>10172,May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease_inhibitors or other coadministered antiretroviral_agents .</p>
<p>10173,May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease_inhibitors or other coadministered antiretroviral_agents .</p>
<p>10174,May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease_inhibitors or other coadministered antiretroviral_agents .</p>
<p>10175,"HMG-CoA_Reductase_inhibitors : lovastatin , simvastatin"</p>
<p>10176,"HMG-CoA_Reductase_inhibitors : lovastatin , simvastatin"</p>
<p>10177,"HMG-CoA_Reductase_inhibitors : lovastatin , simvastatin"</p>
<p>10178,Protease_inhibitor : atazanavir</p>
<p>10179,Both CRIXIVAN and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia.</p>
<p>10180,Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.</p>
<p>10181,Dose reduction of CRIXIVAN to # mg every # hours should be considered when taking delavirdine # mg three times a day.</p>
<p>10182,Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.</p>
<p>10183,"The optimal dose of indinavir , when given in combination with efavirenz , is not known."</p>
<p>10184,Increasing the indinavir dose to # mg every # hours does not compensate for the increased indinavir metabolism due to efavirenz .</p>
<p>10185,Increasing the indinavir dose to # mg every # hours does not compensate for the increased indinavir metabolism due to efavirenz .</p>
<p>10186,Indinavir concentrations may be decreased in the presence of nevirapine .</p>
<p>10187,indinavir concentration  ritonavir concentration</p>
<p>10188,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN # mg q8h.</p>
<p>10189,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN # mg q8h.</p>
<p>10190,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN # mg q8h.</p>
<p>10191,"Antiarrhythmics : bepridil , lidocaine (systemic) and quinidine"</p>
<p>10192,"Antiarrhythmics : bepridil , lidocaine (systemic) and quinidine"</p>
<p>10193,"Antiarrhythmics : bepridil , lidocaine (systemic) and quinidine"</p>
<p>10194,Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN .</p>
<p>10195,"Anticonvulsants : carbamazepine , phenobarbital , phenytoin"</p>
<p>10196,"Anticonvulsants : carbamazepine , phenobarbital , phenytoin"</p>
<p>10197,"Anticonvulsants : carbamazepine , phenobarbital , phenytoin"</p>
<p>10198,"Anticonvulsants : carbamazepine , phenobarbital , phenytoin"</p>
<p>10199,"Anticonvulsants : carbamazepine , phenobarbital , phenytoin"</p>
<p>10200,"Anticonvulsants : carbamazepine , phenobarbital , phenytoin"</p>
<p>10201,CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.</p>
<p>10202,"Calcium_Channel_Blockers , Dihydropyridine : e,g,, felodipine , nifedipine , nicardipine"</p>
<p>10203,"Calcium_Channel_Blockers , Dihydropyridine : e,g,, felodipine , nifedipine , nicardipine"</p>
<p>10204,"Calcium_Channel_Blockers , Dihydropyridine : e,g,, felodipine , nifedipine , nicardipine"</p>
<p>10205,"Calcium_Channel_Blockers , Dihydropyridine : e,g,, felodipine , nifedipine , nicardipine"</p>
<p>10206,"Calcium_Channel_Blockers , Dihydropyridine : e,g,, felodipine , nifedipine , nicardipine"</p>
<p>10207,"Calcium_Channel_Blockers , Dihydropyridine : e,g,, felodipine , nifedipine , nicardipine"</p>
<p>10208,"Calcium_Channel_Blockers , Dihydropyridine : e,g,, felodipine , nifedipine , nicardipine"</p>
<p>10209,"Calcium_Channel_Blockers , Dihydropyridine : e,g,, felodipine , nifedipine , nicardipine"</p>
<p>10210,"Calcium_Channel_Blockers , Dihydropyridine : e,g,, felodipine , nifedipine , nicardipine"</p>
<p>10211,"Calcium_Channel_Blockers , Dihydropyridine : e,g,, felodipine , nifedipine , nicardipine"</p>
<p>10212,clarithromycin concentration  indinavir concentration</p>
<p>10213,HMG-CoA_Reductase_Inhibitor : atorvastatin</p>
<p>10214,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10215,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10216,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10217,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10218,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10219,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10220,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10221,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10222,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10223,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10224,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10225,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA_reductase_inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin , fluvastatin , or rosuvastatin in combination with CRIXIVAN ."</p>
<p>10226,"Immunosuppressants : cyclosporine , tacrolimus , sirolimus"</p>
<p>10227,"Immunosuppressants : cyclosporine , tacrolimus , sirolimus"</p>
<p>10228,"Immunosuppressants : cyclosporine , tacrolimus , sirolimus"</p>
<p>10229,"Immunosuppressants : cyclosporine , tacrolimus , sirolimus"</p>
<p>10230,"Immunosuppressants : cyclosporine , tacrolimus , sirolimus"</p>
<p>10231,"Immunosuppressants : cyclosporine , tacrolimus , sirolimus"</p>
<p>10232,Dose reduction of CRIXIVAN to # mg every # hours is recommended when administering itraconazole concurrently.</p>
<p>10233,indinavir concentration  rifabutin concentration</p>
<p>10234,Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to # mg (three 333-mg capsules) every # hours are recommended when rifabutin and CRIXIVAN are coadministered.</p>
<p>10235,Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to # mg (three 333-mg capsules) every # hours are recommended when rifabutin and CRIXIVAN are coadministered.</p>
<p>10236,Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to # mg (three 333-mg capsules) every # hours are recommended when rifabutin and CRIXIVAN are coadministered.</p>
<p>10237,Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to # mg (three 333-mg capsules) every # hours are recommended when rifabutin and CRIXIVAN are coadministered.</p>
<p>10238,Sildenafil dose should not exceed a maximum of # mg in a 48- hour period in patients receiving concomitant indinavir therapy.</p>
<p>10239,Tadalafil dose should not exceed a maximum of # mg in a 72- hour period in patients receiving concomitant indinavir therapy.</p>
<p>10240,Vardenafil dose should not exceed a maximum of # mg in a 24-hour period in patients receiving concomitant indinavir therapy.</p>
<p>10241,"In normal volunteers receiving indomethacin , the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin ."</p>
<p>10242,"In normal volunteers receiving indomethacin , the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin ."</p>
<p>10243,"In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage."</p>
<p>10244,"Therefore, diflunisal and INDOCIN should not be used concomitantly."</p>
<p>10245,"In a study in normal volunteers, it was found that chronic concurrent administration of # g of aspirin per day decreases indomethacin blood levels approximately 20%."</p>
<p>10246,"The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy."</p>
<p>10247,Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants .</p>
<p>10248,"However, when any additional drug, including INDOCIN , is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time."</p>
<p>10249,"In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN ."</p>
<p>10250,Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.</p>
<p>10251,"When INDOCIN is given to patients receiving probenecid , the plasma levels of indomethacin are likely to be increased."</p>
<p>10252,"When INDOCIN is given to patients receiving probenecid , the plasma levels of indomethacin are likely to be increased."</p>
<p>10253,"When INDOCIN is given to patients receiving probenecid , the plasma levels of indomethacin are likely to be increased."</p>
<p>10254,Caution should be used if INDOCIN is administered simultaneously with methotrexate .</p>
<p>10255,INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.</p>
<p>10256,"Administration of non-steroidal_anti-inflammatory_drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine -induced toxicity, possibly due to decreased synthesis of renal prostacyclin."</p>
<p>10257,"Administration of non-steroidal_anti-inflammatory_drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine -induced toxicity, possibly due to decreased synthesis of renal prostacyclin."</p>
<p>10258,"NSAIDs should be used with caution in patients taking cyclosporine , and renal function should be carefully monitored."</p>
<p>10259,"Capsules INDOCIN # mg t,i,d, produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations."</p>
<p>10260,"Capsules INDOCIN # mg t,i,d, produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations."</p>
<p>10261,"Capsules INDOCIN # mg t,i,d, produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations."</p>
<p>10262,"As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity."</p>
<p>10263,"As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity."</p>
<p>10264,INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin .</p>
<p>10265,INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin .</p>
<p>10266,"Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored."</p>
<p>10267,"Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored."</p>
<p>10268,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics , and thiazide_diuretics ."</p>
<p>10269,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics , and thiazide_diuretics ."</p>
<p>10270,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics , and thiazide_diuretics ."</p>
<p>10271,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics , and thiazide_diuretics ."</p>
<p>10272,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics , and thiazide_diuretics ."</p>
<p>10273,"( Indomethacin ) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."</p>
<p>10274,"( Indomethacin ) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."</p>
<p>10275,"INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion."</p>
<p>10276,It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.</p>
<p>10277,INDOCIN and triamterene should not be administered together.</p>
<p>10278,INDOCIN and potassium-sparing_diuretics each may be associated with increased serum potassium levels.</p>
<p>10279,The potential effects of INDOCIN and potassium-sparing_diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.</p>
<p>10280,"Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN ."</p>
<p>10281,Blunting of the antihypertensive effect of beta-adrenoceptor_blocking_agents by non-steroidal_antiinflammatory_drugs including INDOCIN has been reported.</p>
<p>10282,Blunting of the antihypertensive effect of beta-adrenoceptor_blocking_agents by non-steroidal_antiinflammatory_drugs including INDOCIN has been reported.</p>
<p>10283,Blunting of the antihypertensive effect of beta-adrenoceptor_blocking_agents by non-steroidal_antiinflammatory_drugs including INDOCIN has been reported.</p>
<p>10284,INDOCIN can reduce the antihypertensive effects of captopril and losartan .</p>
<p>10285,INDOCIN can reduce the antihypertensive effects of captopril and losartan .</p>
<p>10286,INDOCIN can reduce the antihypertensive effects of captopril and losartan .</p>
<p>10287,"Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1_antagonist ) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone."</p>
<p>10288,"Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1_antagonist ) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone."</p>
<p>10289,Other TNFa-blocking_agents (including REMICADE ) used in combination with anakinra may also result in similar toxicities.</p>
<p>10290,Other TNFa-blocking_agents (including REMICADE ) used in combination with anakinra may also result in similar toxicities.</p>
<p>10291,"In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal_anti-inflammatory_agents , folic_acid , corticosteroids and/or narcotics ."</p>
<p>10292,"In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal_anti-inflammatory_agents , folic_acid , corticosteroids and/or narcotics ."</p>
<p>10293,"In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal_anti-inflammatory_agents , folic_acid , corticosteroids and/or narcotics ."</p>
<p>10294,"In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal_anti-inflammatory_agents , folic_acid , corticosteroids and/or narcotics ."</p>
<p>10295,"In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal_anti-inflammatory_agents , folic_acid , corticosteroids and/or narcotics ."</p>
<p>10296,"In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal_anti-inflammatory_agents , folic_acid , corticosteroids and/or narcotics ."</p>
<p>10297,"In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal_anti-inflammatory_agents , folic_acid , corticosteroids and/or narcotics ."</p>
<p>10298,"Concomitant Crohn s disease medications were antibiotics , antivirals , corticosteroids , 6-MP / AZA and aminosalicylates."</p>
<p>10299,"In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal_anti-inflammatory_agents , folic_acid and corticosteroids ."</p>
<p>10300,"In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal_anti-inflammatory_agents , folic_acid and corticosteroids ."</p>
<p>10301,"In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal_anti-inflammatory_agents , folic_acid and corticosteroids ."</p>
<p>10302,"Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids , antibiotics ( metronidazole or ciprofloxacin ) and aminosalicylates."</p>
<p>10303,"Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids , antibiotics ( metronidazole or ciprofloxacin ) and aminosalicylates."</p>
<p>10304,"Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids , antibiotics ( metronidazole or ciprofloxacin ) and aminosalicylates."</p>
<p>10305,"Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids , antibiotics ( metronidazole or ciprofloxacin ) and aminosalicylates."</p>
<p>10306,"Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids , antibiotics ( metronidazole or ciprofloxacin ) and aminosalicylates."</p>
<p>10307,"Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids , antibiotics ( metronidazole or ciprofloxacin ) and aminosalicylates."</p>
<p>10308,"Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids , antibiotics ( metronidazole or ciprofloxacin ) and aminosalicylates."</p>
<p>10309,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE_inhibitors , disopyramide , fibrates , fluoxetine , MAO_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10310,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE_inhibitors , disopyramide , fibrates , fluoxetine , MAO_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10311,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE_inhibitors , disopyramide , fibrates , fluoxetine , MAO_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10312,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE_inhibitors , disopyramide , fibrates , fluoxetine , MAO_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10313,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10314,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10315,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10316,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10317,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10318,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10319,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10320,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10321,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10322,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10323,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10324,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10325,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10326,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10327,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10328,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10329,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10330,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10331,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10332,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10333,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10334,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10335,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10336,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10337,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10338,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10339,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10340,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10341,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10342,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10343,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10344,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10345,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10346,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10347,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10348,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10349,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10350,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10351,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10352,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10353,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10354,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10355,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10356,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10357,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10358,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10359,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10360,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10361,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10362,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10363,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10364,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10365,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10366,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10367,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10368,"The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin : corticosteroids , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , albuterol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10369,"Beta-blockers , clonidine , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin ."</p>
<p>10370,"Beta-blockers , clonidine , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin ."</p>
<p>10371,"Beta-blockers , clonidine , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin ."</p>
<p>10372,"Beta-blockers , clonidine , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin ."</p>
<p>10373,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10374,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10375,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10376,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10377,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10378,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10379,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10380,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10381,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10382,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10383,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10384,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic_products , ACE_inhibitors , disopyramide , fibrates , fluoxetine , monoamine_oxidase_(MAO)_inhibitors , propoxyphene , salicylates , somatostatin_analog (e,g,, octreotide ), sulfonamide_antibiotics ."</p>
<p>10385,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10386,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10387,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10388,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10389,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10390,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10391,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10392,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10393,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10394,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10395,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10396,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10397,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10398,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10399,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10400,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10401,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10402,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10403,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10404,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10405,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10406,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10407,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10408,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10409,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10410,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10411,"The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic_agents (e,g,, epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine_derivatives , somatropin , thyroid_hormones , estrogens , progestogens (e,g,, in oral contraceptives )."</p>
<p>10412,"Beta-blockers , clonidine , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin ."</p>
<p>10413,"Beta-blockers , clonidine , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin ."</p>
<p>10414,"Beta-blockers , clonidine , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin ."</p>
<p>10415,"Beta-blockers , clonidine , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin ."</p>
<p>10416,"A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH_human_insulin immediately before injection produced some attenuation in the peak concentration of NovoLog , but that the time to peak and the total bioavailability of NovoLog were not significantly affected."</p>
<p>10417,"A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH_human_insulin immediately before injection produced some attenuation in the peak concentration of NovoLog , but that the time to peak and the total bioavailability of NovoLog were not significantly affected."</p>
<p>10418,"A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH_human_insulin immediately before injection produced some attenuation in the peak concentration of NovoLog , but that the time to peak and the total bioavailability of NovoLog were not significantly affected."</p>
<p>10419,"If NovoLog is mixed with NPH_human_insulin , NovoLog should be drawn into the syringe first."</p>
<p>10420,"If NovoLog is mixed with NPH_human_insulin , NovoLog should be drawn into the syringe first."</p>
<p>10421,"Because there are no data on the compatibility of NovoLog and crystalline zinc_insulin preparations, NovoLog should not be mixed with these preparations."</p>
<p>10422,"Because there are no data on the compatibility of NovoLog and crystalline zinc_insulin preparations, NovoLog should not be mixed with these preparations."</p>
<p>10423,The effects of mixing NovoLog with insulins of animal source or insulin preparations produced by other manufacturers have not been studied .</p>
<p>10424,The effects of mixing NovoLog with insulins of animal source or insulin preparations produced by other manufacturers have not been studied .</p>
<p>10425,"When used in external subcutaneous infusion pumps for insulin , NovoLog should not be mixed with any other insulins or diluent."</p>
<p>10426,"When used in external subcutaneous infusion pumps for insulin , NovoLog should not be mixed with any other insulins or diluent."</p>
<p>10427,"Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or ACTH treatment of relapses for periods of up to # days has been administered to patients (N=180) receiving Betaseron ."</p>
<p>10428,"Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or ACTH treatment of relapses for periods of up to # days has been administered to patients (N=180) receiving Betaseron ."</p>
<p>10429,"Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or ACTH treatment of relapses for periods of up to # days has been administered to patients (N=180) receiving Betaseron ."</p>
<p>10430,Betaseron administration to three cancer patients over a dose range of # mg to # mg led to a dose-dependent inhibition of antipyrine elimination# The effect of alternate-day administration of # mg of Betaseron on drug metabolism in MS patients is unknown.</p>
<p>10431,Betaseron administration to three cancer patients over a dose range of # mg to # mg led to a dose-dependent inhibition of antipyrine elimination# The effect of alternate-day administration of # mg of Betaseron on drug metabolism in MS patients is unknown.</p>
<p>10432,"ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic_bronchodilators , methylxanthines , and steroids , commonly used in the treatment of chronic obstructive pulmonary disease."</p>
<p>10433,"ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic_bronchodilators , methylxanthines , and steroids , commonly used in the treatment of chronic obstructive pulmonary disease."</p>
<p>10434,"ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic_bronchodilators , methylxanthines , and steroids , commonly used in the treatment of chronic obstructive pulmonary disease."</p>
<p>10435,"With the exception of albuterol , there are no formal studies fully evaluating the interaction effects of ATROVENT Inhalation Aerosol and these drugs with respect to effectiveness."</p>
<p>10436,"Anticholinergic_agents : Although ipratropium_bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic_medications ."</p>
<p>10437,Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic -containing drugs.</p>
<p>10438,"However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible."</p>
<p>10439,"In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for # days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin ."</p>
<p>10440,"In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for # days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin ."</p>
<p>10441,"In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for # days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin ."</p>
<p>10442,"In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for # days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin ."</p>
<p>10443,"In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for # days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin ."</p>
<p>10444,"In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for # days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin ."</p>
<p>10445,"In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for # days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin ."</p>
<p>10446,"In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for # days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin ."</p>
<p>10447,"In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for # days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin ."</p>
<p>10448,"In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for # days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin ."</p>
<p>10449,The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide</p>
<p>10450,The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide</p>
<p>10451,The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide</p>
<p>10452,"The adverse effects of CAMPTOSAR , such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic_agents having similar adverse effects."</p>
<p>10453,"Lymphocytopenia has been reported in patients receiving CAMPTOSAR , and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect."</p>
<p>10454,"The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (#%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (#%, 1/80 patients)."</p>
<p>10455,"It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied."</p>
<p>10456,"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR , the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea."</p>
<p>10457,"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR , the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea."</p>
<p>10458,"Isocarboxazid should be administered with caution to patients receiving Antabuse ( disulfiram , Wyeth-Ayerst Laboratories)."</p>
<p>10459,"Isocarboxazid should be administered with caution to patients receiving Antabuse ( disulfiram , Wyeth-Ayerst Laboratories)."</p>
<p>10460,"In a single study, rats given high intraperitoneal doses of an MAO_inhibitor plus disulfiram experienced severe toxicity, including convulsions and death."</p>
<p>10461,Concomitant use of Isocarboxazid and other psychotropic_agents is generally not recommended because of possible potentiating effects.</p>
<p>10462,"May interact with the following: beta-adrenergic_blocking_agents (these medicines may make your condition worse and prevent the adrenergic_bronchodilators from working properly) and disopyramide , quinidine , phenothiazines , and procainamide (these medicines may increase the risk of heart problems)."</p>
<p>10463,"May interact with the following: beta-adrenergic_blocking_agents (these medicines may make your condition worse and prevent the adrenergic_bronchodilators from working properly) and disopyramide , quinidine , phenothiazines , and procainamide (these medicines may increase the risk of heart problems)."</p>
<p>10464,"May interact with the following: beta-adrenergic_blocking_agents (these medicines may make your condition worse and prevent the adrenergic_bronchodilators from working properly) and disopyramide , quinidine , phenothiazines , and procainamide (these medicines may increase the risk of heart problems)."</p>
<p>10465,"May interact with the following: beta-adrenergic_blocking_agents (these medicines may make your condition worse and prevent the adrenergic_bronchodilators from working properly) and disopyramide , quinidine , phenothiazines , and procainamide (these medicines may increase the risk of heart problems)."</p>
<p>10466,"May interact with the following: beta-adrenergic_blocking_agents (these medicines may make your condition worse and prevent the adrenergic_bronchodilators from working properly) and disopyramide , quinidine , phenothiazines , and procainamide (these medicines may increase the risk of heart problems)."</p>
<p>10467,"Isoflurane potentiates the muscle relaxant effect of all muscle_relaxants , most notably nondepolarizing_muscle_relaxants , and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O."</p>
<p>10468,"Isoflurane potentiates the muscle relaxant effect of all muscle_relaxants , most notably nondepolarizing_muscle_relaxants , and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O."</p>
<p>10469,Acetaminophen : A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid .</p>
<p>10470,It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.</p>
<p>10471,"Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites."</p>
<p>10472,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10473,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10474,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10475,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10476,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10477,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10478,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10479,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10480,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10481,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10482,"Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made."</p>
<p>10483,Ketoconazole : Potential interaction of Ketoconazole and Isoniazid may exist.</p>
<p>10484,Ketoconazole : Potential interaction of Ketoconazole and Isoniazid may exist.</p>
<p>10485,Phenytoin : Isoniazid may increase serum levels of phenytoin .</p>
<p>10486,"To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made."</p>
<p>10487,"Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline , and in some instances a slight decrease in the elimination of isoniazid ."</p>
<p>10488,"Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline , and in some instances a slight decrease in the elimination of isoniazid ."</p>
<p>10489,"Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline , and in some instances a slight decrease in the elimination of isoniazid ."</p>
<p>10490,"Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline , and in some instances a slight decrease in the elimination of isoniazid ."</p>
<p>10491,Valproate : A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid .</p>
<p>10492,"Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made."</p>
<p>10493,"Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made."</p>
<p>10494,"Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made."</p>
<p>10495,Isoproterenol_hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.</p>
<p>10496,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic_amines ."</p>
<p>10497,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic_amines ."</p>
<p>10498,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic_amines ."</p>
<p>10499,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic_amines ."</p>
<p>10500,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic_amines ."</p>
<p>10501,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic_amines ."</p>
<p>10502,The vasodilating effects of isosorbide_dinitrate may be additive with those of other vasodilators .</p>
<p>10503,The vasodilating effects of isosorbide_mononitrate may be additive with those of other vasodilators .</p>
<p>10504,Marked symptomatic orthostatic hypotension has been reported when calcium_channel_blockers and organic_nitrates were used in combination.</p>
<p>10505,"Vitamin_A : Because of the relationship of Accutane to vitamin_A , patients should be advised against taking vitamin_supplements containing vitamin_A to avoid additive toxic effects"</p>
<p>10506,"Vitamin_A : Because of the relationship of Accutane to vitamin_A , patients should be advised against taking vitamin_supplements containing vitamin_A to avoid additive toxic effects"</p>
<p>10507,"Vitamin_A : Because of the relationship of Accutane to vitamin_A , patients should be advised against taking vitamin_supplements containing vitamin_A to avoid additive toxic effects"</p>
<p>10508,"Vitamin_A : Because of the relationship of Accutane to vitamin_A , patients should be advised against taking vitamin_supplements containing vitamin_A to avoid additive toxic effects"</p>
<p>10509,"Vitamin_A : Because of the relationship of Accutane to vitamin_A , patients should be advised against taking vitamin_supplements containing vitamin_A to avoid additive toxic effects"</p>
<p>10510,"Tetracyclines : Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines"</p>
<p>10511,"Tetracyclines : Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines"</p>
<p>10512,"Tetracyclines : Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines"</p>
<p>10513,"Tetracyclines : Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines"</p>
<p>10514,"Tetracyclines : Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines"</p>
<p>10515,"Tetracyclines : Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines"</p>
<p>10516,Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen ) may be an inadequate method of contraception during Accutane therapy.</p>
<p>10517,Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen ) may be an inadequate method of contraception during Accutane therapy.</p>
<p>10518,Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen ) may be an inadequate method of contraception during Accutane therapy.</p>
<p>10519,Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen ) may be an inadequate method of contraception during Accutane therapy.</p>
<p>10520,"Although other hormonal_contraceptives are highly effective, there have been reports of pregnancy from women who have used combined_oral_contraceptives , as well as topical/injectable/implantable/insertable hormonal birth control products."</p>
<p>10521,It is not known if hormonal_contraceptives differ in their effectiveness when used with Accutane .</p>
<p>10522,Phenytoin : Accutane has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.</p>
<p>10523,No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between phenytoin and Accutane .</p>
<p>10524,No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between systemic_corticosteroids and Accutane .</p>
<p>10525,Nitroglycerin : DynaCirc  ( isradipine ) has been safely coadministered with nitroglycerin .</p>
<p>10526,Nitroglycerin : DynaCirc  ( isradipine ) has been safely coadministered with nitroglycerin .</p>
<p>10527,Nitroglycerin : DynaCirc  ( isradipine ) has been safely coadministered with nitroglycerin .</p>
<p>10528,Hydrochlorothiazide : A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  ( isradipine ) and hydrochlorothiazide does not result in altered pharmacokinetics of either drug.</p>
<p>10529,Hydrochlorothiazide : A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  ( isradipine ) and hydrochlorothiazide does not result in altered pharmacokinetics of either drug.</p>
<p>10530,"In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect."</p>
<p>10531,"In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect."</p>
<p>10532,"Propranolol : In a single dose study in normal volunteers, coadministration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability."</p>
<p>10533,"propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were 20% between isradipine given singly and in combination with propranolol , and between propranolol given singly and in combination with isradipine ."</p>
<p>10534,"propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were 20% between isradipine given singly and in combination with propranolol , and between propranolol given singly and in combination with isradipine ."</p>
<p>10535,"propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were 20% between isradipine given singly and in combination with propranolol , and between propranolol given singly and in combination with isradipine ."</p>
<p>10536,"propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were 20% between isradipine given singly and in combination with propranolol , and between propranolol given singly and in combination with isradipine ."</p>
<p>10537,"propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were 20% between isradipine given singly and in combination with propranolol , and between propranolol given singly and in combination with isradipine ."</p>
<p>10538,"propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were 20% between isradipine given singly and in combination with propranolol , and between propranolol given singly and in combination with isradipine ."</p>
<p>10539,"Cimetidine : In a study in healthy volunteers, a one-week course of cimetidine at # mg b,i,d, with a single # mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%)."</p>
<p>10540,"Cimetidine : In a study in healthy volunteers, a one-week course of cimetidine at # mg b,i,d, with a single # mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%)."</p>
<p>10541,If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.</p>
<p>10542,"Rifampicin : In a study in healthy volunteers, a six-day course of rifampicin at # mg/day followed by a single # mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits."</p>
<p>10543,"Rifampicin : In a study in healthy volunteers, a six-day course of rifampicin at # mg/day followed by a single # mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits."</p>
<p>10544,"If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine ."</p>
<p>10545,"If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine ."</p>
<p>10546,"Warfarin : In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (# mg/kg body weight) were administered during # days of multipledose treatment with # mg b,i,d, isradipine ."</p>
<p>10547,"Warfarin : In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (# mg/kg body weight) were administered during # days of multipledose treatment with # mg b,i,d, isradipine ."</p>
<p>10548,"Warfarin : In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (# mg/kg body weight) were administered during # days of multipledose treatment with # mg b,i,d, isradipine ."</p>
<p>10549,"Warfarin : In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (# mg/kg body weight) were administered during # days of multipledose treatment with # mg b,i,d, isradipine ."</p>
<p>10550,Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.</p>
<p>10551,"Digoxin : The concomitant administration of DynaCirc  ( isradipine ) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin ."</p>
<p>10552,"Digoxin : The concomitant administration of DynaCirc  ( isradipine ) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin ."</p>
<p>10553,"Digoxin : The concomitant administration of DynaCirc  ( isradipine ) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin ."</p>
<p>10554,"Digoxin : The concomitant administration of DynaCirc  ( isradipine ) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin ."</p>
<p>10555,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta_blocker and a calcium_channel_blocker .</p>
<p>10556,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta_blocker and a calcium_channel_blocker .</p>
<p>10557,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta_blocker and a calcium_channel_blocker .</p>
<p>10558,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta_blocker and a calcium_channel_blocker .</p>
<p>10559,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta_blocker and a calcium_channel_blocker .</p>
<p>10560,"Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine , resulting in rare instances of life- threatening cardiac dysrhythmias and one death."</p>
<p>10561,"Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine , resulting in rare instances of life- threatening cardiac dysrhythmias and one death."</p>
<p>10562,"Another oral azole_antifungal , ketoconazole , inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals."</p>
<p>10563,"Another oral azole_antifungal , ketoconazole , inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals."</p>
<p>10564,"Another oral azole_antifungal , ketoconazole , inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals."</p>
<p>10565,"Another oral azole_antifungal , ketoconazole , inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals."</p>
<p>10566,"Another oral azole_antifungal , ketoconazole , inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals."</p>
<p>10567,"Another oral azole_antifungal , ketoconazole , inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals."</p>
<p>10568,"Another oral azole_antifungal , ketoconazole , inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals."</p>
<p>10569,"Another oral azole_antifungal , ketoconazole , inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals."</p>
<p>10570,"Another oral azole_antifungal , ketoconazole , inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals."</p>
<p>10571,"In vitro data suggest that itraconazole , when compared to ketoconazole , has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole ."</p>
<p>10572,"In vitro data suggest that itraconazole , when compared to ketoconazole , has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole ."</p>
<p>10573,"In vitro data suggest that itraconazole , when compared to ketoconazole , has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole ."</p>
<p>10574,"Based on the chemical resemblance of itraconazole and ketoconazole , coadministration of astemizole with itraconazole is contraindicated."</p>
<p>10575,"Based on the chemical resemblance of itraconazole and ketoconazole , coadministration of astemizole with itraconazole is contraindicated."</p>
<p>10576,"Based on the chemical resemblance of itraconazole and ketoconazole , coadministration of astemizole with itraconazole is contraindicated."</p>
<p>10577,"Based on the chemical resemblance of itraconazole and ketoconazole , coadministration of astemizole with itraconazole is contraindicated."</p>
<p>10578,"Based on the chemical resemblance of itraconazole and ketoconazole , coadministration of astemizole with itraconazole is contraindicated."</p>
<p>10579,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride .</p>
<p>10580,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride .</p>
<p>10581,Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.</p>
<p>10582,In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride ;</p>
<p>10583,therefore concomitant administration of Itraconazole with cisapride is contraindicated.</p>
<p>10584,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.</p>
<p>10585,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.</p>
<p>10586,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.</p>
<p>10587,"Cyclosporine , tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately."</p>
<p>10588,"Cyclosporine , tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately."</p>
<p>10589,"Cyclosporine , tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately."</p>
<p>10590,Rhabdomyolysis has been observed in patients receiving HMG-CoA_reductase_inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive_drugs including cyclosporine .</p>
<p>10591,Rhabdomyolysis has been observed in patients receiving HMG-CoA_reductase_inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive_drugs including cyclosporine .</p>
<p>10592,Rhabdomyolysis has been observed in patients receiving HMG-CoA_reductase_inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive_drugs including cyclosporine .</p>
<p>10593,"When Itraconazole was coadministered with phenytoin , rifampin , or h2 antagonists, reduced plasma concentrations of itraconazole were reported."</p>
<p>10594,"When Itraconazole was coadministered with phenytoin , rifampin , or h2 antagonists, reduced plasma concentrations of itraconazole were reported."</p>
<p>10595,"When Itraconazole was coadministered with phenytoin , rifampin , or h2 antagonists, reduced plasma concentrations of itraconazole were reported."</p>
<p>10596,"When Itraconazole was coadministered with phenytoin , rifampin , or h2 antagonists, reduced plasma concentrations of itraconazole were reported."</p>
<p>10597,"Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin ;"</p>
<p>10598,"Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin ;"</p>
<p>10599,"therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole ."</p>
<p>10600,It has been reported that Itraconazole enhances the anticoagulant effect of coumarin -like drugs.</p>
<p>10601,"Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin -like drugs simultaneously."</p>
<p>10602,Plasma concentrations of azole_antifungal_agents are reduced when given concurrently with isoniazid .</p>
<p>10603,Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.</p>
<p>10604,Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.</p>
<p>10605,Severe hypoglycemia has been reported in patients concomitantly receiving azole_antifungal_agents and oral hypoglycemic_agents .</p>
<p>10606,Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic_agents are coadministered.</p>
<p>10607,Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine .</p>
<p>10608,Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine_calcium_channel_blockers .</p>
<p>10609,"The results from a study in which eight HIV-infected individuals were treated with zidovudine , # +/- # mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of Itraconazole , # mg b,i,d."</p>
<p>10610,"The results from a study in which eight HIV-infected individuals were treated with zidovudine , # +/- # mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of Itraconazole , # mg b,i,d."</p>
<p>10611,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics ( penicillins or cephalosporins ) may result in a significant mutual inactivation.</p>
<p>10612,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics ( penicillins or cephalosporins ) may result in a significant mutual inactivation.</p>
<p>10613,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics ( penicillins or cephalosporins ) may result in a significant mutual inactivation.</p>
<p>10614,"Even when an aminoglycoside and a penicillin -type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function."</p>
<p>10615,"Even when an aminoglycoside and a penicillin -type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function."</p>
<p>10616,Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine .</p>
<p>10617,Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine .</p>
<p>10618,Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine .</p>
<p>10619,Ketamine is clinically compatible with the commonly used general and local anesthetic_agents when an adequate respiratory exchange is maintained.</p>
<p>10620,"The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine , resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite."</p>
<p>10621,"The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine , resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite."</p>
<p>10622,"Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole , resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals."</p>
<p>10623,"Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole , resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals."</p>
<p>10624,"Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole , resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals."</p>
<p>10625,Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.</p>
<p>10626,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride .</p>
<p>10627,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride .</p>
<p>10628,Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.</p>
<p>10629,Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.</p>
<p>10630,"Ketoconazole tablets may alter the metabolism of cyclosporine , tacrolimus , and methylprednisolone , resulting in elevated plasma concentrations of the latter drugs."</p>
<p>10631,"Ketoconazole tablets may alter the metabolism of cyclosporine , tacrolimus , and methylprednisolone , resulting in elevated plasma concentrations of the latter drugs."</p>
<p>10632,"Ketoconazole tablets may alter the metabolism of cyclosporine , tacrolimus , and methylprednisolone , resulting in elevated plasma concentrations of the latter drugs."</p>
<p>10633,"Dosage adjustment may be required if cyclosporine , tacrolimus , or methylprednisolone are given concomitantly with NIZORAL  Tablets."</p>
<p>10634,"Dosage adjustment may be required if cyclosporine , tacrolimus , or methylprednisolone are given concomitantly with NIZORAL  Tablets."</p>
<p>10635,"Dosage adjustment may be required if cyclosporine , tacrolimus , or methylprednisolone are given concomitantly with NIZORAL  Tablets."</p>
<p>10636,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.</p>
<p>10637,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.</p>
<p>10638,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.</p>
<p>10639,"It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole ."</p>
<p>10640,"When taken orally , imidazole_compounds like ketoconazole may enhance the anticoagulant effect of coumarin -like drugs."</p>
<p>10641,"When taken orally , imidazole_compounds like ketoconazole may enhance the anticoagulant effect of coumarin -like drugs."</p>
<p>10642,"When taken orally , imidazole_compounds like ketoconazole may enhance the anticoagulant effect of coumarin -like drugs."</p>
<p>10643,"In simultaneous treatment with imidazole_drugs and coumarin_drugs , the anticoagulant effect should be carefully titrated and monitored."</p>
<p>10644,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole ) and oral hypoglycemic_agents , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole ) can not be ruled out."</p>
<p>10645,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole ) and oral hypoglycemic_agents , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole ) can not be ruled out."</p>
<p>10646,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole ) and oral hypoglycemic_agents , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole ) can not be ruled out."</p>
<p>10647,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole ) and oral hypoglycemic_agents , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole ) can not be ruled out."</p>
<p>10648,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole ) and oral hypoglycemic_agents , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole ) can not be ruled out."</p>
<p>10649,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole ) and oral hypoglycemic_agents , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole ) can not be ruled out."</p>
<p>10650,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole ) and oral hypoglycemic_agents , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole ) can not be ruled out."</p>
<p>10651,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole ) and oral hypoglycemic_agents , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole ) can not be ruled out."</p>
<p>10652,Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.</p>
<p>10653,It is suggested to monitor both ketoconazole and phenytoin .</p>
<p>10654,Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.</p>
<p>10655,INH ( Isoniazid ) is also reported to affect ketoconazole concentrations adversely.</p>
<p>10656,INH ( Isoniazid ) is also reported to affect ketoconazole concentrations adversely.</p>
<p>10657,"After the coadministration of # mg oral ketoconazole twice daily and one # mg dose of loratadine to # subjects, the AUC and Cmax of loratadine averaged 302% ( # S,D,) and 251% ( # S,D,), respectively, of those obtained after co-treatment with placebo."</p>
<p>10658,"After the coadministration of # mg oral ketoconazole twice daily and one # mg dose of loratadine to # subjects, the AUC and Cmax of loratadine averaged 302% ( # S,D,) and 251% ( # S,D,), respectively, of those obtained after co-treatment with placebo."</p>
<p>10659,"Also, there were no clinically significant differences in adverse events when loratadine was administered with or without ketoconazole ."</p>
<p>10660,The possibility of increased interaction should be kept in mind when Orudis doses greater than # mg as a single dose or # mg of ketoprofen per day are used concomitantly with highly bound drugs.</p>
<p>10661,Antacids : Concomitant administration of magnesium_hydroxide and aluminum_hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .</p>
<p>10662,Antacids : Concomitant administration of magnesium_hydroxide and aluminum_hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .</p>
<p>10663,Antacids : Concomitant administration of magnesium_hydroxide and aluminum_hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .</p>
<p>10664,Antacids : Concomitant administration of magnesium_hydroxide and aluminum_hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .</p>
<p>10665,Antacids : Concomitant administration of magnesium_hydroxide and aluminum_hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .</p>
<p>10666,Antacids : Concomitant administration of magnesium_hydroxide and aluminum_hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .</p>
<p>10667,Antacids : Concomitant administration of magnesium_hydroxide and aluminum_hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .</p>
<p>10668,Antacids : Concomitant administration of magnesium_hydroxide and aluminum_hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .</p>
<p>10669,Antacids : Concomitant administration of magnesium_hydroxide and aluminum_hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .</p>
<p>10670,Antacids : Concomitant administration of magnesium_hydroxide and aluminum_hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .</p>
<p>10671,Aspirin : Ketoprofen does not alter aspirin absorption;</p>
<p>10672,"however, in a study of # normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from # L/kg/h without aspirin to # L/kg/h with aspirin ."</p>
<p>10673,"however, in a study of # normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from # L/kg/h without aspirin to # L/kg/h with aspirin ."</p>
<p>10674,"however, in a study of # normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from # L/kg/h without aspirin to # L/kg/h with aspirin ."</p>
<p>10675,"however, in a study of # normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from # L/kg/h without aspirin to # L/kg/h with aspirin ."</p>
<p>10676,"however, in a study of # normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from # L/kg/h without aspirin to # L/kg/h with aspirin ."</p>
<p>10677,"however, in a study of # normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from # L/kg/h without aspirin to # L/kg/h with aspirin ."</p>
<p>10678,"Therefore, concurrent use of aspirin and ketoprofen is not recommended."</p>
<p>10679,"Diuretic : Hydrochlorothiazide , given concomitantly with ketoprofen , produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone."</p>
<p>10680,"Diuretic : Hydrochlorothiazide , given concomitantly with ketoprofen , produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone."</p>
<p>10681,"Diuretic : Hydrochlorothiazide , given concomitantly with ketoprofen , produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone."</p>
<p>10682,"Diuretic : Hydrochlorothiazide , given concomitantly with ketoprofen , produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone."</p>
<p>10683,"Diuretic : Hydrochlorothiazide , given concomitantly with ketoprofen , produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone."</p>
<p>10684,"Digoxin : In a study in # patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin ."</p>
<p>10685,"Digoxin : In a study in # patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin ."</p>
<p>10686,"Digoxin : In a study in # patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin ."</p>
<p>10687,"Digoxin : In a study in # patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin ."</p>
<p>10688,"Warfarin : In a short-term controlled study in # normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time."</p>
<p>10689,Bleeding from a number of sites may be a complication of warfarin treatment and GI bleeding a complication of ketoprofen treatment.</p>
<p>10690,"Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs."</p>
<p>10691,"Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs."</p>
<p>10692,"Probenecid : Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding."</p>
<p>10693,"Probenecid : Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding."</p>
<p>10694,"Therefore, the combination of ketoprofen and probenecid is not recommended."</p>
<p>10695,"Methotrexate : Ketoprofen , like other NSAIDs , may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity."</p>
<p>10696,"Methotrexate : Ketoprofen , like other NSAIDs , may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity."</p>
<p>10697,"Methotrexate : Ketoprofen , like other NSAIDs , may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity."</p>
<p>10698,"Methotrexate : Ketoprofen , like other NSAIDs , may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity."</p>
<p>10699,"Methotrexate : Ketoprofen , like other NSAIDs , may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity."</p>
<p>10700,Lithium : Nonsteroidal_anti-inflammatory_agents have been reported to increase steadystate plasma lithium levels.</p>
<p>10701,It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium .</p>
<p>10702,It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium .</p>
<p>10703,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10704,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10705,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10706,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10707,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10708,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10709,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10710,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10711,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10712,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10713,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10714,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10715,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10716,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10717,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10718,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10719,"Warfarin , Digoxin , Salicylate , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac_tromethamine (#% control vs #%) when ketorolac plasma concentrations reach # to10 m g/mL."</p>
<p>10720,Ketorolac does not alter digoxin protein binding.</p>
<p>10721,"In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately #% to #%, representing a potential twofold increase in unbound ketorolac plasma levels."</p>
<p>10722,"In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately #% to #%, representing a potential twofold increase in unbound ketorolac plasma levels."</p>
<p>10723,"Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac_tromethamine protein binding."</p>
<p>10724,"Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac_tromethamine protein binding."</p>
<p>10725,"Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac_tromethamine protein binding."</p>
<p>10726,"Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac_tromethamine protein binding."</p>
<p>10727,"Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac_tromethamine protein binding."</p>
<p>10728,"Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac_tromethamine protein binding."</p>
<p>10729,"Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac_tromethamine protein binding."</p>
<p>10730,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin , the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored."</p>
<p>10731,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin , the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored."</p>
<p>10732,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin , the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored."</p>
<p>10733,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin , the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored."</p>
<p>10734,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin , the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored."</p>
<p>10735,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin , the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored."</p>
<p>10736,Furosemide : TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).</p>
<p>10737,Furosemide : TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).</p>
<p>10738,Furosemide : TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).</p>
<p>10739,Probenecid : Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from # to # m g/h/mL) and terminal half-life increased approximately twofold from # to # hours.</p>
<p>10740,Probenecid : Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from # to # m g/h/mL) and terminal half-life increased approximately twofold from # to # hours.</p>
<p>10741,Probenecid : Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from # to # m g/h/mL) and terminal half-life increased approximately twofold from # to # hours.</p>
<p>10742,Probenecid : Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from # to # m g/h/mL) and terminal half-life increased approximately twofold from # to # hours.</p>
<p>10743,Probenecid : Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from # to # m g/h/mL) and terminal half-life increased approximately twofold from # to # hours.</p>
<p>10744,Probenecid : Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from # to # m g/h/mL) and terminal half-life increased approximately twofold from # to # hours.</p>
<p>10745,Probenecid : Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from # to # m g/h/mL) and terminal half-life increased approximately twofold from # to # hours.</p>
<p>10746,Probenecid : Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from # to # m g/h/mL) and terminal half-life increased approximately twofold from # to # hours.</p>
<p>10747,"Therefore, concomitant use of TORADOL and probenecid is contraindicated."</p>
<p>10748,"The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported."</p>
<p>10749,"The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported."</p>
<p>10750,"The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported."</p>
<p>10751,"The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported."</p>
<p>10752,"Methotrexate : Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate , enhancing the toxicity of methotrexate ."</p>
<p>10753,"Methotrexate : Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate , enhancing the toxicity of methotrexate ."</p>
<p>10754,"Methotrexate : Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate , enhancing the toxicity of methotrexate ."</p>
<p>10755,"Methotrexate : Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate , enhancing the toxicity of methotrexate ."</p>
<p>10756,The effect of TORADOL on methotrexate clearance has not been studied.</p>
<p>10757,The concurrent use of TORADOL with muscle_relaxants has not been formally studied.</p>
<p>10758,"Antiepileptic_Drugs : Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic_drugs ( phenytoin , carbamazepine )."</p>
<p>10759,"Antiepileptic_Drugs : Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic_drugs ( phenytoin , carbamazepine )."</p>
<p>10760,"Antiepileptic_Drugs : Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic_drugs ( phenytoin , carbamazepine )."</p>
<p>10761,"Psychoactive_Drugs : Hallucinations have been reported when TORADOL was used in patients taking psychoactive_drugs ( fluoxetine , thiothixene , alprazolam )."</p>
<p>10762,"Psychoactive_Drugs : Hallucinations have been reported when TORADOL was used in patients taking psychoactive_drugs ( fluoxetine , thiothixene , alprazolam )."</p>
<p>10763,"Psychoactive_Drugs : Hallucinations have been reported when TORADOL was used in patients taking psychoactive_drugs ( fluoxetine , thiothixene , alprazolam )."</p>
<p>10764,"Psychoactive_Drugs : Hallucinations have been reported when TORADOL was used in patients taking psychoactive_drugs ( fluoxetine , thiothixene , alprazolam )."</p>
<p>10765,Do not mix TORADOL and morphine in the same syringe.</p>
<p>10766,Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin .</p>
<p>10767,Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin .</p>
<p>10768,Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.</p>
<p>10769,Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.</p>
<p>10770,Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.</p>
<p>10771,Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.</p>
<p>10772,"Sildenafil_citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil_citrate , may potentiate the effects of the drug."</p>
<p>10773,"Sildenafil_citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil_citrate , may potentiate the effects of the drug."</p>
<p>10774,Human_growth_hormone - Concomitant use of L-glutamine and human_growth_hormone may enhance nutrient absorption in those with severe short bowel syndrome.</p>
<p>10775,Human_growth_hormone - Concomitant use of L-glutamine and human_growth_hormone may enhance nutrient absorption in those with severe short bowel syndrome.</p>
<p>10776,Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin .</p>
<p>10777,Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin .</p>
<p>10778,Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin .</p>
<p>10779,Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.</p>
<p>10780,Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.</p>
<p>10781,"In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate -related toxicity when given supplemental L-glutamine at a dose of # gram/kilogram/day."</p>
<p>10782,"Paclitaxel - In one report, L-glutamine at a dose of # grams three times daily, given # hours after receiving paclitaxel , appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel ."</p>
<p>10783,"Paclitaxel - In one report, L-glutamine at a dose of # grams three times daily, given # hours after receiving paclitaxel , appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel ."</p>
<p>10784,"Paclitaxel - In one report, L-glutamine at a dose of # grams three times daily, given # hours after receiving paclitaxel , appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel ."</p>
<p>10785,Medroxyprogesterone_Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone_acetate in reducing the number of human breast cancer cells that were in the S phase.</p>
<p>10786,Medroxyprogesterone_Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone_acetate in reducing the number of human breast cancer cells that were in the S phase.</p>
<p>10787,"H1_Blockers and H2_Blockers - Although not reported, L-histidine , via its metabolism to histamine, might decrease the efficacy of H1_blockers and H2_blockers ."</p>
<p>10788,"H1_Blockers and H2_Blockers - Although not reported, L-histidine , via its metabolism to histamine, might decrease the efficacy of H1_blockers and H2_blockers ."</p>
<p>10789,"H1_Blockers and H2_Blockers - Although not reported, L-histidine , via its metabolism to histamine, might decrease the efficacy of H1_blockers and H2_blockers ."</p>
<p>10790,"H1_Blockers and H2_Blockers - Although not reported, L-histidine , via its metabolism to histamine, might decrease the efficacy of H1_blockers and H2_blockers ."</p>
<p>10791,"H1_Blockers and H2_Blockers - Although not reported, L-histidine , via its metabolism to histamine, might decrease the efficacy of H1_blockers and H2_blockers ."</p>
<p>10792,"H1_Blockers and H2_Blockers - Although not reported, L-histidine , via its metabolism to histamine, might decrease the efficacy of H1_blockers and H2_blockers ."</p>
<p>10793,"H1_Blockers and H2_Blockers - Although not reported, L-histidine , via its metabolism to histamine, might decrease the efficacy of H1_blockers and H2_blockers ."</p>
<p>10794,"H1_Blockers and H2_Blockers - Although not reported, L-histidine , via its metabolism to histamine, might decrease the efficacy of H1_blockers and H2_blockers ."</p>
<p>10795,Concomitant use of calcium supplements and L-lysine may increase calcium absorption</p>
<p>10796,Concomitant use of calcium supplements and L-lysine may increase calcium absorption</p>
<p>10797,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate .</p>
<p>10798,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate .</p>
<p>10799,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate .</p>
<p>10800,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate .</p>
<p>10801,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate .</p>
<p>10802,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate .</p>
<p>10803,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate .</p>
<p>10804,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate .</p>
<p>10805,Gentamicin - Methionine may protect against the ototoxic effects of gentamicin .</p>
<p>10806,Gentamicin - Methionine may protect against the ototoxic effects of gentamicin .</p>
<p>10807,"Non-selective_monoamine_oxidase_(MAO)_inhibitors - including phenelzine_sulfate , tranylcypromine_sulfate and pargyline HC1."</p>
<p>10808,"Non-selective_monoamine_oxidase_(MAO)_inhibitors - including phenelzine_sulfate , tranylcypromine_sulfate and pargyline HC1."</p>
<p>10809,"Non-selective_monoamine_oxidase_(MAO)_inhibitors - including phenelzine_sulfate , tranylcypromine_sulfate and pargyline HC1."</p>
<p>10810,Concomitant use of L-phenylalanine and non-selective_MAO_inhibitors may cause hypertension.</p>
<p>10811,Selegiline - L-phenylalanine and the selective_MAO_inhibitor  selegiline may have synergistic antidepressant activity if used concomitantly.</p>
<p>10812,Selegiline - L-phenylalanine and the selective_MAO_inhibitor  selegiline may have synergistic antidepressant activity if used concomitantly.</p>
<p>10813,Selegiline - L-phenylalanine and the selective_MAO_inhibitor  selegiline may have synergistic antidepressant activity if used concomitantly.</p>
<p>10814,Selegiline - L-phenylalanine and the selective_MAO_inhibitor  selegiline may have synergistic antidepressant activity if used concomitantly.</p>
<p>10815,Selegiline - L-phenylalanine and the selective_MAO_inhibitor  selegiline may have synergistic antidepressant activity if used concomitantly.</p>
<p>10816,Neuroleptic_Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic_drugs if used concomitantly with them.</p>
<p>10817,Neuroleptic_Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic_drugs if used concomitantly with them.</p>
<p>10818,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10819,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10820,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10821,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10822,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10823,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10824,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10825,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10826,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10827,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10828,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10829,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10830,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10831,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10832,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10833,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10834,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10835,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10836,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10837,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10838,"Monoamine_oxidase_(MAO)_inhibitors such as isocarboxazid (e,g,, Marplan ), phenelzine (e,g,, Nardil ), procarbazine (e,g,, Matulane ), selegiline (e,g,, Eldepryl ), and tranylcypromine (e,g,, Parnate ): Using these medicines with L-tryptophan may increase the chance of side effects."</p>
<p>10839,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10840,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10841,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10842,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10843,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10844,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10845,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10846,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10847,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10848,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10849,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10850,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10851,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10852,"Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO_inhibitors may cause hypertension."</p>
<p>10853,"In one survey, #% of patients taking labetalol_HCl in combination with tricyclic_antidepressants experienced tremor, as compared to #% reported to occur with labetalol_HCl alone."</p>
<p>10854,"In one survey, #% of patients taking labetalol_HCl in combination with tricyclic_antidepressants experienced tremor, as compared to #% reported to occur with labetalol_HCl alone."</p>
<p>10855,Cimetidine has been shown to increase the bioavailability of labetalol_HCl .</p>
<p>10856,Synergism has been shown between halothane anesthesia and intravenously administered labetalol_HCl .</p>
<p>10857,"During controlled hypotensive anesthesia using labetalol_HCl in association with halothane , high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure."</p>
<p>10858,"During controlled hypotensive anesthesia using labetalol_HCl in association with halothane , high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure."</p>
<p>10859,Labetalol_HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.</p>
<p>10860,"If labetalol_HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur."</p>
<p>10861,Care should be taken if labetalol is used concomitantly with calcium_antagonist s of the verapamil type.</p>
<p>10862,Care should be taken if labetalol is used concomitantly with calcium_antagonist s of the verapamil type.</p>
<p>10863,Care should be taken if labetalol is used concomitantly with calcium_antagonist s of the verapamil type.</p>
<p>10864,"Labetalol_HCl has also been reported to produce a false positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A (thin-layer chromatographic assay) and Emit-d,a,u, (radioenzymatic assay)."</p>
<p>10865,When patients being treated with labetalol have a positive urine test for amphetamine using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique.</p>
<p>10866,Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose -induced drop in colonic pH.</p>
<p>10867,Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose -induced drop in colonic pH.</p>
<p>10868,There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP / SMX such as those used to treat Pneumocystis carinii pneumonia.</p>
<p>10869,There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP / SMX such as those used to treat Pneumocystis carinii pneumonia.</p>
<p>10870,Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.</p>
<p>10871,"Therefore, use of lamivudine in combination with zalcitabine is not recommended"</p>
<p>10872,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects."</p>
<p>10873,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects."</p>
<p>10874,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects."</p>
<p>10875,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects."</p>
<p>10876,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects."</p>
<p>10877,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects."</p>
<p>10878,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects."</p>
<p>10879,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects."</p>
<p>10880,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects."</p>
<p>10881,"Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin , antipyrine , indomethacin , ibuprofen , phenytoin , propranolol , prednisone , diazepam , clarithromycin , or terfenadine in healthy subjects."</p>
<p>10882,"When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen."</p>
<p>10883,"When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen."</p>
<p>10884,"Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels."</p>
<p>10885,Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin .</p>
<p>10886,"In a single-dose crossover study examining lansoprazole # mg and omeprazole # mg each administered alone and concomitantly with sucralfate # gram, absorption of the proton_pump_inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate ."</p>
<p>10887,"In a single-dose crossover study examining lansoprazole # mg and omeprazole # mg each administered alone and concomitantly with sucralfate # gram, absorption of the proton_pump_inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate ."</p>
<p>10888,"In a single-dose crossover study examining lansoprazole # mg and omeprazole # mg each administered alone and concomitantly with sucralfate # gram, absorption of the proton_pump_inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate ."</p>
<p>10889,"In a single-dose crossover study examining lansoprazole # mg and omeprazole # mg each administered alone and concomitantly with sucralfate # gram, absorption of the proton_pump_inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate ."</p>
<p>10890,"In a single-dose crossover study examining lansoprazole # mg and omeprazole # mg each administered alone and concomitantly with sucralfate # gram, absorption of the proton_pump_inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate ."</p>
<p>10891,"In a single-dose crossover study examining lansoprazole # mg and omeprazole # mg each administered alone and concomitantly with sucralfate # gram, absorption of the proton_pump_inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate ."</p>
<p>10892,"In a single-dose crossover study examining lansoprazole # mg and omeprazole # mg each administered alone and concomitantly with sucralfate # gram, absorption of the proton_pump_inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate ."</p>
<p>10893,"In a single-dose crossover study examining lansoprazole # mg and omeprazole # mg each administered alone and concomitantly with sucralfate # gram, absorption of the proton_pump_inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate ."</p>
<p>10894,"In a single-dose crossover study examining lansoprazole # mg and omeprazole # mg each administered alone and concomitantly with sucralfate # gram, absorption of the proton_pump_inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate ."</p>
<p>10895,"Therefore, proton_pump_inhibitors should be taken at least # minutes prior to sucralfate ."</p>
<p>10896,"In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules;"</p>
<p>10897,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e,g, ketoconazole , ampicillin esters, iron salts, digoxin )."</p>
<p>10898,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e,g, ketoconazole , ampicillin esters, iron salts, digoxin )."</p>
<p>10899,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e,g, ketoconazole , ampicillin esters, iron salts, digoxin )."</p>
<p>10900,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e,g, ketoconazole , ampicillin esters, iron salts, digoxin )."</p>
<p>10901,"Ketoconazole : In healthy subjects receiving ketoconazole , a CYP3A4 inhibitor, at # mg twice daily for # days, systemic exposure (AUC) to lapatinib was increased to approximately #-fold of control and half-life increased to #-fold of control."</p>
<p>10902,"Carbamazepine : In healthy subjects receiving the CYP3A4 inducer, carbamazepine , at # mg twice daily for # days and # mg twice daily for # days, systemic exposure (AUC) to lapatinib was decreased approximately 72%."</p>
<p>10903,"If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised."</p>
<p>10904,"Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine )."</p>
<p>10905,"Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine )."</p>
<p>10906,In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost .</p>
<p>10907,Cholestyramine and Charcoal Administration of cholestyramine or activated_charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .</p>
<p>10908,Cholestyramine and Charcoal Administration of cholestyramine or activated_charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .</p>
<p>10909,Cholestyramine and Charcoal Administration of cholestyramine or activated_charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .</p>
<p>10910,Cholestyramine and Charcoal Administration of cholestyramine or activated_charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .</p>
<p>10911,Cholestyramine and Charcoal Administration of cholestyramine or activated_charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .</p>
<p>10912,Cholestyramine and Charcoal Administration of cholestyramine or activated_charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .</p>
<p>10913,Cholestyramine and Charcoal Administration of cholestyramine or activated_charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .</p>
<p>10914,Cholestyramine and Charcoal Administration of cholestyramine or activated_charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .</p>
<p>10915,"In a small (n=30) combination study of ARAVA with methotrexate , a 2- to 3-fold elevation in liver enzymes was seen in # of # patients."</p>
<p>10916,"NSAIDs : In in vitro studies, M1 was shown to cause increases ranging from # - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range."</p>
<p>10917,"NSAIDs : In in vitro studies, M1 was shown to cause increases ranging from # - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range."</p>
<p>10918,"NSAIDs : In in vitro studies, M1 was shown to cause increases ranging from # - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range."</p>
<p>10919,"Rifampin : Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin , M1 peak levels were increased (~40%) over those seen when ARAVA was given alone."</p>
<p>10920,"Rifampin : Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin , M1 peak levels were increased (~40%) over those seen when ARAVA was given alone."</p>
<p>10921,"Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin ."</p>
<p>10922,"Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin ."</p>
<p>10923,Warfarin : Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.</p>
<p>10924,Warfarin : Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.</p>
<p>10925,Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  ( lenalidomide ) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.</p>
<p>10926,Co-administration of multiple doses of # mg of lenalidomide had no effect on the single dose pharmacokinetics of R-_warfarin and S-_warfarin .</p>
<p>10927,Co-administration of multiple doses of # mg of lenalidomide had no effect on the single dose pharmacokinetics of R-_warfarin and S-_warfarin .</p>
<p>10928,Co-administration of multiple doses of # mg of lenalidomide had no effect on the single dose pharmacokinetics of R-_warfarin and S-_warfarin .</p>
<p>10929,Co-administration of single 25-mg dose warfarin had no effect on the pharmacokinetics of total lenalidomide .</p>
<p>10930,"Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration."</p>
<p>10931,"Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase ) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation"</p>
<p>10932,"Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase ) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation"</p>
<p>10933,Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.</p>
<p>10934,Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.</p>
<p>10935,Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.</p>
<p>10936,(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen # mg daily resulted in a reduction of letrozole plasma levels by 38% on average.</p>
<p>10937,(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen # mg daily resulted in a reduction of letrozole plasma levels by 38% on average.</p>
<p>10938,(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen # mg daily resulted in a reduction of letrozole plasma levels by 38% on average.</p>
<p>10939,"Folic_acid in large amounts may counteract the antiepileptic effect of phenobarbital , phenytoin and primidone , and increase the frequency of seizures in susceptible pediatric patients."</p>
<p>10940,"Folic_acid in large amounts may counteract the antiepileptic effect of phenobarbital , phenytoin and primidone , and increase the frequency of seizures in susceptible pediatric patients."</p>
<p>10941,"Folic_acid in large amounts may counteract the antiepileptic effect of phenobarbital , phenytoin and primidone , and increase the frequency of seizures in susceptible pediatric patients."</p>
<p>10942,"Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain # to # orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration."</p>
<p>10943,"However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate ."</p>
<p>10944,Leucovorin may enhance the toxicity of 5-fluorouracil .</p>
<p>10945,ERGAMISOL  ( levamisole_hydrochloride ) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol .</p>
<p>10946,ERGAMISOL  ( levamisole_hydrochloride ) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol .</p>
<p>10947,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin_sodium , it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin_sodium or other coumarin -like drugs should be adjusted accordingly, in patients taking both drugs."</p>
<p>10948,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin_sodium , it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin_sodium or other coumarin -like drugs should be adjusted accordingly, in patients taking both drugs."</p>
<p>10949,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin_sodium , it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin_sodium or other coumarin -like drugs should be adjusted accordingly, in patients taking both drugs."</p>
<p>10950,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin_sodium , it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin_sodium or other coumarin -like drugs should be adjusted accordingly, in patients taking both drugs."</p>
<p>10951,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin_sodium , it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin_sodium or other coumarin -like drugs should be adjusted accordingly, in patients taking both drugs."</p>
<p>10952,"In addition, levetiracetam does not affect the in vitro glucuronidation of valproic_acid ."</p>
<p>10953,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10954,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10955,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10956,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10957,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10958,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10959,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10960,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10961,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10962,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10963,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10964,Drug-Drug Interactions Between Keppra  And Other Antiepileptic_Drugs ( AEDs ) Phenytoin  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.</p>
<p>10965,Pharmacokinetics of levetiracetam were also not affected by phenytoin .</p>
<p>10966,Valproate  Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.</p>
<p>10967,Valproate  Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.</p>
<p>10968,Valproate # mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion.</p>
<p>10969,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10970,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10971,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10972,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10973,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10974,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10975,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10976,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10977,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10978,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10979,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10980,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10981,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10982,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10983,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10984,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10985,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10986,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10987,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10988,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10989,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10990,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10991,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10992,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10993,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10994,"Potential drug interactions between Keppra  and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies."</p>
<p>10995,These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam .</p>
<p>10996,These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam .</p>
<p>10997,These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam .</p>
<p>10998,These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam .</p>
<p>10999,Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs .</p>
<p>11000,Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs .</p>
<p>11001,"Dose adjustment is not recommended, Levetiracetam had no effect on plasma concentrations of carbamazepine , valproate , topiramate , or lamotrigine ."</p>
<p>11002,"Dose adjustment is not recommended, Levetiracetam had no effect on plasma concentrations of carbamazepine , valproate , topiramate , or lamotrigine ."</p>
<p>11003,"Dose adjustment is not recommended, Levetiracetam had no effect on plasma concentrations of carbamazepine , valproate , topiramate , or lamotrigine ."</p>
<p>11004,"Dose adjustment is not recommended, Levetiracetam had no effect on plasma concentrations of carbamazepine , valproate , topiramate , or lamotrigine ."</p>
<p>11005,"Other Drug Interactions Oral Contraceptives  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing # mg ethinyl_estradiol and # mg levonorgestrel , or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely."</p>
<p>11006,"Other Drug Interactions Oral Contraceptives  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing # mg ethinyl_estradiol and # mg levonorgestrel , or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely."</p>
<p>11007,"Other Drug Interactions Oral Contraceptives  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing # mg ethinyl_estradiol and # mg levonorgestrel , or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely."</p>
<p>11008,"Other Drug Interactions Oral Contraceptives  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing # mg ethinyl_estradiol and # mg levonorgestrel , or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely."</p>
<p>11009,"Other Drug Interactions Oral Contraceptives  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing # mg ethinyl_estradiol and # mg levonorgestrel , or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely."</p>
<p>11010,"Other Drug Interactions Oral Contraceptives  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing # mg ethinyl_estradiol and # mg levonorgestrel , or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely."</p>
<p>11011,"Other Drug Interactions Oral Contraceptives  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing # mg ethinyl_estradiol and # mg levonorgestrel , or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely."</p>
<p>11012,"Other Drug Interactions Oral Contraceptives  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing # mg ethinyl_estradiol and # mg levonorgestrel , or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely."</p>
<p>11013,"Other Drug Interactions Oral Contraceptives  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing # mg ethinyl_estradiol and # mg levonorgestrel , or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely."</p>
<p>11014,Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam .</p>
<p>11015,Digoxin  Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a # mg dose every day.</p>
<p>11016,Digoxin  Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a # mg dose every day.</p>
<p>11017,Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam .</p>
<p>11018,Warfarin  Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R_warfarin and S_warfarin .</p>
<p>11019,Warfarin  Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R_warfarin and S_warfarin .</p>
<p>11020,Warfarin  Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R_warfarin and S_warfarin .</p>
<p>11021,Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam .</p>
<p>11022,"Probenecid : Probenecid , a renal tubular secretion blocking agent, administered at a dose of # mg four times a day, did not change the pharmacokinetics of levetiracetam # mg twice daily."</p>
<p>11023,"Probenecid : Probenecid , a renal tubular secretion blocking agent, administered at a dose of # mg four times a day, did not change the pharmacokinetics of levetiracetam # mg twice daily."</p>
<p>11024,The effect of Keppra  on probenecid was not studied.</p>
<p>11025,"Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur."</p>
<p>11026,"Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur."</p>
<p>11027,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine , because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension."</p>
<p>11028,"Patients receiving beta-adrenergic_blocking_agents along with either oral or intravenous calcium_antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension."</p>
<p>11029,The concomitant use of beta-adrenergic_blocking_agents with digitalis and calcium_antagonist s may have additive effects on prolonging atrioventricular conduction time.</p>
<p>11030,The concomitant use of beta-adrenergic_blocking_agents with digitalis and calcium_antagonist s may have additive effects on prolonging atrioventricular conduction time.</p>
<p>11031,The concomitant use of beta-adrenergic_blocking_agents with digitalis and calcium_antagonist s may have additive effects on prolonging atrioventricular conduction time.</p>
<p>11032,Phenothiazine-related_compounds and beta-adrenergic_blocking_agents may have additive hypotensite effects due to the inhibition of each other s metabolism.</p>
<p>11033,Chirocaine  should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.</p>
<p>11034,"In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl_levobupivacaine and 3-hydroxy_levobupivacaine , respectively."</p>
<p>11035,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin , phenobarbital , rifampin ), CYP3A4 inhibitors (azole antimycotics e,g,, ketoconazole ;"</p>
<p>11036,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin , phenobarbital , rifampin ), CYP3A4 inhibitors (azole antimycotics e,g,, ketoconazole ;"</p>
<p>11037,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin , phenobarbital , rifampin ), CYP3A4 inhibitors (azole antimycotics e,g,, ketoconazole ;"</p>
<p>11038,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin , phenobarbital , rifampin ), CYP3A4 inhibitors (azole antimycotics e,g,, ketoconazole ;"</p>
<p>11039,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin , phenobarbital , rifampin ), CYP3A4 inhibitors (azole antimycotics e,g,, ketoconazole ;"</p>
<p>11040,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin , phenobarbital , rifampin ), CYP3A4 inhibitors (azole antimycotics e,g,, ketoconazole ;"</p>
<p>11041,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin , phenobarbital , rifampin ), CYP3A4 inhibitors (azole antimycotics e,g,, ketoconazole ;"</p>
<p>11042,"macrolide_antibiotics e,g,, erythromycin ;"</p>
<p>11043,"and calcium_channel_antagonists e,g,, verapamil ), CYP1A2 inducers ( omeprazole ) and CYP1A2 inhibitors ( furafylline and clarithromycin )."</p>
<p>11044,"and calcium_channel_antagonists e,g,, verapamil ), CYP1A2 inducers ( omeprazole ) and CYP1A2 inhibitors ( furafylline and clarithromycin )."</p>
<p>11045,"and calcium_channel_antagonists e,g,, verapamil ), CYP1A2 inducers ( omeprazole ) and CYP1A2 inhibitors ( furafylline and clarithromycin )."</p>
<p>11046,"and calcium_channel_antagonists e,g,, verapamil ), CYP1A2 inducers ( omeprazole ) and CYP1A2 inhibitors ( furafylline and clarithromycin )."</p>
<p>11047,"and calcium_channel_antagonists e,g,, verapamil ), CYP1A2 inducers ( omeprazole ) and CYP1A2 inhibitors ( furafylline and clarithromycin )."</p>
<p>11048,"and calcium_channel_antagonists e,g,, verapamil ), CYP1A2 inducers ( omeprazole ) and CYP1A2 inhibitors ( furafylline and clarithromycin )."</p>
<p>11049,"and calcium_channel_antagonists e,g,, verapamil ), CYP1A2 inducers ( omeprazole ) and CYP1A2 inhibitors ( furafylline and clarithromycin )."</p>
<p>11050,"and calcium_channel_antagonists e,g,, verapamil ), CYP1A2 inducers ( omeprazole ) and CYP1A2 inhibitors ( furafylline and clarithromycin )."</p>
<p>11051,"and calcium_channel_antagonists e,g,, verapamil ), CYP1A2 inducers ( omeprazole ) and CYP1A2 inhibitors ( furafylline and clarithromycin )."</p>
<p>11052,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11053,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11054,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11055,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11056,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11057,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11058,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11059,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11060,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11061,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11062,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11063,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11064,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11065,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11066,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly."</p>
<p>11067,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11068,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11069,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11070,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11071,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11072,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11073,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11074,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11075,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11076,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11077,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11078,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects."</p>
<p>11079,"Although no interaction between MAO_inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO_inhibitors ."</p>
<p>11080,"Although no interaction between MAO_inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO_inhibitors ."</p>
<p>11081,"Most cases of serious or fatal adverse events involving Levo-Dromoran reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of levorphanol with other drugs affecting respiration."</p>
<p>11082,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11083,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11084,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11085,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11086,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11087,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11088,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11089,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11090,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11091,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11092,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11093,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11094,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11095,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11096,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11097,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11098,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11099,"Interactions with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (eg, pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure_agonist_opioid_analgesic such as Levo-Dromoran ."</p>
<p>11100,"In opioid -dependent patients, mixed_agonist/antagonist_analgesics may precipitate withdrawal symptoms."</p>
<p>11101,"No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide_mononitrate , carvedilol , ethanol or itraconazole ."</p>
<p>11102,"No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide_mononitrate , carvedilol , ethanol or itraconazole ."</p>
<p>11103,"No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide_mononitrate , carvedilol , ethanol or itraconazole ."</p>
<p>11104,"No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide_mononitrate , carvedilol , ethanol or itraconazole ."</p>
<p>11105,"No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide_mononitrate , carvedilol , ethanol or itraconazole ."</p>
<p>11106,"No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide_mononitrate , carvedilol , ethanol or itraconazole ."</p>
<p>11107,"No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide_mononitrate , carvedilol , ethanol or itraconazole ."</p>
<p>11108,"No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide_mononitrate , carvedilol , ethanol or itraconazole ."</p>
<p>11109,"No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide_mononitrate , carvedilol , ethanol or itraconazole ."</p>
<p>11110,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11111,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11112,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11113,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11114,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11115,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11116,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11117,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11118,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11119,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11120,"Levothyroxine_Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine_sodium from the gastrointestinal tract: aluminum_hydoxide , cholestyramine resin, colestipol_hydrochloride , ferrous_sulfate , sodium_polystyrene_sulfonate , soybean flour (e,g,, infant formula), sucralfate ."</p>
<p>11121,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11122,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11123,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11124,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11125,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11126,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11127,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11128,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11129,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11130,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11131,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11132,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11133,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11134,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11135,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11136,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11137,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11138,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11139,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11140,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11141,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11142,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11143,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11144,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11145,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11146,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11147,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11148,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11149,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11150,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11151,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11152,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11153,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11154,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11155,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11156,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11157,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11158,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11159,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11160,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11161,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11162,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11163,"Binding to Serum Proteins: The following agents may either inhibit levothyroxine_sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic_hormones , asparaginase , clofibrate , estrogens and estrogen-containing_compounds , 5-fluorouracil , furosemide , glucocorticoids , meclofenamic_acid , mefenamic_acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen ."</p>
<p>11164,"Antidiabetic_Agents ( Insulin , Sulfonylureas ): Requirements for insulin or oral antidiabetic_agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."</p>
<p>11165,Ketamine : Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine_sodium and ketamine .</p>
<p>11166,"Sodium_Iodide (123I and 131I), Sodium_Pertechnetate_Tc99m : Uptake of radiolabeled ions may be decreased."</p>
<p>11167,Somatrem / Somatropin : Excessive concurrent use of thyroid_hormone may accelerate epiphyseal closure.</p>
<p>11168,Somatrem / Somatropin : Excessive concurrent use of thyroid_hormone may accelerate epiphyseal closure.</p>
<p>11169,Somatrem / Somatropin : Excessive concurrent use of thyroid_hormone may accelerate epiphyseal closure.</p>
<p>11170,Untreated hypothyroidism may interfere with the growth response to somatrem or somatropin .</p>
<p>11171,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>11172,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>11173,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>11174,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>11175,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>11176,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>11177,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>11178,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>11179,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>11180,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine .</p>
<p>11181,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine .</p>
<p>11182,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine .</p>
<p>11183,"Concurrent administration of vasopressor_drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type_oxytocic_drugs may cause severe, persistent hypertension or cerebrovascular accidents."</p>
<p>11184,Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular_blocking_agents .</p>
<p>11185,Antagonism between lincomycin and erythromycin in vitro has been demonstrated.</p>
<p>11186,"Therefore, linezolid has the potential for interaction with adrenergic and serotonergic_agents ."</p>
<p>11187,"Therefore, linezolid has the potential for interaction with adrenergic and serotonergic_agents ."</p>
<p>11188,"Therefore, linezolid has the potential for interaction with adrenergic and serotonergic_agents ."</p>
<p>11189,"Adrenergic_Agents :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , vasopressor or dopaminergic_agents ."</p>
<p>11190,"Adrenergic_Agents :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , vasopressor or dopaminergic_agents ."</p>
<p>11191,"Adrenergic_Agents :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , vasopressor or dopaminergic_agents ."</p>
<p>11192,"Adrenergic_Agents :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , vasopressor or dopaminergic_agents ."</p>
<p>11193,"Adrenergic_Agents :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , vasopressor or dopaminergic_agents ."</p>
<p>11194,"Adrenergic_Agents :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , vasopressor or dopaminergic_agents ."</p>
<p>11195,"Adrenergic_Agents :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , vasopressor or dopaminergic_agents ."</p>
<p>11196,"Adrenergic_Agents :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , vasopressor or dopaminergic_agents ."</p>
<p>11197,"Adrenergic_Agents :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , vasopressor or dopaminergic_agents ."</p>
<p>11198,Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied.</p>
<p>11199,"Initial doses of adrenergic_agents , such as dopamine or epinephrine , should be reduced and titrated to achieve the desired response."</p>
<p>11200,"Initial doses of adrenergic_agents , such as dopamine or epinephrine , should be reduced and titrated to achieve the desired response."</p>
<p>11201,"Initial doses of adrenergic_agents , such as dopamine or epinephrine , should be reduced and titrated to achieve the desired response."</p>
<p>11202,"Serotonergic_Agents : Co-administration of linezolid and serotonergic_agents was not associated with serotonin syndrome in Phase 1, # or # studies."</p>
<p>11203,"Serotonergic_Agents : Co-administration of linezolid and serotonergic_agents was not associated with serotonin syndrome in Phase 1, # or # studies."</p>
<p>11204,"Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic_agents , including antidepressants such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported."</p>
<p>11205,"Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic_agents , including antidepressants such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported."</p>
<p>11206,"Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic_agents , including antidepressants such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported."</p>
<p>11207,"Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic_agents , including antidepressants such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported."</p>
<p>11208,"Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic_agents , including antidepressants such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported."</p>
<p>11209,"Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic_agents , including antidepressants such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported."</p>
<p>11210,"Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic_agents , including antidepressants such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported."</p>
<p>11211,"Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic_agents , including antidepressants such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported."</p>
<p>11212,"Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic_agents , including antidepressants such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported."</p>
<p>11213,"Patients who are treated with ZYVOX and concomitant serotonergic_agents should be closely observed for signs and symptoms of serotonin syndrome (e,g,, cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination)."</p>
<p>11214,Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.</p>
<p>11215,Insulin or Oral Hypoglycemics : Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.</p>
<p>11216,Insulin or Oral Hypoglycemics : Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.</p>
<p>11217,Insulin or Oral Hypoglycemics : Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.</p>
<p>11218,Insulin or Oral Hypoglycemics : Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.</p>
<p>11219,Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.</p>
<p>11220,"Cholestyramine : Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid_hormones ."</p>
<p>11221,"Cholestyramine : Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid_hormones ."</p>
<p>11222,"Cholestyramine : Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid_hormones ."</p>
<p>11223,"Cholestyramine : Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid_hormones ."</p>
<p>11224,"Cholestyramine : Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid_hormones ."</p>
<p>11225,"Cholestyramine : Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid_hormones ."</p>
<p>11226,"Therefore, # to # hours should elapse between administration of cholestyramine and thyroid_hormones ."</p>
<p>11227,"Estrogen , Oral Contraceptives : Estrogens tend to increase serum thyroxine-binding globulin (TBg)."</p>
<p>11228,"In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements."</p>
<p>11229,"In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements."</p>
<p>11230,"In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements."</p>
<p>11231,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen -containing oral contraceptives are given."</p>
<p>11232,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen -containing oral contraceptives are given."</p>
<p>11233,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen -containing oral contraceptives are given."</p>
<p>11234,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen -containing oral contraceptives are given."</p>
<p>11235,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen -containing oral contraceptives are given."</p>
<p>11236,Tricyclic_Antidepressants : Use of thyroid_products with imipramine and other tricyclic_antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.</p>
<p>11237,Tricyclic_Antidepressants : Use of thyroid_products with imipramine and other tricyclic_antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.</p>
<p>11238,Tricyclic_Antidepressants : Use of thyroid_products with imipramine and other tricyclic_antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.</p>
<p>11239,Tricyclic_Antidepressants : Use of thyroid_products with imipramine and other tricyclic_antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.</p>
<p>11240,Tricyclic_Antidepressants : Use of thyroid_products with imipramine and other tricyclic_antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.</p>
<p>11241,Digitalis : Thyroid_preparations may potentiate the toxic effects of digitalis .</p>
<p>11242,"Ketamine : When administered to patients on a thyroid_preparation , this parenteral anesthetic may cause hypertension and tachycardia."</p>
<p>11243,Vasopressor s: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine .</p>
<p>11244,Vasopressor s: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine .</p>
<p>11245,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11246,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11247,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11248,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11249,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11250,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11251,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11252,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11253,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11254,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11255,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11256,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11257,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11258,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11259,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11260,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11261,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11262,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11263,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11264,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11265,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11266,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11267,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11268,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11269,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11270,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid_hormone therapy: androgens , corticosteroids , estrogens , oral contraceptives containing estrogens , iodine -containing preparations and the numerous preparations containing salicylates ."</p>
<p>11271,Pregnancy estrogens and estrogen -containing oral contraceptives increase TBg concentrations.</p>
<p>11272,Pregnancy estrogens and estrogen -containing oral contraceptives increase TBg concentrations.</p>
<p>11273,"Decreases in TBg concentrations are observed in nephrosis, acromegaly and after androgen or corticosteroid therapy."</p>
<p>11274,"Urinary acidifying agents These agents ( ammonium_chloride , sodium_acid_phosphate , etc,) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion."</p>
<p>11275,"Urinary acidifying agents These agents ( ammonium_chloride , sodium_acid_phosphate , etc,) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion."</p>
<p>11276,Adrenergic_blockers  Adrenergic_blockers are inhibited by amphetamines .</p>
<p>11277,Adrenergic_blockers  Adrenergic_blockers are inhibited by amphetamines .</p>
<p>11278,"Antidepressants , tricyclic  Amphetamines may enhance the activity of tricyclic_antidepressants or sympathomimetic_agents ;"</p>
<p>11279,"Antidepressants , tricyclic  Amphetamines may enhance the activity of tricyclic_antidepressants or sympathomimetic_agents ;"</p>
<p>11280,"Antidepressants , tricyclic  Amphetamines may enhance the activity of tricyclic_antidepressants or sympathomimetic_agents ;"</p>
<p>11281,"Antidepressants , tricyclic  Amphetamines may enhance the activity of tricyclic_antidepressants or sympathomimetic_agents ;"</p>
<p>11282,"Antidepressants , tricyclic  Amphetamines may enhance the activity of tricyclic_antidepressants or sympathomimetic_agents ;"</p>
<p>11283,"Antidepressants , tricyclic  Amphetamines may enhance the activity of tricyclic_antidepressants or sympathomimetic_agents ;"</p>
<p>11284,"Antidepressants , tricyclic  Amphetamines may enhance the activity of tricyclic_antidepressants or sympathomimetic_agents ;"</p>
<p>11285,"Antidepressants , tricyclic  Amphetamines may enhance the activity of tricyclic_antidepressants or sympathomimetic_agents ;"</p>
<p>11286,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>11287,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>11288,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>11289,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>11290,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>11291,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>11292,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>11293,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>11294,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>11295,"MAO_inhibitors  MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>11296,"MAO_inhibitors  MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>11297,"MAO_inhibitors  MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>11298,"MAO_inhibitors  MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>11299,"MAO_inhibitors  MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>11300,"MAO_inhibitors  MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>11301,Antihistamines : Amphetamines may counteract the sedative effect of antihistamines .</p>
<p>11302,Antihypertensives : Amphetamines may antagonize the hypotensive effects of antihypertensives .</p>
<p>11303,"Chlorpromazine : Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning."</p>
<p>11304,"Chlorpromazine : Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning."</p>
<p>11305,Ethosuximide : Amphetamines may delay intestinal absorption of ethosuximide .</p>
<p>11306,"Haloperidol : Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines ."</p>
<p>11307,"Haloperidol : Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines ."</p>
<p>11308,Lithium_carbonate : The anorectic and stimulatory effects of amphetamines may be inhibited by lithium_carbonate .</p>
<p>11309,Meperidine : Amphetamines potentiate the analgesic effect of meperidine .</p>
<p>11310,"Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy."</p>
<p>11311,"Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy."</p>
<p>11312,Norepinephrine : Amphetamines enhance the adrenergic effect of norepinephrine .</p>
<p>11313,Phenobarbital : Amphetamines may delay intestinal absorption of phenobarbital ;</p>
<p>11314,Phenytoin : Amphetamines may delay intestinal absorption of phenytoin ;</p>
<p>11315,"Propoxyphene : In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur."</p>
<p>11316,Veratrum_alkaloids : Amphetamines inhibit the hypotensive effect of veratrum_alkaloids .</p>
<p>11317,"Hypotension - Patients on Diuretic Therapy: Patients on diuretics , and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL ."</p>
<p>11318,The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL .</p>
<p>11319,The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL .</p>
<p>11320,"If it is necessary to continue the diuretic , initiate therapy with PRINIVIL at a dose of # mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized."</p>
<p>11321,"When a diuretic is added to the therapy of a patient receiving PRINIVIL , an additional antihypertensive effect is usually observed."</p>
<p>11322,Studies with ACE_inhibitors in combination with diuretics indicate that the dose of the ACE_inhibitor can be reduced when it is given with a diuretic .</p>
<p>11323,Studies with ACE_inhibitors in combination with diuretics indicate that the dose of the ACE_inhibitor can be reduced when it is given with a diuretic .</p>
<p>11324,Studies with ACE_inhibitors in combination with diuretics indicate that the dose of the ACE_inhibitor can be reduced when it is given with a diuretic .</p>
<p>11325,Studies with ACE_inhibitors in combination with diuretics indicate that the dose of the ACE_inhibitor can be reduced when it is given with a diuretic .</p>
<p>11326,"Non-steroidal_Anti-inflammatory_Agents : In some patients with compromised renal function who are being treated with non-steroidal_anti-inflammatory_drugs , the co-administration of lisinopril may result in a further deterioration of renal function."</p>
<p>11327,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE_inhibitors , including lisinopril ."</p>
<p>11328,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE_inhibitors , including lisinopril ."</p>
<p>11329,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE_inhibitors , including lisinopril ."</p>
<p>11330,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE_inhibitors .</p>
<p>11331,"In a study in # patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin , the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant."</p>
<p>11332,"In a study in # patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin , the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant."</p>
<p>11333,"In a study in # patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin , the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant."</p>
<p>11334,"In a study in # patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin , the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant."</p>
<p>11335,Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.</p>
<p>11336,Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.</p>
<p>11337,Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.</p>
<p>11338,No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide .</p>
<p>11339,No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide .</p>
<p>11340,No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide .</p>
<p>11341,Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type_diuretics .</p>
<p>11342,"Use of PRINIVIL with potassium-sparing_diuretics (e,g,, spironolactone , triamterene , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium."</p>
<p>11343,"Use of PRINIVIL with potassium-sparing_diuretics (e,g,, spironolactone , triamterene , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium."</p>
<p>11344,"Use of PRINIVIL with potassium-sparing_diuretics (e,g,, spironolactone , triamterene , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium."</p>
<p>11345,"Use of PRINIVIL with potassium-sparing_diuretics (e,g,, spironolactone , triamterene , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium."</p>
<p>11346,"Use of PRINIVIL with potassium-sparing_diuretics (e,g,, spironolactone , triamterene , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium."</p>
<p>11347,"Use of PRINIVIL with potassium-sparing_diuretics (e,g,, spironolactone , triamterene , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium."</p>
<p>11348,"Use of PRINIVIL with potassium-sparing_diuretics (e,g,, spironolactone , triamterene , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium."</p>
<p>11349,"Use of PRINIVIL with potassium-sparing_diuretics (e,g,, spironolactone , triamterene , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium."</p>
<p>11350,"Lithium : Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE_inhibitors ."</p>
<p>11351,"Lithium : Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE_inhibitors ."</p>
<p>11352,Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE_inhibitor .</p>
<p>11353,Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE_inhibitor .</p>
<p>11354,It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium .</p>
<p>11355,It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium .</p>
<p>11356,"- Lofexidine may enhance the CNS depressive effects of alcohol , barbiturates and other sedatives"</p>
<p>11357,"- Lofexidine may enhance the CNS depressive effects of alcohol , barbiturates and other sedatives"</p>
<p>11358,"- Lofexidine may enhance the CNS depressive effects of alcohol , barbiturates and other sedatives"</p>
<p>11359,- Lofexidine may enhance the effects of anti-hypertensive_drug therapy</p>
<p>11360,- Concomitant use of tricyclic_antidepressants may reduce the efficacy of lofexidine .</p>
<p>11361,"Theophylline : In three pharmacokinetic studies including # normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of lomefloxacin ."</p>
<p>11362,"In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance."</p>
<p>11363,"In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance."</p>
<p>11364,"In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance."</p>
<p>11365,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11366,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11367,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11368,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11369,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11370,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11371,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11372,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11373,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11374,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11375,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11376,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11377,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11378,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11379,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11380,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11381,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11382,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11383,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11384,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11385,"Antacids and sucralfate : Sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as Videx  ( didanosine ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability."</p>
<p>11386,Sucralfate administered # hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by # hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).</p>
<p>11387,"Magnesium - and aluminum -containing antacids , administered concomitantly with lomefloxacin , significantly decreased the bioavailability (48%) of lomefloxacin ."</p>
<p>11388,"Magnesium - and aluminum -containing antacids , administered concomitantly with lomefloxacin , significantly decreased the bioavailability (48%) of lomefloxacin ."</p>
<p>11389,"Magnesium - and aluminum -containing antacids , administered concomitantly with lomefloxacin , significantly decreased the bioavailability (48%) of lomefloxacin ."</p>
<p>11390,"Magnesium - and aluminum -containing antacids , administered concomitantly with lomefloxacin , significantly decreased the bioavailability (48%) of lomefloxacin ."</p>
<p>11391,"Magnesium - and aluminum -containing antacids , administered concomitantly with lomefloxacin , significantly decreased the bioavailability (48%) of lomefloxacin ."</p>
<p>11392,"Magnesium - and aluminum -containing antacids , administered concomitantly with lomefloxacin , significantly decreased the bioavailability (48%) of lomefloxacin ."</p>
<p>11393,"Magnesium - and aluminum -containing antacids , administered concomitantly with lomefloxacin , significantly decreased the bioavailability (48%) of lomefloxacin ."</p>
<p>11394,"Magnesium - and aluminum -containing antacids , administered concomitantly with lomefloxacin , significantly decreased the bioavailability (48%) of lomefloxacin ."</p>
<p>11395,"Magnesium - and aluminum -containing antacids , administered concomitantly with lomefloxacin , significantly decreased the bioavailability (48%) of lomefloxacin ."</p>
<p>11396,Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;</p>
<p>11397,"Caffeine : Two hundred mg of caffeine (equivalent to # to # cups of American coffee) was administered to # normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at # mg qd."</p>
<p>11398,"This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either caffeine or its major metabolite, paraxanthine ."</p>
<p>11399,"Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine , resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine ."</p>
<p>11400,"Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine , resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine ."</p>
<p>11401,Cimetidine : Cimetidine has been demonstrated to interfere with the elimination of other quinolones .</p>
<p>11402,The interaction between lomefloxacin and cimetidine has not been studied.</p>
<p>11403,Cyclosporine : Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone_class .</p>
<p>11404,Cyclosporine : Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone_class .</p>
<p>11405,Cyclosporine : Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone_class .</p>
<p>11406,Interaction between lomefloxacin and cyclosporine has not been studied.</p>
<p>11407,"Omeprazole : No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin # mg was given after multiple doses of omeprazole (20 mg qd) in # healthy volunteers."</p>
<p>11408,"Omeprazole : No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin # mg was given after multiple doses of omeprazole (20 mg qd) in # healthy volunteers."</p>
<p>11409,"Phenytoin : No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin_sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in # healthy males."</p>
<p>11410,"Phenytoin : No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin_sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in # healthy males."</p>
<p>11411,Lomefloxacin is unlikely to have a significant effect on phenytoin metabolism.</p>
<p>11412,"Terfenadine : No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in # healthy males."</p>
<p>11413,"Terfenadine : No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in # healthy males."</p>
<p>11414,"Terfenadine : No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in # healthy males."</p>
<p>11415,"Terfenadine : No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in # healthy males."</p>
<p>11416,"Warfarin : Quinolones may enhance the effects of the oral anticoagulant , warfarin , or its derivatives."</p>
<p>11417,"Warfarin : Quinolones may enhance the effects of the oral anticoagulant , warfarin , or its derivatives."</p>
<p>11418,"Warfarin : Quinolones may enhance the effects of the oral anticoagulant , warfarin , or its derivatives."</p>
<p>11419,"However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of # healthy males who received both warfarin and lomefloxacin under steady-state conditions."</p>
<p>11420,"However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of # healthy males who received both warfarin and lomefloxacin under steady-state conditions."</p>
<p>11421,"Probenecid : As with other b-lactam_antibiotics , renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef ."</p>
<p>11422,"Probenecid : As with other b-lactam_antibiotics , renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef ."</p>
<p>11423,"Probenecid : As with other b-lactam_antibiotics , renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef ."</p>
<p>11424,"Probenecid : As with other b-lactam_antibiotics , renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef ."</p>
<p>11425,"Probenecid : As with other b-lactam_antibiotics , renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef ."</p>
<p>11426,"Probenecid : As with other b-lactam_antibiotics , renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef ."</p>
<p>11427,"Probenecid : As with other b-lactam_antibiotics , renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef ."</p>
<p>11428,"Probenecid : As with other b-lactam_antibiotics , renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef ."</p>
<p>11429,"Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin , cimetidine , and ketoconazole in controlled clinical pharmacology studies in adult volunteers."</p>
<p>11430,"Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin , cimetidine , and ketoconazole in controlled clinical pharmacology studies in adult volunteers."</p>
<p>11431,"Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin , cimetidine , and ketoconazole in controlled clinical pharmacology studies in adult volunteers."</p>
<p>11432,No effects on plasma concentrations of cimetidine or ketoconazole were observed.</p>
<p>11433,Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.</p>
<p>11434,Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.</p>
<p>11435,There does not appear to be an increase in adverse events in subjects who received oral contraceptives and loratadine .</p>
<p>11436,"Tablets: The benzodiazepines , including lorazepam , produce CNS-depressant effects when administered with such medications as barbiturates or alcohol ."</p>
<p>11437,"Tablets: The benzodiazepines , including lorazepam , produce CNS-depressant effects when administered with such medications as barbiturates or alcohol ."</p>
<p>11438,"Tablets: The benzodiazepines , including lorazepam , produce CNS-depressant effects when administered with such medications as barbiturates or alcohol ."</p>
<p>11439,"Tablets: The benzodiazepines , including lorazepam , produce CNS-depressant effects when administered with such medications as barbiturates or alcohol ."</p>
<p>11440,"Tablets: The benzodiazepines , including lorazepam , produce CNS-depressant effects when administered with such medications as barbiturates or alcohol ."</p>
<p>11441,"Tablets: The benzodiazepines , including lorazepam , produce CNS-depressant effects when administered with such medications as barbiturates or alcohol ."</p>
<p>11442,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11443,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11444,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11445,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11446,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11447,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11448,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11449,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11450,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11451,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11452,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11453,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11454,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11455,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11456,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11457,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11458,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11459,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11460,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11461,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11462,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11463,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11464,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11465,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11466,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11467,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11468,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11469,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11470,"Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed."</p>
<p>11471,"Rifampin , an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite."</p>
<p>11472,"Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan , and erythromycin had no clinically significant effect after oral administration."</p>
<p>11473,"Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan , and erythromycin had no clinically significant effect after oral administration."</p>
<p>11474,"Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan , and erythromycin had no clinically significant effect after oral administration."</p>
<p>11475,"Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan , and erythromycin had no clinically significant effect after oral administration."</p>
<p>11476,"Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan , and erythromycin had no clinically significant effect after oral administration."</p>
<p>11477,"Fluconazole , an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration."</p>
<p>11478,"As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing_diuretics (e,g,, spironolactone , triamterene , amiloride ), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium."</p>
<p>11479,"As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing_diuretics (e,g,, spironolactone , triamterene , amiloride ), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium."</p>
<p>11480,"As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing_diuretics (e,g,, spironolactone , triamterene , amiloride ), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium."</p>
<p>11481,"As with other antihypertensive_agents , the antihypertensive effect of losartan may be blunted by the non-steroidal_anti-inflammatory_drug  indomethacin"</p>
<p>11482,"As with other antihypertensive_agents , the antihypertensive effect of losartan may be blunted by the non-steroidal_anti-inflammatory_drug  indomethacin"</p>
<p>11483,"As with other antihypertensive_agents , the antihypertensive effect of losartan may be blunted by the non-steroidal_anti-inflammatory_drug  indomethacin"</p>
<p>11484,"As with other antihypertensive_agents , the antihypertensive effect of losartan may be blunted by the non-steroidal_anti-inflammatory_drug  indomethacin"</p>
<p>11485,"As with other antihypertensive_agents , the antihypertensive effect of losartan may be blunted by the non-steroidal_anti-inflammatory_drug  indomethacin"</p>
<p>11486,"As with other antihypertensive_agents , the antihypertensive effect of losartan may be blunted by the non-steroidal_anti-inflammatory_drug  indomethacin"</p>
<p>11487,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11488,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11489,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11490,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11491,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11492,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11493,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11494,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11495,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11496,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11497,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11498,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11499,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11500,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11501,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11502,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11503,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11504,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11505,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11506,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11507,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11508,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11509,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11510,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11511,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11512,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11513,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11514,Itraconazole  Ketoconazole  Erythromycin  Clarithromycin  Telithromycin  HIV_protease_inhibitors  Nefazodone  Cyclosporine Large quantities of grapefruit juice ( # quart daily)</p>
<p>11515,Gemfibrozil Other fibrates  Niacin ( nicotinic_acid ) (=1 g/day)</p>
<p>11516,Gemfibrozil Other fibrates  Niacin ( nicotinic_acid ) (=1 g/day)</p>
<p>11517,Gemfibrozil Other fibrates  Niacin ( nicotinic_acid ) (=1 g/day)</p>
<p>11518,Gemfibrozil Other fibrates  Niacin ( nicotinic_acid ) (=1 g/day)</p>
<p>11519,Gemfibrozil Other fibrates  Niacin ( nicotinic_acid ) (=1 g/day)</p>
<p>11520,"Danazol : The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis)."</p>
<p>11521,"Amiodarone or Verapamil : The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA_reductase_inhibitor_class (see WARNINGS, Myopathy/Rhabdomyolysis)."</p>
<p>11522,"Amiodarone or Verapamil : The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA_reductase_inhibitor_class (see WARNINGS, Myopathy/Rhabdomyolysis)."</p>
<p>11523,"Amiodarone or Verapamil : The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA_reductase_inhibitor_class (see WARNINGS, Myopathy/Rhabdomyolysis)."</p>
<p>11524,"Amiodarone or Verapamil : The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA_reductase_inhibitor_class (see WARNINGS, Myopathy/Rhabdomyolysis)."</p>
<p>11525,"Coumarin_Anticoagulant s: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected."</p>
<p>11526,"However, another HMG-CoA_reductase_inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin ."</p>
<p>11527,"Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin_anticoagulant s concomitantly with lovastatin ."</p>
<p>11528,"It is recommended that in patients taking anticoagulants , prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs."</p>
<p>11529,Lovastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants .</p>
<p>11530,"Propranolol : In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol ."</p>
<p>11531,"Propranolol : In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol ."</p>
<p>11532,"Digoxin : In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations."</p>
<p>11533,"Digoxin : In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations."</p>
<p>11534,"Digoxin : In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations."</p>
<p>11535,"Oral Hypoglycemic_Agents : In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide"</p>
<p>11536,"Oral Hypoglycemic_Agents : In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide"</p>
<p>11537,"Oral Hypoglycemic_Agents : In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide"</p>
<p>11538,"There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam ."</p>
<p>11539,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements."</p>
<p>11540,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements."</p>
<p>11541,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements."</p>
<p>11542,Oral contraceptives may be less effective while you are taking lymecycline .</p>
<p>11543,Warfarin : Meclofenamate_sodium enhances the effect of warfarin .</p>
<p>11544,"Therefore, when meclofenamate_sodium is given to a patient receiving warfarin , the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time."</p>
<p>11545,"Therefore, when meclofenamate_sodium is given to a patient receiving warfarin , the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time."</p>
<p>11546,"Aspirin : Concurrent administration of aspirin may lower meclofenamate_sodium plasma levels, possibly by competing for protein-binding sites."</p>
<p>11547,"Aspirin : Concurrent administration of aspirin may lower meclofenamate_sodium plasma levels, possibly by competing for protein-binding sites."</p>
<p>11548,"The urinary excretion of meclofenamate_sodium is unaffected by aspirin , indicating no change in meclofenamate_sodium absorption."</p>
<p>11549,"The urinary excretion of meclofenamate_sodium is unaffected by aspirin , indicating no change in meclofenamate_sodium absorption."</p>
<p>11550,Meclofenamate_sodium does not affect serum salicylate levels.</p>
<p>11551,Propoxyphene : The concurrent administration of propoxyphene_hydrochloride does not affect the bioavailability of meclofenamate_sodium .</p>
<p>11552,Antacids : Concomitant administration of aluminum_hydroxide s and magnesium_hydroxide s does not interfere with absorption of meclofenamate_sodium .</p>
<p>11553,Antacids : Concomitant administration of aluminum_hydroxide s and magnesium_hydroxide s does not interfere with absorption of meclofenamate_sodium .</p>
<p>11554,Antacids : Concomitant administration of aluminum_hydroxide s and magnesium_hydroxide s does not interfere with absorption of meclofenamate_sodium .</p>
<p>11555,Antacids : Concomitant administration of aluminum_hydroxide s and magnesium_hydroxide s does not interfere with absorption of meclofenamate_sodium .</p>
<p>11556,Antacids : Concomitant administration of aluminum_hydroxide s and magnesium_hydroxide s does not interfere with absorption of meclofenamate_sodium .</p>
<p>11557,Antacids : Concomitant administration of aluminum_hydroxide s and magnesium_hydroxide s does not interfere with absorption of meclofenamate_sodium .</p>
<p>11558,"Aspirin : As with other NSAIDs , concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects."</p>
<p>11559,"Aspirin : As with other NSAIDs , concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects."</p>
<p>11560,"Aspirin : As with other NSAIDs , concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects."</p>
<p>11561,"Aspirin : As with other NSAIDs , concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects."</p>
<p>11562,"Aspirin : As with other NSAIDs , concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects."</p>
<p>11563,Methotrexate : NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.</p>
<p>11564,Caution should be used when NSAIDs are administered concomitantly with methotrexate .</p>
<p>11565,ACE_inhibitors : Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE_inhibitors .</p>
<p>11566,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE_inhibitors .</p>
<p>11567,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>11568,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>11569,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>11570,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>11571,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>11572,"During concomitant therapy of Ponstel with furosemide , the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy."</p>
<p>11573,Lithium : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.</p>
<p>11574,Lithium : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.</p>
<p>11575,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."</p>
<p>11576,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."</p>
<p>11577,"Warfarin : The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."</p>
<p>11578,"Antacids : In a single dose study (n=6), ingestion of an antacid containing #-gram of magnesium_hydroxide with 500-mg of mefenamic_acid increased the Cmax and AUC of mefenamic_acid by 125% and 36%, respectively, A number of compounds are inhibitors of CYP2C9 including fluconazole , lovastatin and trimethoprim ."</p>
<p>11579,"Antacids : In a single dose study (n=6), ingestion of an antacid containing #-gram of magnesium_hydroxide with 500-mg of mefenamic_acid increased the Cmax and AUC of mefenamic_acid by 125% and 36%, respectively, A number of compounds are inhibitors of CYP2C9 including fluconazole , lovastatin and trimethoprim ."</p>
<p>11580,"Antacids : In a single dose study (n=6), ingestion of an antacid containing #-gram of magnesium_hydroxide with 500-mg of mefenamic_acid increased the Cmax and AUC of mefenamic_acid by 125% and 36%, respectively, A number of compounds are inhibitors of CYP2C9 including fluconazole , lovastatin and trimethoprim ."</p>
<p>11581,"Antacids : In a single dose study (n=6), ingestion of an antacid containing #-gram of magnesium_hydroxide with 500-mg of mefenamic_acid increased the Cmax and AUC of mefenamic_acid by 125% and 36%, respectively, A number of compounds are inhibitors of CYP2C9 including fluconazole , lovastatin and trimethoprim ."</p>
<p>11582,"Antacids : In a single dose study (n=6), ingestion of an antacid containing #-gram of magnesium_hydroxide with 500-mg of mefenamic_acid increased the Cmax and AUC of mefenamic_acid by 125% and 36%, respectively, A number of compounds are inhibitors of CYP2C9 including fluconazole , lovastatin and trimethoprim ."</p>
<p>11583,"Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine ."</p>
<p>11584,"Concomitant administration of Mefloquine and other related compounds (eg, quinine , quinidine and chloroquine ) may produce electrocardiographic abnormalities and increase the risk of convulsions."</p>
<p>11585,"Concomitant administration of Mefloquine and other related compounds (eg, quinine , quinidine and chloroquine ) may produce electrocardiographic abnormalities and increase the risk of convulsions."</p>
<p>11586,"Concomitant administration of Mefloquine and other related compounds (eg, quinine , quinidine and chloroquine ) may produce electrocardiographic abnormalities and increase the risk of convulsions."</p>
<p>11587,"This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval."</p>
<p>11588,"This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval."</p>
<p>11589,"This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval."</p>
<p>11590,"This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval."</p>
<p>11591,"This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval."</p>
<p>11592,"This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval."</p>
<p>11593,"This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval."</p>
<p>11594,"In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant ."</p>
<p>11595,"In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant ."</p>
<p>11596,"In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant ."</p>
<p>11597,"In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant ."</p>
<p>11598,"In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant ."</p>
<p>11599,"In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant ."</p>
<p>11600,"In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant ."</p>
<p>11601,"In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant ."</p>
<p>11602,"In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant ."</p>
<p>11603,"In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant ."</p>
<p>11604,"When Mefloquine is taken concurrently with oral live_typhoid_vaccines , attenuation of immunization cannot be excluded."</p>
<p>11605,"Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants , should be checked before departure."</p>
<p>11606,"In clinical trials, the concomitant administration of sulfadoxine and pyrimethamine did not alter the adverse reaction profile."</p>
<p>11607,Broad-Spectrum_Antibiotics - Broad-spectrum_antibiotics may sterilize the bowel and decrease the vitamin_K contribution to the body by the intestinal microflora.</p>
<p>11608,Broad-Spectrum_Antibiotics - Broad-spectrum_antibiotics may sterilize the bowel and decrease the vitamin_K contribution to the body by the intestinal microflora.</p>
<p>11609,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11610,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11611,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11612,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11613,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11614,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11615,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11616,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11617,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11618,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11619,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11620,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11621,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11622,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11623,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11624,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11625,"Cephalosporins - Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia."</p>
<p>11626,Cholestyramine -Concomitant intake of cholestyramine and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11627,Cholestyramine -Concomitant intake of cholestyramine and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11628,Cholestyramine -Concomitant intake of cholestyramine and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11629,Cholestyramine -Concomitant intake of cholestyramine and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11630,Colestipol -Concomitant intake of colestipol and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11631,Colestipol -Concomitant intake of colestipol and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11632,Colestipol -Concomitant intake of colestipol and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11633,Colestipol -Concomitant intake of colestipol and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11634,Mineral_Oil -Concomitant intake of mineral_oil and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11635,Mineral_Oil -Concomitant intake of mineral_oil and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11636,Mineral_Oil -Concomitant intake of mineral_oil and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11637,Mineral_Oil -Concomitant intake of mineral_oil and vitamin_K may reduce the absorption of vitamin_K .</p>
<p>11638,Orlistat - Orlistat may decrease the absorption of vitamin_K .</p>
<p>11639,Orlistat - Orlistat may decrease the absorption of vitamin_K .</p>
<p>11640,Warfarin - Vitamin_K can antagonize the effect of warfarin</p>
<p>11641,Warfarin - Vitamin_K can antagonize the effect of warfarin</p>
<p>11642,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11643,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11644,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11645,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11646,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11647,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11648,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11649,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11650,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11651,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11652,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11653,"Nabilone should be administered with caution to patients who are taking other psychoactive_drugs or CNS_depressants , including alcohol , barbiturates and narcotic_analgesics , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia)."</p>
<p>11654,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam , secobarbitone_sodium , alcohol or codeine ."</p>
<p>11655,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam , secobarbitone_sodium , alcohol or codeine ."</p>
<p>11656,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam , secobarbitone_sodium , alcohol or codeine ."</p>
<p>11657,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam , secobarbitone_sodium , alcohol or codeine ."</p>
<p>11658,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs .</p>
<p>11659,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs .</p>
<p>11660,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs .</p>
<p>11661,Concomitant administration of an aluminum -containing antacid had no significant effect in the bioavailability of 6MNA .</p>
<p>11662,Concomitant administration of an aluminum -containing antacid had no significant effect in the bioavailability of 6MNA .</p>
<p>11663,Concomitant administration of an aluminum -containing antacid had no significant effect in the bioavailability of 6MNA .</p>
<p>11664,"When administered concurrently, the following drugs may interact with beta-adrenergic_receptor_blocking_agents : Anesthetics , general: exaggeration of the hypotension induced by general anesthetics ."</p>
<p>11665,"When administered concurrently, the following drugs may interact with beta-adrenergic_receptor_blocking_agents : Anesthetics , general: exaggeration of the hypotension induced by general anesthetics ."</p>
<p>11666,"Tetracycline , a bacteriostatic_antibiotic , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided."</p>
<p>11667,"Tetracycline , a bacteriostatic_antibiotic , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided."</p>
<p>11668,"Tetracycline , a bacteriostatic_antibiotic , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided."</p>
<p>11669,Elevated plasma levels of theophylline have been reported with concomitant quinolone use.</p>
<p>11670,There have been reports of theophylline -related side effects in patients on concomitant therapy with quinolones and theophylline .</p>
<p>11671,There have been reports of theophylline -related side effects in patients on concomitant therapy with quinolones and theophylline .</p>
<p>11672,Quinolones have been shown to interfere with the metabolism of caffeine .</p>
<p>11673,"Quinolones , including nalidixic_acid , may enhance the effects of the oral anticoagulant  warfarin or its derivatives."</p>
<p>11674,"Quinolones , including nalidixic_acid , may enhance the effects of the oral anticoagulant  warfarin or its derivatives."</p>
<p>11675,"Quinolones , including nalidixic_acid , may enhance the effects of the oral anticoagulant  warfarin or its derivatives."</p>
<p>11676,"Quinolones , including nalidixic_acid , may enhance the effects of the oral anticoagulant  warfarin or its derivatives."</p>
<p>11677,"Quinolones , including nalidixic_acid , may enhance the effects of the oral anticoagulant  warfarin or its derivatives."</p>
<p>11678,"Quinolones , including nalidixic_acid , may enhance the effects of the oral anticoagulant  warfarin or its derivatives."</p>
<p>11679,Nitrofurantoin interferes with the therapeutic action of nalidixic_acid .</p>
<p>11680,"Antacids containing magnesium , aluminum , or calcium ;"</p>
<p>11681,"Antacids containing magnesium , aluminum , or calcium ;"</p>
<p>11682,"Antacids containing magnesium , aluminum , or calcium ;"</p>
<p>11683,sucralfate or divalent or trivalent cations such as iron ;</p>
<p>11684,multivitamins containing zinc ;</p>
<p>11685,"and Videx , ( Didanosine ), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones , resulting in systemic levels considerably lower than desired."</p>
<p>11686,"and Videx , ( Didanosine ), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones , resulting in systemic levels considerably lower than desired."</p>
<p>11687,"and Videx , ( Didanosine ), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones , resulting in systemic levels considerably lower than desired."</p>
<p>11688,Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine .</p>
<p>11689,Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine .</p>
<p>11690,Studies to evaluate possible interactions between REVIA and drugs other than opiates have not been performed.</p>
<p>11691,"The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks."</p>
<p>11692,Lethargy and somnolence have been reported following doses of REVIA and thioridazine .</p>
<p>11693,"Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid_analgesics ."</p>
<p>11694,"Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid_analgesics ."</p>
<p>11695,"In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA , the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged."</p>
<p>11696,The use of NSAIDs in patients who are receiving ACE_inhibitors may potentiate renal disease states.</p>
<p>11697,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations and peak plasma levels."</p>
<p>11698,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations and peak plasma levels."</p>
<p>11699,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations and peak plasma levels."</p>
<p>11700,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations and peak plasma levels."</p>
<p>11701,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers .</p>
<p>11702,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers .</p>
<p>11703,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers .</p>
<p>11704,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers .</p>
<p>11705,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers .</p>
<p>11706,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers .</p>
<p>11707,Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.</p>
<p>11708,Caution should be used if naproxen is administered concomitantly with methotrexate .</p>
<p>11709,"Naproxen , naproxen_sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate ."</p>
<p>11710,"Naproxen , naproxen_sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate ."</p>
<p>11711,"Naproxen , naproxen_sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate ."</p>
<p>11712,"Naproxen , naproxen_sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate ."</p>
<p>11713,"Naproxen , naproxen_sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate ."</p>
<p>11714,"Naproxen , naproxen_sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate ."</p>
<p>11715,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and naratriptan within # hours is contraindicated."</p>
<p>11716,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and naratriptan within # hours is contraindicated."</p>
<p>11717,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and naratriptan within # hours is contraindicated."</p>
<p>11718,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and naratriptan within # hours is contraindicated."</p>
<p>11719,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and naratriptan within # hours is contraindicated."</p>
<p>11720,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and naratriptan within # hours is contraindicated."</p>
<p>11721,The administration of naratriptan with other 5-HT1_agonists has not been evaluated in migraine patients.</p>
<p>11722,"Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1_agonists within # hours of each other is not recommended."</p>
<p>11723,"If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised."</p>
<p>11724,"After multiple dosing, interferon_beta-1a ( AVONEX  # mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%."</p>
<p>11725,"After multiple dosing, interferon_beta-1a ( AVONEX  # mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%."</p>
<p>11726,"After multiple dosing, interferon_beta-1a ( AVONEX  # mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%."</p>
<p>11727,"The similarity of the TYSABRI -associated adverse event profile between Study # (without co-administered AVONEX ) and Study # (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General)."</p>
<p>11728,"The similarity of the TYSABRI -associated adverse event profile between Study # (without co-administered AVONEX ) and Study # (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General)."</p>
<p>11729,"The similarity of the TYSABRI -associated adverse event profile between Study # (without co-administered AVONEX ) and Study # (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General)."</p>
<p>11730,"The similarity of the TYSABRI -associated adverse event profile between Study # (without co-administered AVONEX ) and Study # (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General)."</p>
<p>11731,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11732,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11733,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11734,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11735,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11736,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11737,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11738,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11739,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11740,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11741,Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon_beta-1a ( AVONEX  # mcg IM once weekly) or glatiramer_acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer_acetate .</p>
<p>11742,Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide .</p>
<p>11743,"Glyburide : In a randomized, multiple-dose crossover study, patients with Type # diabetes were administered # mg Starlix three times a day before meals for # day in combination with glyburide # mg daily."</p>
<p>11744,"Glyburide : In a randomized, multiple-dose crossover study, patients with Type # diabetes were administered # mg Starlix three times a day before meals for # day in combination with glyburide # mg daily."</p>
<p>11745,"Metformin : When Starlix # mg three times daily before meals was administered in combination with metformin # mg three times daily to patients with Type # diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent."</p>
<p>11746,"Digoxin : When Starlix # mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent."</p>
<p>11747,"Warfarin : When healthy subjects were administered Starlix # mg three times daily before meals for four days in combination with a single dose of warfarin # mg on day 2, there were no alterations in the pharmacokinetics of either agent."</p>
<p>11748,Diclofenac : Administration of morning and lunch doses of Starlix # mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.</p>
<p>11749,Diclofenac : Administration of morning and lunch doses of Starlix # mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.</p>
<p>11750,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11751,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11752,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11753,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11754,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11755,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11756,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11757,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11758,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11759,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11760,"In vitro displacement studies with highly protein-bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic_acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding."</p>
<p>11761,"Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic_acid , and tolbutamide in vitro ."</p>
<p>11762,"Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic_acid , and tolbutamide in vitro ."</p>
<p>11763,"Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic_acid , and tolbutamide in vitro ."</p>
<p>11764,"Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic_acid , and tolbutamide in vitro ."</p>
<p>11765,"Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic_acid , and tolbutamide in vitro ."</p>
<p>11766,"Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic_acid , and tolbutamide in vitro ."</p>
<p>11767,"Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic_acid , and tolbutamide in vitro ."</p>
<p>11768,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11769,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11770,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11771,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11772,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11773,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11774,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11775,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11776,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11777,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11778,"Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11779,"Certain drugs including thiazides , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11780,"Certain drugs including thiazides , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11781,"Certain drugs including thiazides , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11782,"Certain drugs including thiazides , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11783,"Certain drugs including thiazides , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11784,"Certain drugs including thiazides , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11785,"Certain drugs including thiazides , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11786,"Certain drugs including thiazides , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11787,"Certain drugs including thiazides , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic_drugs ."</p>
<p>11788,"In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators , and inhaled corticosteroids , with no evidence of increased frequency of adverse events or laboratory abnormalities."</p>
<p>11789,"In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators , and inhaled corticosteroids , with no evidence of increased frequency of adverse events or laboratory abnormalities."</p>
<p>11790,"In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators , and inhaled corticosteroids , with no evidence of increased frequency of adverse events or laboratory abnormalities."</p>
<p>11791,"Coadministration of VIRACEPT and drugs primarily metabolized by CYP3A (e,g,, dihydropyridine_calcium_channel_blockers ) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects."</p>
<p>11792,Coadministration of VIRACEPT and drugs that induce CYP3A may decrease nelfinavir plasma concentrations and reduce its therapeutic effect.</p>
<p>11793,Coadministration of VIRACEPT and drugs that inhibit CYP3A may increase nelfinavir plasma concentrations.</p>
<p>11794,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11795,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11796,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11797,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11798,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11799,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11800,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11801,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11802,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11803,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11804,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11805,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11806,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11807,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11808,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11809,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11810,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11811,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11812,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11813,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11814,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11815,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11816,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11817,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11818,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11819,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11820,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11821,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11822,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11823,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11824,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11825,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11826,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11827,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11828,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11829,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11830,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11831,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11832,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11833,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11834,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11835,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11836,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11837,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11838,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11839,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11840,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11841,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11842,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11843,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11844,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11845,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11846,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11847,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11848,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11849,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11850,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11851,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11852,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11853,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11854,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11855,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11856,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11857,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11858,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11859,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11860,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11861,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11862,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11863,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11864,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11865,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11866,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11867,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11868,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11869,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11870,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11871,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11872,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11873,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11874,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11875,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11876,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11877,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11878,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11879,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11880,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11881,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11882,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11883,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11884,"Drugs That Should Not Be Coadministered With VIRACEPT  Antiarrhythmics : amiodarone , quinidine  Antihistamines : astemizole , terfenadine Antimigraine: ergot_derivatives  Antimycobacterial_agents : rifampin  Benzodiazepines  midazolam , triazolam GI motility agents: cisapride"</p>
<p>11885,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT  Antimycobacterial_agents : rifabutin</p>
<p>11886,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT  Antimycobacterial_agents : rifabutin</p>
<p>11887,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT  Antimycobacterial_agents : rifabutin</p>
<p>11888,* This table is not all inclusive ** VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly</p>
<p>11889,Terfenadine : Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;</p>
<p>11890,Terfenadine : Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;</p>
<p>11891,Terfenadine : Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;</p>
<p>11892,"therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias."</p>
<p>11893,"Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole ."</p>
<p>11894,"Indinavir : Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A,C."</p>
<p>11895,"Indinavir : Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A,C."</p>
<p>11896,"Indinavir : Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A,C."</p>
<p>11897,"Indinavir : Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A,C."</p>
<p>11898,"Indinavir : Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A,C."</p>
<p>11899,"Indinavir : Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A,C."</p>
<p>11900,"Indinavir : Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A,C."</p>
<p>11901,"Ritonavir : Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A,C."</p>
<p>11902,"Ritonavir : Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A,C."</p>
<p>11903,"Ritonavir : Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A,C."</p>
<p>11904,"Ritonavir : Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A,C."</p>
<p>11905,"Ritonavir : Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A,C."</p>
<p>11906,"Ritonavir : Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A,C."</p>
<p>11907,"Ritonavir : Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A,C."</p>
<p>11908,"Saquinavir : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A,C."</p>
<p>11909,"Saquinavir : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A,C."</p>
<p>11910,"Saquinavir : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A,C."</p>
<p>11911,"Saquinavir : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A,C."</p>
<p>11912,"Saquinavir : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A,C."</p>
<p>11913,"Saquinavir : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A,C."</p>
<p>11914,"Saquinavir : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A,C."</p>
<p>11915,"Saquinavir : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A,C."</p>
<p>11916,"Saquinavir : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A,C."</p>
<p>11917,"Ketoconazole : Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A,C."</p>
<p>11918,"Ketoconazole : Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A,C."</p>
<p>11919,"Ketoconazole : Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A,C."</p>
<p>11920,"Ketoconazole : Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A,C."</p>
<p>11921,"Ketoconazole : Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A,C."</p>
<p>11922,This change was not considered clinically significant and no dose adjustment is needed when ketoconazole and VIRACEPT are coadministered.</p>
<p>11923,"therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine ."</p>
<p>11924,A dose adjustment is not needed when zidovudine is administered with VIRACEPT .</p>
<p>11925,Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with lamivudine or stavudine .</p>
<p>11926,Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with lamivudine or stavudine .</p>
<p>11927,Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with lamivudine or stavudine .</p>
<p>11928,"Rifabutin : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A,C."</p>
<p>11929,"Rifabutin : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A,C."</p>
<p>11930,"Rifabutin : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A,C."</p>
<p>11931,"Rifabutin : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A,C."</p>
<p>11932,"Rifabutin : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A,C."</p>
<p>11933,"Rifabutin : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A,C."</p>
<p>11934,"Rifabutin : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A,C."</p>
<p>11935,It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT .</p>
<p>11936,"Rifampin : Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A,C."</p>
<p>11937,"Rifampin : Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A,C."</p>
<p>11938,"Rifampin : Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A,C."</p>
<p>11939,"Rifampin : Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A,C."</p>
<p>11940,"Rifampin : Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A,C."</p>
<p>11941,VIRACEPT and rifampin should not be coadministered.</p>
<p>11942,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11943,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11944,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11945,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11946,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11947,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11948,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11949,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11950,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11951,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11952,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11953,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11954,Ethinyl_Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl_estradiol and an 18% decrease in norethindrone plasma concentrations.</p>
<p>11955,Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin_sulfate neuromuscular blocking effects.</p>
<p>11956,Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin_sulfate neuromuscular blocking effects.</p>
<p>11957,Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin_sulfate neuromuscular blocking effects.</p>
<p>11958,"Oral neomycin inhibits the gastrointestinal absorption of penicillin_V , oral vitamin_B-12 , methotrexate and 5-fluorouracil ."</p>
<p>11959,"Oral neomycin inhibits the gastrointestinal absorption of penicillin_V , oral vitamin_B-12 , methotrexate and 5-fluorouracil ."</p>
<p>11960,"Oral neomycin inhibits the gastrointestinal absorption of penicillin_V , oral vitamin_B-12 , methotrexate and 5-fluorouracil ."</p>
<p>11961,"Oral neomycin inhibits the gastrointestinal absorption of penicillin_V , oral vitamin_B-12 , methotrexate and 5-fluorouracil ."</p>
<p>11962,Oral neomycin_sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.</p>
<p>11963,Oral neomycin_sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.</p>
<p>11964,Oral neomycin_sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.</p>
<p>11965,"These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage."</p>
<p>11966,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11967,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11968,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11969,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11970,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11971,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11972,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11973,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11974,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11975,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11976,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11977,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11978,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11979,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11980,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11981,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11982,"The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV ACE_inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials)."</p>
<p>11983,Netilmicin should not be administered concomitantly with potent loop_diuretics such as furosemide and ethacrynic_acid as the potential for ototoxicity is enhanced by the combination.</p>
<p>11984,Netilmicin should not be administered concomitantly with potent loop_diuretics such as furosemide and ethacrynic_acid as the potential for ototoxicity is enhanced by the combination.</p>
<p>11985,Netilmicin should not be administered concomitantly with potent loop_diuretics such as furosemide and ethacrynic_acid as the potential for ototoxicity is enhanced by the combination.</p>
<p>11986,Netilmicin should not be administered concomitantly with potent loop_diuretics such as furosemide and ethacrynic_acid as the potential for ototoxicity is enhanced by the combination.</p>
<p>11987,Netilmicin should not be administered concomitantly with potent loop_diuretics such as furosemide and ethacrynic_acid as the potential for ototoxicity is enhanced by the combination.</p>
<p>11988,Netilmicin should not be administered concomitantly with potent loop_diuretics such as furosemide and ethacrynic_acid as the potential for ototoxicity is enhanced by the combination.</p>
<p>11989,The in vitro interaction between nevirapine and the antithrombotic_agent  warfarin is complex.</p>
<p>11990,The in vitro interaction between nevirapine and the antithrombotic_agent  warfarin is complex.</p>
<p>11991,The in vitro interaction between nevirapine and the antithrombotic_agent  warfarin is complex.</p>
<p>11992,"When warfarin is co-administered with nevirapine , anticoagulation levels should be monitored frequently."</p>
<p>11993,Clarithromycin exposure was significantly decreased by nevirapine ;</p>
<p>11994,"Alternatives to clarithromycin ,such as azithromycin , should be considered."</p>
<p>11995,Ethinyl_estradiol and Norethindrone</p>
<p>11996,Ethinyl_estradiol  Norethindrone</p>
<p>11997,"Oral contraceptives and other hormonal methods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine , since nevirapine may lower the plasma levels of these medications."</p>
<p>11998,Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug.</p>
<p>11999,Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug.</p>
<p>12000,Lopinavir / Ritonavir</p>
<p>12001,A dose increase of lopinavir / ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine .</p>
<p>12002,A dose increase of lopinavir / ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine .</p>
<p>12003,"Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal, Methadone maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly."</p>
<p>12004,"Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal, Methadone maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly."</p>
<p>12005,"Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal, Methadone maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly."</p>
<p>12006,"The appropriate dose for nelfinavir incombination with nevirapine , with respectto safety and efficacy, has not been established."</p>
<p>12007,Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy ofthe drug.</p>
<p>12008,Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy ofthe drug.</p>
<p>12009,Physicians needing to treat patients co-infected with tuberculosis and using a nevirapine containing regimen may use rifabutin instead.</p>
<p>12010,"aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone ."</p>
<p>12011,"aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone ."</p>
<p>12012,"Amiodarone , disopyramide , lidocaine"</p>
<p>12013,"Amiodarone , disopyramide , lidocaine"</p>
<p>12014,"Amiodarone , disopyramide , lidocaine"</p>
<p>12015,"Carbamazepine , clonazepam , ethosuximide"</p>
<p>12016,"Carbamazepine , clonazepam , ethosuximide"</p>
<p>12017,"Carbamazepine , clonazepam , ethosuximide"</p>
<p>12018,"Diltiazem , nifedipine , verapamil"</p>
<p>12019,"Diltiazem , nifedipine , verapamil"</p>
<p>12020,"Diltiazem , nifedipine , verapamil"</p>
<p>12021,"Cyclosporin , tacrolimus , sirolimus"</p>
<p>12022,"Cyclosporin , tacrolimus , sirolimus"</p>
<p>12023,"Cyclosporin , tacrolimus , sirolimus"</p>
<p>12024,Interactions for Vitamin_B3 ( Niacin ): Antihypertensive Therapy: Nicotinic_acid may potentiate the effects of ganglionic_blocking_agents and vasoactive drugs resulting in postural hypotension.</p>
<p>12025,Interactions for Vitamin_B3 ( Niacin ): Antihypertensive Therapy: Nicotinic_acid may potentiate the effects of ganglionic_blocking_agents and vasoactive drugs resulting in postural hypotension.</p>
<p>12026,Interactions for Vitamin_B3 ( Niacin ): Antihypertensive Therapy: Nicotinic_acid may potentiate the effects of ganglionic_blocking_agents and vasoactive drugs resulting in postural hypotension.</p>
<p>12027,Aspirin : Concomitant aspirin may decrease the metabolic clearance of nicotinic_acid .</p>
<p>12028,Aspirin : Concomitant aspirin may decrease the metabolic clearance of nicotinic_acid .</p>
<p>12029,"Beta-Blockers : In controlled clinical studies, adrenergic_beta-receptor_blockers have been frequently administered concomitantly with nicardipine_HCl ."</p>
<p>12030,"Beta-Blockers : In controlled clinical studies, adrenergic_beta-receptor_blockers have been frequently administered concomitantly with nicardipine_HCl ."</p>
<p>12031,"Beta-Blockers : In controlled clinical studies, adrenergic_beta-receptor_blockers have been frequently administered concomitantly with nicardipine_HCl ."</p>
<p>12032,Cimetidine : Cimetidine increases nicardipine_HCl plasma levels.</p>
<p>12033,Digoxin : Some calcium_blockers may increase the concentration of digitalis_preparations in the blood.</p>
<p>12034,"Nicardipine_HCl usually does not alter the plasma levels of digoxin , however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine_HCl is initiated."</p>
<p>12035,"Nicardipine_HCl usually does not alter the plasma levels of digoxin , however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine_HCl is initiated."</p>
<p>12036,"Nicardipine_HCl usually does not alter the plasma levels of digoxin , however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine_HCl is initiated."</p>
<p>12037,"Nicardipine_HCl usually does not alter the plasma levels of digoxin , however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine_HCl is initiated."</p>
<p>12038,Maalox * Coadministration of Maalox_TC had no effect on nicardipine_HCl absorption.</p>
<p>12039,Maalox * Coadministration of Maalox_TC had no effect on nicardipine_HCl absorption.</p>
<p>12040,Cyclosporine : Concomitant administration of nicardipine and cyclosporine levels.</p>
<p>12041,Cyclosporine : Concomitant administration of nicardipine and cyclosporine levels.</p>
<p>12042,"Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine ."</p>
<p>12043,"When therapeutic concentrations of furosemide , propranolol , dipyridamole , warfarin , quinidine , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine_HCl was not altered."</p>
<p>12044,"When therapeutic concentrations of furosemide , propranolol , dipyridamole , warfarin , quinidine , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine_HCl was not altered."</p>
<p>12045,"When therapeutic concentrations of furosemide , propranolol , dipyridamole , warfarin , quinidine , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine_HCl was not altered."</p>
<p>12046,"When therapeutic concentrations of furosemide , propranolol , dipyridamole , warfarin , quinidine , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine_HCl was not altered."</p>
<p>12047,"When therapeutic concentrations of furosemide , propranolol , dipyridamole , warfarin , quinidine , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine_HCl was not altered."</p>
<p>12048,"When therapeutic concentrations of furosemide , propranolol , dipyridamole , warfarin , quinidine , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine_HCl was not altered."</p>
<p>12049,"Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic_antidepressants and theophylline ."</p>
<p>12050,"Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic_antidepressants and theophylline ."</p>
<p>12051,"Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic_antidepressants and theophylline ."</p>
<p>12052,"Beta-adrenergic_Blocking_Agents : Experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking_agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina."</p>
<p>12053,"Beta-adrenergic_Blocking_Agents : Experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking_agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina."</p>
<p>12054,"Beta-adrenergic_Blocking_Agents : Experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking_agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina."</p>
<p>12055,"Long Acting Nitrates : Nifedipine may be safely co-administered with nitrates , but there have been no controlled studies to evaluate the antianginal effectiveness of this combination."</p>
<p>12056,"Digitalis : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization."</p>
<p>12057,"Digitalis : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization."</p>
<p>12058,"Digitalis : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization."</p>
<p>12059,"Digitalis : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization."</p>
<p>12060,"Digitalis : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization."</p>
<p>12061,"Digitalis : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization."</p>
<p>12062,Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in # of # normal volunteers.</p>
<p>12063,Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in # of # normal volunteers.</p>
<p>12064,"Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization."</p>
<p>12065,"Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization."</p>
<p>12066,Quinidine : Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine ).</p>
<p>12067,Quinidine : Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine ).</p>
<p>12068,Coumarin_Anticoagulants : There have been rare reports of increased prothrombin time in patients taking coumarin_anticoagulants to whom nifedipine was administered.</p>
<p>12069,Cimetidine : A study in # healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a # week course of cimetidine at # mg per day and nifedipine at # mg per day.</p>
<p>12070,Cimetidine : A study in # healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a # week course of cimetidine at # mg per day and nifedipine at # mg per day.</p>
<p>12071,"The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of nifedipine ."</p>
<p>12072,"If nifedipine therapy is initiated in a patient currently receiving cimetidine , cautious titration is advised."</p>
<p>12073,"For example, when vitamin_K_antagonists are administered concomitantly with nilutamide , prothrombin time should be carefully monitored and if necessary, the dosage of vitamin_K_antagonists should be reduced."</p>
<p>12074,"For example, when vitamin_K_antagonists are administered concomitantly with nilutamide , prothrombin time should be carefully monitored and if necessary, the dosage of vitamin_K_antagonists should be reduced."</p>
<p>12075,It is possible that the cardiovascular action of other calcium_channel_blockers could be enhanced by the addition of Nimotop .</p>
<p>12076,"In Europe, Nimotop  was observed to occasionally intensify the effect of antihypertensive_compounds taken concomitantly by patients suffering from hypertension;"</p>
<p>12077,"A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at # mg/day."</p>
<p>12078,"A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at # mg/day."</p>
<p>12079,"This effect may be mediated by the known inhibition of hepatic cytochrome P- # by cimetidine , which could decrease first pass metabolism of nimodipine ."</p>
<p>12080,A # to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine_400_mg twice daily.</p>
<p>12081,Ranitidine # mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).</p>
<p>12082,Coadministration of phenytoin with # mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.</p>
<p>12083,Coadministration of phenytoin with # mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.</p>
<p>12084,Coadministration of phenytoin with # mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.</p>
<p>12085,Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.</p>
<p>12086,Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.</p>
<p>12087,Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.</p>
<p>12088,"Pharmacokinetic interactions between nisoldipine and beta-blockers ( atenolol , propranolol ) were variable and not significant."</p>
<p>12089,"Pharmacokinetic interactions between nisoldipine and beta-blockers ( atenolol , propranolol ) were variable and not significant."</p>
<p>12090,"Pharmacokinetic interactions between nisoldipine and beta-blockers ( atenolol , propranolol ) were variable and not significant."</p>
<p>12091,Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine .</p>
<p>12092,The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.</p>
<p>12093,The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.</p>
<p>12094,The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.</p>
<p>12095,"Quinidine at # mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration."</p>
<p>12096,"The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%."</p>
<p>12097,"Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e,g,, warfarin )."</p>
<p>12098,"INOmax has been administered with tolazoline , dopamine , dobutamine , steroids , surfactant , and high-frequency ventilation."</p>
<p>12099,"INOmax has been administered with tolazoline , dopamine , dobutamine , steroids , surfactant , and high-frequency ventilation."</p>
<p>12100,"INOmax has been administered with tolazoline , dopamine , dobutamine , steroids , surfactant , and high-frequency ventilation."</p>
<p>12101,"INOmax has been administered with tolazoline , dopamine , dobutamine , steroids , surfactant , and high-frequency ventilation."</p>
<p>12102,"INOmax has been administered with tolazoline , dopamine , dobutamine , steroids , surfactant , and high-frequency ventilation."</p>
<p>12103,"Although there are no study data to evaluate the possibility, nitric_oxide_donor_compounds , including sodium_nitroprusside and nitroglycerin , may have an additive effect with INOmax on the risk of developing methemoglobinemia."</p>
<p>12104,"Although there are no study data to evaluate the possibility, nitric_oxide_donor_compounds , including sodium_nitroprusside and nitroglycerin , may have an additive effect with INOmax on the risk of developing methemoglobinemia."</p>
<p>12105,"Although there are no study data to evaluate the possibility, nitric_oxide_donor_compounds , including sodium_nitroprusside and nitroglycerin , may have an additive effect with INOmax on the risk of developing methemoglobinemia."</p>
<p>12106,"Although there are no study data to evaluate the possibility, nitric_oxide_donor_compounds , including sodium_nitroprusside and nitroglycerin , may have an additive effect with INOmax on the risk of developing methemoglobinemia."</p>
<p>12107,"Although there are no study data to evaluate the possibility, nitric_oxide_donor_compounds , including sodium_nitroprusside and nitroglycerin , may have an additive effect with INOmax on the risk of developing methemoglobinemia."</p>
<p>12108,"Although there are no study data to evaluate the possibility, nitric_oxide_donor_compounds , including sodium_nitroprusside and nitroglycerin , may have an additive effect with INOmax on the risk of developing methemoglobinemia."</p>
<p>12109,"Antacids containing magnesium_trisilicate , when administered concomitantly with nitrofurantoin , reduce both the rate and extent of absorption."</p>
<p>12110,"Antacids containing magnesium_trisilicate , when administered concomitantly with nitrofurantoin , reduce both the rate and extent of absorption."</p>
<p>12111,"Antacids containing magnesium_trisilicate , when administered concomitantly with nitrofurantoin , reduce both the rate and extent of absorption."</p>
<p>12112,The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium_trisilicate .</p>
<p>12113,"Uricosuric_drugs , such as probenecid and sulfinpyrazone , can inhibit renal tubular secretion of nitrofurantoin ."</p>
<p>12114,"Uricosuric_drugs , such as probenecid and sulfinpyrazone , can inhibit renal tubular secretion of nitrofurantoin ."</p>
<p>12115,"Uricosuric_drugs , such as probenecid and sulfinpyrazone , can inhibit renal tubular secretion of nitrofurantoin ."</p>
<p>12116,"Uricosuric_drugs , such as probenecid and sulfinpyrazone , can inhibit renal tubular secretion of nitrofurantoin ."</p>
<p>12117,"Uricosuric_drugs , such as probenecid and sulfinpyrazone , can inhibit renal tubular secretion of nitrofurantoin ."</p>
<p>12118,"Uricosuric_drugs , such as probenecid and sulfinpyrazone , can inhibit renal tubular secretion of nitrofurantoin ."</p>
<p>12119,"The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial ."</p>
<p>12120,The vasodilating effects of nitroglycerin may be additive with those of other vasodilators .</p>
<p>12121,Marked symptomatic orthostatic hypotension has been reported when calcium_channel_blockers and organic nitrates were used in combination.</p>
<p>12122,"The hypotensive effect of sodium_nitroprusside is augmented by that of most other hypotensive_drugs , including ganglionic_blocking_agents , negative inotropic agents, and inhaled anesthetics ."</p>
<p>12123,"The hypotensive effect of sodium_nitroprusside is augmented by that of most other hypotensive_drugs , including ganglionic_blocking_agents , negative inotropic agents, and inhaled anesthetics ."</p>
<p>12124,"The hypotensive effect of sodium_nitroprusside is augmented by that of most other hypotensive_drugs , including ganglionic_blocking_agents , negative inotropic agents, and inhaled anesthetics ."</p>
<p>12125,"The hypotensive effect of sodium_nitroprusside is augmented by that of most other hypotensive_drugs , including ganglionic_blocking_agents , negative inotropic agents, and inhaled anesthetics ."</p>
<p>12126,"The hypotensive effect of sodium_nitroprusside is augmented by that of most other hypotensive_drugs , including ganglionic_blocking_agents , negative inotropic agents, and inhaled anesthetics ."</p>
<p>12127,"The hypotensive effect of sodium_nitroprusside is augmented by that of most other hypotensive_drugs , including ganglionic_blocking_agents , negative inotropic agents, and inhaled anesthetics ."</p>
<p>12128,"In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine , # mg b,i,d,, was administered concurrently."</p>
<p>12129,"In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine , # mg b,i,d,, was administered concurrently."</p>
<p>12130,"In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine , # mg b,i,d,, was administered concurrently."</p>
<p>12131,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12132,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12133,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12134,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12135,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12136,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12137,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12138,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12139,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12140,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12141,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12142,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12143,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12144,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12145,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12146,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12147,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12148,"The effectiveness of progestin -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug  rifampin ."</p>
<p>12149,Elevated plasma levels of theophylline have been reported with concomitant quinolone use.</p>
<p>12150,There have been reports of theophylline -related side effects in patients on concomitant therapy with norfloxacin and theophylline .</p>
<p>12151,There have been reports of theophylline -related side effects in patients on concomitant therapy with norfloxacin and theophylline .</p>
<p>12152,Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin .</p>
<p>12153,Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin .</p>
<p>12154,"Quinolones , including norfloxacin , may enhance the effects of oral anticoagulants , including warfarin or its derivatives or similar agents."</p>
<p>12155,"Quinolones , including norfloxacin , may enhance the effects of oral anticoagulants , including warfarin or its derivatives or similar agents."</p>
<p>12156,"Quinolones , including norfloxacin , may enhance the effects of oral anticoagulants , including warfarin or its derivatives or similar agents."</p>
<p>12157,"Quinolones , including norfloxacin , may enhance the effects of oral anticoagulants , including warfarin or its derivatives or similar agents."</p>
<p>12158,"Quinolones , including norfloxacin , may enhance the effects of oral anticoagulants , including warfarin or its derivatives or similar agents."</p>
<p>12159,"Quinolones , including norfloxacin , may enhance the effects of oral anticoagulants , including warfarin or its derivatives or similar agents."</p>
<p>12160,"The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea_agent ) has, on rare occasions, resulted in severe hypoglycemia."</p>
<p>12161,"The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea_agent ) has, on rare occasions, resulted in severe hypoglycemia."</p>
<p>12162,"The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea_agent ) has, on rare occasions, resulted in severe hypoglycemia."</p>
<p>12163,"The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea_agent ) has, on rare occasions, resulted in severe hypoglycemia."</p>
<p>12164,"The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea_agent ) has, on rare occasions, resulted in severe hypoglycemia."</p>
<p>12165,Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin .</p>
<p>12166,Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin .</p>
<p>12167,The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.</p>
<p>12168,The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.</p>
<p>12169,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12170,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12171,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12172,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12173,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12174,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12175,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12176,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12177,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12178,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12179,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12180,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12181,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12182,"Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12183,"Videx ( Didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12184,"Videx ( Didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12185,"Videx ( Didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12186,"Videx ( Didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within # hours of, the administration of norfloxacin , because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin ."</p>
<p>12187,Some quinolones have also been shown to interfere with the metabolism of caffeine .</p>
<p>12188,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12189,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12190,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12191,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12192,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12193,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12194,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12195,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12196,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12197,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12198,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12199,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12200,"A similar association, though less marked, has been suggested with barbiturates , phenylbutazone , phenytoin_sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72."</p>
<p>12201,Steady-state serum concentrations of tricyclic_antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.</p>
<p>12202,"Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic_antidepressants when cimetidine is added to the drug regimen."</p>
<p>12203,"In addition, higher-than expected steady-state serum concentrations of tricyclic_antidepressants have been observed when therapy is initiated in patients already taking cimetidine ."</p>
<p>12204,"In well-controlled patients undergoing concurrent therapy with cimetidine , a decrease in the steady-state serum concentrations of tricyclic_antidepressants may occur when cime-tidine therapy is discontinued."</p>
<p>12205,The therapeutic efficacy of tricyclic_antidepressants may be compromised in these patients when cimetidine is discontinued.</p>
<p>12206,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants , including nortriptyline , when fluoxetine_hydrochloride has been administered in combination with these agents."</p>
<p>12207,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants , including nortriptyline , when fluoxetine_hydrochloride has been administered in combination with these agents."</p>
<p>12208,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants , including nortriptyline , when fluoxetine_hydrochloride has been administered in combination with these agents."</p>
<p>12209,Administration of reserpine during therapy with a tricyclic_antidepressant has been shown to produce a stimulating effect in some depressed patients.</p>
<p>12210,Close supervision and careful adjustment of the dosage are required when nortriptyline_hydrochloride is used with other anticholinergic_drugs or sympathomimetic_drugs .</p>
<p>12211,Close supervision and careful adjustment of the dosage are required when nortriptyline_hydrochloride is used with other anticholinergic_drugs or sympathomimetic_drugs .</p>
<p>12212,Close supervision and careful adjustment of the dosage are required when nortriptyline_hydrochloride is used with other anticholinergic_drugs or sympathomimetic_drugs .</p>
<p>12213,"Such individuals are referred to as poor metabolizers of drugs such as debrisoquin , dextromethorphan , and the tricyclic_antidepressants ."</p>
<p>12214,"Such individuals are referred to as poor metabolizers of drugs such as debrisoquin , dextromethorphan , and the tricyclic_antidepressants ."</p>
<p>12215,"Such individuals are referred to as poor metabolizers of drugs such as debrisoquin , dextromethorphan , and the tricyclic_antidepressants ."</p>
<p>12216,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12217,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12218,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12219,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12220,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12221,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12222,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12223,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12224,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12225,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12226,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12227,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12228,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12229,"Therefore, co-administration of tricyclic_antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (eg, propafenone , flecainide , and encainide ), or that inhibit this enzyme (eg, quinidine ), should be approached with caution."</p>
<p>12230,"In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD ."</p>
<p>12231,"In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD ."</p>
<p>12232,"In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD ."</p>
<p>12233,"Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite ( MHD ) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated (CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9 and CYP4A11) with the exception of CYP2C19 and CYP3A4/5."</p>
<p>12234,"Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance."</p>
<p>12235,"The inhibition of CYP-2C19 by OXC and MHD , however, is clinically relevant."</p>
<p>12236,Increases of 22% with MHD and 47% with oxcarbazepine were observed.</p>
<p>12237,"As MHD , the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e,g,, valproic_acid , lamotrigine )."</p>
<p>12238,"As MHD , the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e,g,, valproic_acid , lamotrigine )."</p>
<p>12239,"In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine_calcium_antagonists and oral contraceptives , resulting in a lower plasma concentration of these drugs."</p>
<p>12240,"In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine_calcium_antagonists and oral contraceptives , resulting in a lower plasma concentration of these drugs."</p>
<p>12241,"In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine_calcium_antagonists and oral contraceptives , resulting in a lower plasma concentration of these drugs."</p>
<p>12242,"In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine_calcium_antagonists and oral contraceptives , resulting in a lower plasma concentration of these drugs."</p>
<p>12243,"In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine_calcium_antagonists and oral contraceptives , resulting in a lower plasma concentration of these drugs."</p>
<p>12244,"In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine_calcium_antagonists and oral contraceptives , resulting in a lower plasma concentration of these drugs."</p>
<p>12245,Antiepileptic_drugs : Potential interactions between Trileptal and other AEDs were assessed in clinical studies.</p>
<p>12246,Antiepileptic_drugs : Potential interactions between Trileptal and other AEDs were assessed in clinical studies.</p>
<p>12247,Antiepileptic_drugs : Potential interactions between Trileptal and other AEDs were assessed in clinical studies.</p>
<p>12248,"Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval)"</p>
<p>12249,"Influence of AED On MHD Concentration (Mean change, 90% Confidence Interval)"</p>
<p>12250,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above # mg/day."</p>
<p>12251,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above # mg/day."</p>
<p>12252,"Therefore, when using doses of Trileptal greater than # mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required."</p>
<p>12253,"The increase of phenobarbital level, however, is small (15%) when given with Trileptal ."</p>
<p>12254,"Strong inducers of cytochrome P450 enzymes (i,e, carbamazepine , phenytoin and phenobarbital ) have been shown to decrease the plasma levels of MHD (29-40%)."</p>
<p>12255,"Strong inducers of cytochrome P450 enzymes (i,e, carbamazepine , phenytoin and phenobarbital ) have been shown to decrease the plasma levels of MHD (29-40%)."</p>
<p>12256,"Strong inducers of cytochrome P450 enzymes (i,e, carbamazepine , phenytoin and phenobarbital ) have been shown to decrease the plasma levels of MHD (29-40%)."</p>
<p>12257,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG)."</p>
<p>12258,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG)."</p>
<p>12259,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG)."</p>
<p>12260,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG)."</p>
<p>12261,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG)."</p>
<p>12262,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG)."</p>
<p>12263,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG)."</p>
<p>12264,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG)."</p>
<p>12265,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG)."</p>
<p>12266,"Therefore, concurrent use of Trileptal with hormonal_contraceptives may render these contraceptives less effective."</p>
<p>12267,"Therefore, concurrent use of Trileptal with hormonal_contraceptives may render these contraceptives less effective."</p>
<p>12268,"Calcium_Antagonist s: After repeated co-administration of Trileptal , the AUC of felodipine was lowered by 28% [90% CI: 20-33]."</p>
<p>12269,Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD .</p>
<p>12270,"Other drug interactions Cimetidine , erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD ."</p>
<p>12271,"Other drug interactions Cimetidine , erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD ."</p>
<p>12272,"Other drug interactions Cimetidine , erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD ."</p>
<p>12273,Results with warfarin show no evidence of interaction with either single or repeated doses of Trileptal .</p>
<p>12274,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or # mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin )."</p>
<p>12275,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or # mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin )."</p>
<p>12276,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or # mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin )."</p>
<p>12277,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or # mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin )."</p>
<p>12278,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or # mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin )."</p>
<p>12279,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or # mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin )."</p>
<p>12280,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or # mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin )."</p>
<p>12281,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or # mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin )."</p>
<p>12282,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or # mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin )."</p>
<p>12283,Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin .</p>
<p>12284,Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin .</p>
<p>12285,Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin .</p>
<p>12286,"Potential interactions between TAXOL , a substrate of CYP3A4, and protease_inhibitors ( ritonavir , saquinavir , indinavir , and nelfinavir ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."</p>
<p>12287,"Potential interactions between TAXOL , a substrate of CYP3A4, and protease_inhibitors ( ritonavir , saquinavir , indinavir , and nelfinavir ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."</p>
<p>12288,"Potential interactions between TAXOL , a substrate of CYP3A4, and protease_inhibitors ( ritonavir , saquinavir , indinavir , and nelfinavir ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."</p>
<p>12289,"Potential interactions between TAXOL , a substrate of CYP3A4, and protease_inhibitors ( ritonavir , saquinavir , indinavir , and nelfinavir ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."</p>
<p>12290,"Potential interactions between TAXOL , a substrate of CYP3A4, and protease_inhibitors ( ritonavir , saquinavir , indinavir , and nelfinavir ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."</p>
<p>12291,Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol ) may be increased when paclitaxel and doxorubicin are used in combination.</p>
<p>12292,Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol ) may be increased when paclitaxel and doxorubicin are used in combination.</p>
<p>12293,Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol ) may be increased when paclitaxel and doxorubicin are used in combination.</p>
<p>12294,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL ."</p>
<p>12295,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL ."</p>
<p>12296,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL ."</p>
<p>12297,"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone ), diphen-hydramine and H2_antagonists (such as cimetidine or ranitidine )."</p>
<p>12298,"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone ), diphen-hydramine and H2_antagonists (such as cimetidine or ranitidine )."</p>
<p>12299,"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone ), diphen-hydramine and H2_antagonists (such as cimetidine or ranitidine )."</p>
<p>12300,"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone ), diphen-hydramine and H2_antagonists (such as cimetidine or ranitidine )."</p>
<p>12301,"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone ), diphen-hydramine and H2_antagonists (such as cimetidine or ranitidine )."</p>
<p>12302,"However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators , angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy."</p>
<p>12303,Treatment with PEGASYS once weekly for # weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.</p>
<p>12304,Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS .</p>
<p>12305,Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS .</p>
<p>12306,"In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS , PEGASYS treatment did not affect ribavirin distribution or clearance."</p>
<p>12307,"In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS , PEGASYS treatment did not affect ribavirin distribution or clearance."</p>
<p>12308,"In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS , PEGASYS treatment did not affect ribavirin distribution or clearance."</p>
<p>12309,"In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS , PEGASYS treatment did not affect ribavirin distribution or clearance."</p>
<p>12310,"In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS , PEGASYS treatment did not affect ribavirin distribution or clearance."</p>
<p>12311,Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.</p>
<p>12312,Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.</p>
<p>12313,Stavudine and Zidovudine  Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.</p>
<p>12314,Stavudine and Zidovudine  Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.</p>
<p>12315,Stavudine and Zidovudine  Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.</p>
<p>12316,Stavudine and Zidovudine  Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.</p>
<p>12317,Stavudine and Zidovudine  Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.</p>
<p>12318,Stavudine and Zidovudine  Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.</p>
<p>12319,Stavudine and Zidovudine  Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.</p>
<p>12320,Stavudine and Zidovudine  Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.</p>
<p>12321,The effect of orally ingested peginterferon or ribavirin from breast milk on the nursing infant has not been evaluated.</p>
<p>12322,"Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue PEGASYS and COPEGUS treatment."</p>
<p>12323,"Pediatric Use The safety and effectiveness of PEGASYS , alone or in combination with COPEGUS in patients below the age of # years have not been established."</p>
<p>12324,PEGASYS contains benzyl_alcohol .</p>
<p>12325,Clinical studies of PEGASYS alone or in combination with COPEGUS did not include sufficient numbers of subjects aged # or over to determine whether they respond differently from younger subjects.</p>
<p>12326,"Adverse reactions related to alpha_interferon s, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of PEGASYS in this population."</p>
<p>12327,"PEGASYS and COPEGUS are excreted by the kidney, and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function."</p>
<p>12328,PEGASYS should be used with caution in patients with creatinine clearance # mL/min and COPEGUS should not be administered to patients with creatinine clearance # mL/min</p>
<p>12329,Aminoglycosides : The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside .</p>
<p>12330,Aminoglycosides : The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside .</p>
<p>12331,"Vecuronium : When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium ."</p>
<p>12332,"In one controlled clinical study, the ureidopenicillins, including piperacillin , were reported to prolong the action of vecuronium ."</p>
<p>12333,"Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing_muscle_relaxants could be prolonged in the presence of piperacillin ."</p>
<p>12334,Probenecid : The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.</p>
<p>12335,Probenecid : The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.</p>
<p>12336,Probenecid : The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.</p>
<p>12337,"Anticoagulants : Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin , oral anticoagulants , or other drugs that may affect the blood coagulation system or the thrombocyte function."</p>
<p>12338,Methotrexate : Piperacillin_sodium may reduce the excretion of methotrexate .</p>
<p>12339,"Drug/Laboratory Test Interactions As with other penicillins , the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper-reduction method."</p>
<p>12340,Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).</p>
<p>12341,Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).</p>
<p>12342,"Pyrantel (e,g,, Antiminth ) - Taking piperazine and pyrantel together may decrease the effects of piperazine ."</p>
<p>12343,"Pyrantel (e,g,, Antiminth ) - Taking piperazine and pyrantel together may decrease the effects of piperazine ."</p>
<p>12344,"Pyrantel (e,g,, Antiminth ) - Taking piperazine and pyrantel together may decrease the effects of piperazine ."</p>
<p>12345,"Pyrantel (e,g,, Antiminth ) - Taking piperazine and pyrantel together may decrease the effects of piperazine ."</p>
<p>12346,"Pyrantel (e,g,, Antiminth ) - Taking piperazine and pyrantel together may decrease the effects of piperazine ."</p>
<p>12347,"Pyrantel (e,g,, Antiminth ) - Taking piperazine and pyrantel together may decrease the effects of piperazine ."</p>
<p>12348,"Pyrantel (e,g,, Antiminth ) - Taking piperazine and pyrantel together may decrease the effects of piperazine ."</p>
<p>12349,ACE_inhibitors : Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin_Converting_Enzyme_(ACE)_inhibitors .</p>
<p>12350,"In patients with mild to moderate hypertension, administration of # mg daily of VIOXX with the ACE_inhibitor  benazepril , # to # mg for # weeks, was associated with an average increase in mean arterial pressure of about # mm Hg compared to ACE_inhibitor alone."</p>
<p>12351,"In patients with mild to moderate hypertension, administration of # mg daily of VIOXX with the ACE_inhibitor  benazepril , # to # mg for # weeks, was associated with an average increase in mean arterial pressure of about # mm Hg compared to ACE_inhibitor alone."</p>
<p>12352,"In patients with mild to moderate hypertension, administration of # mg daily of VIOXX with the ACE_inhibitor  benazepril , # to # mg for # weeks, was associated with an average increase in mean arterial pressure of about # mm Hg compared to ACE_inhibitor alone."</p>
<p>12353,"In patients with mild to moderate hypertension, administration of # mg daily of VIOXX with the ACE_inhibitor  benazepril , # to # mg for # weeks, was associated with an average increase in mean arterial pressure of about # mm Hg compared to ACE_inhibitor alone."</p>
<p>12354,"In patients with mild to moderate hypertension, administration of # mg daily of VIOXX with the ACE_inhibitor  benazepril , # to # mg for # weeks, was associated with an average increase in mean arterial pressure of about # mm Hg compared to ACE_inhibitor alone."</p>
<p>12355,This interaction should be given consideration in patients taking VIOXX concomitantly with ACE_inhibitors .</p>
<p>12356,"Aspirin : Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone."</p>
<p>12357,"Aspirin : Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone."</p>
<p>12358,"Aspirin : Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone."</p>
<p>12359,"Aspirin : Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone."</p>
<p>12360,"In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX # mg daily, as compared to those taking ibuprofen # mg daily alone."</p>
<p>12361,"In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX # mg daily, as compared to those taking ibuprofen # mg daily alone."</p>
<p>12362,"In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX # mg daily, as compared to those taking ibuprofen # mg daily alone."</p>
<p>12363,Patients taking low-dose aspirin plus ibuprofen were not studied.</p>
<p>12364,"At steady state, VIOXX # mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin , as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood."</p>
<p>12365,"Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis."</p>
<p>12366,"Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted."</p>
<p>12367,"Cimetidine : Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%."</p>
<p>12368,"Cimetidine : Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%."</p>
<p>12369,Digoxin : Rofecoxib # mg once daily for # days does not alter the plasma concentration profile or renal elimination of digoxin after a single # mg oral dose.</p>
<p>12370,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>12371,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>12372,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>12373,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>12374,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>12375,Ketoconazole : Ketoconazole # mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib .</p>
<p>12376,Lithium : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.</p>
<p>12377,Lithium : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.</p>
<p>12378,"Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."</p>
<p>12379,"Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."</p>
<p>12380,"Methotrexate  VIOXX #, 25, and # mg, each dose administered once daily for # days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of # to # mg for rheumatoid arthritis."</p>
<p>12381,"Methotrexate  VIOXX #, 25, and # mg, each dose administered once daily for # days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of # to # mg for rheumatoid arthritis."</p>
<p>12382,"Methotrexate  VIOXX #, 25, and # mg, each dose administered once daily for # days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of # to # mg for rheumatoid arthritis."</p>
<p>12383,"At higher than recommended doses, VIOXX # mg administered once daily for # days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate # to # mg/week for rheumatoid arthritis."</p>
<p>12384,"At # hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with # mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL)."</p>
<p>12385,"At # hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with # mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL)."</p>
<p>12386,"At # hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with # mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL)."</p>
<p>12387,Standard monitoring of methotrexate -related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.</p>
<p>12388,Standard monitoring of methotrexate -related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.</p>
<p>12389,Oral Contraceptives  Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl_estradiol and norethindrone .</p>
<p>12390,Oral Contraceptives  Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl_estradiol and norethindrone .</p>
<p>12391,Oral Contraceptives  Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl_estradiol and norethindrone .</p>
<p>12392,Oral Contraceptives  Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl_estradiol and norethindrone .</p>
<p>12393,Oral Contraceptives  Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl_estradiol and norethindrone .</p>
<p>12394,Oral Contraceptives  Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl_estradiol and norethindrone .</p>
<p>12395,Prednisone / prednisolone : Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone .</p>
<p>12396,Prednisone / prednisolone : Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone .</p>
<p>12397,Prednisone / prednisolone : Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone .</p>
<p>12398,Prednisone / prednisolone : Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone .</p>
<p>12399,"Rifampin : Co-administration of VIOXX with rifampin # mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations."</p>
<p>12400,"Rifampin : Co-administration of VIOXX with rifampin # mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations."</p>
<p>12401,"Rifampin : Co-administration of VIOXX with rifampin # mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations."</p>
<p>12402,"Rifampin : Co-administration of VIOXX with rifampin # mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations."</p>
<p>12403,"Rifampin : Co-administration of VIOXX with rifampin # mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations."</p>
<p>12404,"Theophylline  VIOXX #, 25, and # mg administered once daily for # days increased plasma theophylline concentrations (AUC(0- )) by # to 60% in healthy subjects administered a single 300-mg dose of theophylline ."</p>
<p>12405,"Theophylline  VIOXX #, 25, and # mg administered once daily for # days increased plasma theophylline concentrations (AUC(0- )) by # to 60% in healthy subjects administered a single 300-mg dose of theophylline ."</p>
<p>12406,"Theophylline  VIOXX #, 25, and # mg administered once daily for # days increased plasma theophylline concentrations (AUC(0- )) by # to 60% in healthy subjects administered a single 300-mg dose of theophylline ."</p>
<p>12407,Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline .</p>
<p>12408,Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline .</p>
<p>12409,"Warfarin : Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications."</p>
<p>12410,"In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib , prothrombin time (measured as INR) was increased by approximately 8% to 11%."</p>
<p>12411,"In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin ."</p>
<p>12412,Several drug interaction studies have been completed with both INVIRASE and FORTOVASE .</p>
<p>12413,Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE .</p>
<p>12414,Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below.</p>
<p>12415,"Antiarrhythmics : Amiodarone , bepridil , flecainide , propafenone , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions."</p>
<p>12416,"Antiarrhythmics : Amiodarone , bepridil , flecainide , propafenone , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions."</p>
<p>12417,"Antiarrhythmics : Amiodarone , bepridil , flecainide , propafenone , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions."</p>
<p>12418,"Antiarrhythmics : Amiodarone , bepridil , flecainide , propafenone , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions."</p>
<p>12419,"Antiarrhythmics : Amiodarone , bepridil , flecainide , propafenone , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions."</p>
<p>12420,"Antihistamines : astemizole *, terfenadine * CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias."</p>
<p>12421,"Antihistamines : astemizole *, terfenadine * CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias."</p>
<p>12422,"Antihistamines : astemizole *, terfenadine * CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias."</p>
<p>12423,"Ergot_Derivatives : Dihydroergotamine , ergonovine , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."</p>
<p>12424,"Ergot_Derivatives : Dihydroergotamine , ergonovine , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."</p>
<p>12425,"Ergot_Derivatives : Dihydroergotamine , ergonovine , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."</p>
<p>12426,"Ergot_Derivatives : Dihydroergotamine , ergonovine , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."</p>
<p>12427,"Ergot_Derivatives : Dihydroergotamine , ergonovine , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."</p>
<p>12428,"Ergot_Derivatives : Dihydroergotamine , ergonovine , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."</p>
<p>12429,"Ergot_Derivatives : Dihydroergotamine , ergonovine , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."</p>
<p>12430,"Ergot_Derivatives : Dihydroergotamine , ergonovine , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."</p>
<p>12431,Antimycobacterial_Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .</p>
<p>12432,Antimycobacterial_Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .</p>
<p>12433,Antimycobacterial_Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .</p>
<p>12434,Antimycobacterial_Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .</p>
<p>12435,Antimycobacterial_Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .</p>
<p>12436,Antimycobacterial_Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .</p>
<p>12437,Antimycobacterial_Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .</p>
<p>12438,Antimycobacterial_Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .</p>
<p>12439,Antimycobacterial_Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .</p>
<p>12440,Garlic Capsules Garlic capsules should not be used while taking saquinavir ( FORTOVASE ) as the sole protease_inhibitor due to the risk of decreased saquinavir plasma concentrations.</p>
<p>12441,Garlic Capsules Garlic capsules should not be used while taking saquinavir ( FORTOVASE ) as the sole protease_inhibitor due to the risk of decreased saquinavir plasma concentrations.</p>
<p>12442,Garlic Capsules Garlic capsules should not be used while taking saquinavir ( FORTOVASE ) as the sole protease_inhibitor due to the risk of decreased saquinavir plasma concentrations.</p>
<p>12443,Garlic Capsules Garlic capsules should not be used while taking saquinavir ( FORTOVASE ) as the sole protease_inhibitor due to the risk of decreased saquinavir plasma concentrations.</p>
<p>12444,"HMG-CoA_Reductase_Inhibitors : lovastatin , simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis."</p>
<p>12445,"HMG-CoA_Reductase_Inhibitors : lovastatin , simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis."</p>
<p>12446,"HMG-CoA_Reductase_Inhibitors : lovastatin , simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis."</p>
<p>12447,"Sedatives / Hypnotics : triazolam , midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."</p>
<p>12448,"Sedatives / Hypnotics : triazolam , midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."</p>
<p>12449,"Sedatives / Hypnotics : triazolam , midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."</p>
<p>12450,"Sedatives / Hypnotics : triazolam , midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."</p>
<p>12451,"Sedatives / Hypnotics : triazolam , midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."</p>
<p>12452,"Sedatives / Hypnotics : triazolam , midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."</p>
<p>12453,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12454,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12455,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12456,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12457,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12458,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12459,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12460,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12461,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12462,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12463,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12464,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12465,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12466,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12467,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12468,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium_channel_blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot_derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;"</p>
<p>12469,"Since INVIRASE is coadministered with ritonavir , the ritonavir label should be reviewed for additional drugs that should not be coadministered."</p>
<p>12470,"Since INVIRASE is coadministered with ritonavir , the ritonavir label should be reviewed for additional drugs that should not be coadministered."</p>
<p>12471,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital , phenytoin , dexamethasone , carbamazepine ) may result in decreased plasma levels of saquinavir ."</p>
<p>12472,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital , phenytoin , dexamethasone , carbamazepine ) may result in decreased plasma levels of saquinavir ."</p>
<p>12473,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital , phenytoin , dexamethasone , carbamazepine ) may result in decreased plasma levels of saquinavir ."</p>
<p>12474,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital , phenytoin , dexamethasone , carbamazepine ) may result in decreased plasma levels of saquinavir ."</p>
<p>12475,Sulfacetamide preparations are incompatible with silver preparations.</p>
<p>12476,"Sulfapyridine may interact with any of the following: - Acetaminophen (e,g,, Tylenol ) (with long-term, high-dose use) or"</p>
<p>12477,"Sulfapyridine may interact with any of the following: - Acetaminophen (e,g,, Tylenol ) (with long-term, high-dose use) or"</p>
<p>12478,- Oral contraceptives (birth control pills) containing estrogen or</p>
<p>12479,"- Valproic_acid (e,g,, Depakene ) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver"</p>
<p>12480,"- Valproic_acid (e,g,, Depakene ) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver"</p>
<p>12481,"- Vitamin_K (e,g,, AquaMEPHYTON , Synkayvite ) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood"</p>
<p>12482,"- Vitamin_K (e,g,, AquaMEPHYTON , Synkayvite ) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood"</p>
<p>12483,"- Vitamin_K (e,g,, AquaMEPHYTON , Synkayvite ) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood"</p>
<p>12484,"- Mephenytoin (e,g,, Mesantoin ) Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines"</p>
<p>12485,"- Mephenytoin (e,g,, Mesantoin ) Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines"</p>
<p>12486,"- Antidiabetics , oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics"</p>
<p>12487,"- Antidiabetics , oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics"</p>
<p>12488,"- Antidiabetics , oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics"</p>
<p>12489,"- Methotrexate (e,g,, Mexate ) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate"</p>
<p>12490,"- Methotrexate (e,g,, Mexate ) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate"</p>
<p>12491,"- Methotrexate (e,g,, Mexate ) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate"</p>
<p>12492,"- Methotrexate (e,g,, Mexate ) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate"</p>
<p>12493,"- Methotrexate (e,g,, Mexate ) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate"</p>
<p>12494,"- Methotrexate (e,g,, Mexate ) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate"</p>
<p>12495,"- Methyldopa (e,g,, Aldomet ) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood"</p>
<p>12496,"- Methyldopa (e,g,, Aldomet ) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood"</p>
<p>12497,"- Methyldopa (e,g,, Aldomet ) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood"</p>
<p>12498,"- Methyldopa (e,g,, Aldomet ) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood"</p>
<p>12499,"- Phenytoin (e,g,, Dilantin ) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin"</p>
<p>12500,"- Phenytoin (e,g,, Dilantin ) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin"</p>
<p>12501,"- Phenytoin (e,g,, Dilantin ) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin"</p>
<p>12502,"- Phenytoin (e,g,, Dilantin ) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin"</p>
<p>12503,"- Phenytoin (e,g,, Dilantin ) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin"</p>
<p>12504,"- Phenytoin (e,g,, Dilantin ) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin"</p>
<p>12505,valproate and gabapentin are not.</p>
<p>12506,GABITRIL is considered to be a non-enzyme inducing AED .</p>
<p>12507,Effects of GABITRIL on other Antiepilepsy Drugs ( AEDs ) : Phenytoin : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.</p>
<p>12508,Effects of GABITRIL on other Antiepilepsy Drugs ( AEDs ) : Phenytoin : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.</p>
<p>12509,Effects of GABITRIL on other Antiepilepsy Drugs ( AEDs ) : Phenytoin : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.</p>
<p>12510,Effects of GABITRIL on other Antiepilepsy Drugs ( AEDs ) : Phenytoin : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.</p>
<p>12511,Carbamazepine : Tiagabine had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.</p>
<p>12512,Valproate : Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.</p>
<p>12513,Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone .</p>
<p>12514,Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone .</p>
<p>12515,Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone .</p>
<p>12516,Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone .</p>
<p>12517,The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.</p>
<p>12518,The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.</p>
<p>12519,The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.</p>
<p>12520,Effects of other Antiepilepsy Drugs ( AEDs ) on GABITRIL : Carbamazepine : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs .</p>
<p>12521,Effects of other Antiepilepsy Drugs ( AEDs ) on GABITRIL : Carbamazepine : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs .</p>
<p>12522,Effects of other Antiepilepsy Drugs ( AEDs ) on GABITRIL : Carbamazepine : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs .</p>
<p>12523,Effects of other Antiepilepsy Drugs ( AEDs ) on GABITRIL : Carbamazepine : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs .</p>
<p>12524,Effects of other Antiepilepsy Drugs ( AEDs ) on GABITRIL : Carbamazepine : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs .</p>
<p>12525,Effects of other Antiepilepsy Drugs ( AEDs ) on GABITRIL : Carbamazepine : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs .</p>
<p>12526,Phenytoin : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs .</p>
<p>12527,Phenytoin : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs .</p>
<p>12528,Phenytoin : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs .</p>
<p>12529,Phenobarbital ( Primidone ): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital ( primidone ) with or without other enzyme-inducing AEDs .</p>
<p>12530,Phenobarbital ( Primidone ): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital ( primidone ) with or without other enzyme-inducing AEDs .</p>
<p>12531,Phenobarbital ( Primidone ): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital ( primidone ) with or without other enzyme-inducing AEDs .</p>
<p>12532,Phenobarbital ( Primidone ): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital ( primidone ) with or without other enzyme-inducing AEDs .</p>
<p>12533,Phenobarbital ( Primidone ): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital ( primidone ) with or without other enzyme-inducing AEDs .</p>
<p>12534,"Valproate : The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from # to #%, which resulted in an increase of approximately 40% in the free tiagabine concentration."</p>
<p>12535,"Valproate : The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from # to #%, which resulted in an increase of approximately 40% in the free tiagabine concentration."</p>
<p>12536,"Valproate : The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from # to #%, which resulted in an increase of approximately 40% in the free tiagabine concentration."</p>
<p>12537,"Valproate : The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from # to #%, which resulted in an increase of approximately 40% in the free tiagabine concentration."</p>
<p>12538,"Valproate : The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from # to #%, which resulted in an increase of approximately 40% in the free tiagabine concentration."</p>
<p>12539,"Valproate : The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from # to #%, which resulted in an increase of approximately 40% in the free tiagabine concentration."</p>
<p>12540,Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.</p>
<p>12541,Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.</p>
<p>12542,Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.</p>
<p>12543,Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.</p>
<p>12544,Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.</p>
<p>12545,Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.</p>
<p>12546,Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.</p>
<p>12547,Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.</p>
<p>12548,Theophylline : A single # mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.</p>
<p>12549,Warfarin : No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.</p>
<p>12550,Warfarin : No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.</p>
<p>12551,Warfarin : No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.</p>
<p>12552,Digoxin : Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin .</p>
<p>12553,Digoxin : Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin .</p>
<p>12554,Digoxin : Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin .</p>
<p>12555,Ethanol or Triazolam : No significant differences were observed in the pharmacokinetics of triazolam (# mg) and tiagabine (10 mg) when given together as a single dose.</p>
<p>12556,Ethanol or Triazolam : No significant differences were observed in the pharmacokinetics of triazolam (# mg) and tiagabine (10 mg) when given together as a single dose.</p>
<p>12557,The pharmacokinetics of ethanol were not affected by multiple-dose administration of tiagabine .</p>
<p>12558,Tiagabine has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or alcohol .</p>
<p>12559,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine ."</p>
<p>12560,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine ."</p>
<p>12561,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine ."</p>
<p>12562,Oral Contraceptives : Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.</p>
<p>12563,Antipyrine : Antipyrine pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.</p>
<p>12564,This indicates that tiagabine does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of antipyrine .</p>
<p>12565,Aspirin : Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.</p>
<p>12566,Aspirin : Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.</p>
<p>12567,Aspirin : Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.</p>
<p>12568,Aspirin : Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.</p>
<p>12569,Because of its lack of anti-platelet effect valdecoxib is not a substitute for aspirin for cardiovascular prophylaxis.</p>
<p>12570,"In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at # mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro aspirin -mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation."</p>
<p>12571,"In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at # mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro aspirin -mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation."</p>
<p>12572,Methotrexate : Valdecoxib_10_mg BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate .</p>
<p>12573,ACE-inhibitors :Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors .</p>
<p>12574,ACE-inhibitors :Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors .</p>
<p>12575,This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors .</p>
<p>12576,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>12577,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>12578,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>12579,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>12580,"Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>12581,Anticonvulsants ( Phenytoin ): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for # days) was decreased by 27% when co-administered with multiple doses (300 mg QD for # days) of phenytoin (a CYP 3A4 inducer).</p>
<p>12582,Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.</p>
<p>12583,Valdecoxib did not have a statistically significant effect on the pharmacokinetics of phenytoin (a CYP 2C9 and CYP 2C19 substrate).</p>
<p>12584,"Coadministration with valdecoxib (40 mg BID for # days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6."</p>
<p>12585,"Coadministration with valdecoxib (40 mg BID for # days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6."</p>
<p>12586,Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.</p>
<p>12587,Lithium : Valdecoxib # mg BID for # days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.</p>
<p>12588,Lithium : Valdecoxib # mg BID for # days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.</p>
<p>12589,Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium .</p>
<p>12590,Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium .</p>
<p>12591,Lithium_carbonate (450 mg BID for # days) had no effect on valdecoxib pharmacokinetics.</p>
<p>12592,Warfarin : The effect of valdecoxib on the anticoagulant effect of warfarin (1 - # mg/day) was studied in healthy subjects by coadministration of BEXTRA # mg BID for # days.</p>
<p>12593,Warfarin : The effect of valdecoxib on the anticoagulant effect of warfarin (1 - # mg/day) was studied in healthy subjects by coadministration of BEXTRA # mg BID for # days.</p>
<p>12594,Warfarin : The effect of valdecoxib on the anticoagulant effect of warfarin (1 - # mg/day) was studied in healthy subjects by coadministration of BEXTRA # mg BID for # days.</p>
<p>12595,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin ."</p>
<p>12596,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin ."</p>
<p>12597,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin ."</p>
<p>12598,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin ."</p>
<p>12599,"Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents."</p>
<p>12600,"Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents."</p>
<p>12601,"Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents."</p>
<p>12602,"Fluconazole and Ketoconazole : Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively."</p>
<p>12603,"Fluconazole and Ketoconazole : Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively."</p>
<p>12604,Concomitant single dose administration of valdecoxib # mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib .</p>
<p>12605,Concomitant single dose administration of valdecoxib # mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib .</p>
<p>12606,Concomitant single dose administration of valdecoxib # mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib .</p>
<p>12607,Concomitant single dose administration of valdecoxib # mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib .</p>
<p>12608,Concomitant single dose administration of valdecoxib # mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib .</p>
<p>12609,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole .</p>
<p>12610,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole .</p>
<p>12611,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole .</p>
<p>12612,Coadministration of valdecoxib (10 mg BID for # days) with glyburide (5 mg QD or # mg BID) did not affect the pharmacokinetics (exposure) of glyburide .</p>
<p>12613,Coadministration of valdecoxib (10 mg BID for # days) with glyburide (5 mg QD or # mg BID) did not affect the pharmacokinetics (exposure) of glyburide .</p>
<p>12614,Coadministration of valdecoxib (40 mg BID (day 1) and # mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide .</p>
<p>12615,Coadministration of valdecoxib (40 mg BID (day 1) and # mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide .</p>
<p>12616,Coadministration of valdecoxib (40 mg BID (day 1) and # mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.</p>
<p>12617,Coadministration of valdecoxib (40 mg BID (day 1) and # mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.</p>
<p>12618,Coadministration of valdecoxib (40 mg BID (day 1) and # mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.</p>
<p>12619,Coadministration of valdecoxib (40 mg BID (day 1) and # mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.</p>
<p>12620,"Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near # mg/dL, dose adjustment for glyburide (5 mg QD and # mg BID) with valdecoxib coadministration (up to # mg QD) is not indicated."</p>
<p>12621,"Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near # mg/dL, dose adjustment for glyburide (5 mg QD and # mg BID) with valdecoxib coadministration (up to # mg QD) is not indicated."</p>
<p>12622,"Coadministration of glyburide with doses higher than # mg valdecoxib (e,g,, # mg BID) have not been studied."</p>
<p>12623,Valdecoxib steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of omeprazole (40 mg QD).</p>
<p>12624,Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.</p>
<p>12625,Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of omeprazole and valdecoxib .</p>
<p>12626,Coadministration of valdecoxib with doses higher than # mg QD omeprazole has not been studied.</p>
<p>12627,"Oral Contraceptives : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  norethindrone / ethinyl_estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 )."</p>
<p>12628,"Oral Contraceptives : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  norethindrone / ethinyl_estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 )."</p>
<p>12629,"Oral Contraceptives : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  norethindrone / ethinyl_estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 )."</p>
<p>12630,"Oral Contraceptives : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  norethindrone / ethinyl_estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 )."</p>
<p>12631,"Oral Contraceptives : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  norethindrone / ethinyl_estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 )."</p>
<p>12632,"Oral Contraceptives : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  norethindrone / ethinyl_estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 )."</p>
<p>12633,"Oral Contraceptives : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  norethindrone / ethinyl_estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 )."</p>
<p>12634,"Oral Contraceptives : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  norethindrone / ethinyl_estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 )."</p>
<p>12635,"Oral Contraceptives : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  norethindrone / ethinyl_estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 )."</p>
<p>12636,"Coadministration of valdecoxib and Ortho-Novum 1/35 increased the exposure of norethindrone and ethinyl_estradiol by 20% and 34%, respectively."</p>
<p>12637,"Coadministration of valdecoxib and Ortho-Novum 1/35 increased the exposure of norethindrone and ethinyl_estradiol by 20% and 34%, respectively."</p>
<p>12638,"Coadministration of valdecoxib and Ortho-Novum 1/35 increased the exposure of norethindrone and ethinyl_estradiol by 20% and 34%, respectively."</p>
<p>12639,"Coadministration of valdecoxib and Ortho-Novum 1/35 increased the exposure of norethindrone and ethinyl_estradiol by 20% and 34%, respectively."</p>
<p>12640,"Coadministration of valdecoxib and Ortho-Novum 1/35 increased the exposure of norethindrone and ethinyl_estradiol by 20% and 34%, respectively."</p>
<p>12641,"Coadministration of valdecoxib and Ortho-Novum 1/35 increased the exposure of norethindrone and ethinyl_estradiol by 20% and 34%, respectively."</p>
<p>12642,These increased exposures of norethindrone and ethinyl_estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib .</p>
<p>12643,These increased exposures of norethindrone and ethinyl_estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib .</p>
<p>12644,These increased exposures of norethindrone and ethinyl_estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib .</p>
<p>12645,These increased exposures of norethindrone and ethinyl_estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib .</p>
<p>12646,These increased exposures of norethindrone and ethinyl_estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib .</p>
<p>12647,These increased exposures of norethindrone and ethinyl_estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib .</p>
<p>12648,"Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for # days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for # days."</p>
<p>12649,"Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for # days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for # days."</p>
<p>12650,"Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for # days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for # days."</p>
<p>12651,"Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for # days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for # days."</p>
<p>12652,"Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance."</p>
<p>12653,"Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance."</p>
<p>12654,"Cimetidine (400 mg b,i,d,) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with # mg Vardenafil in healthy volunteers."</p>
<p>12655,"Cimetidine (400 mg b,i,d,) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with # mg Vardenafil in healthy volunteers."</p>
<p>12656,"Cimetidine (400 mg b,i,d,) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with # mg Vardenafil in healthy volunteers."</p>
<p>12657,"Erythromycin (500 mg t,i,d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil # mg in healthy volunteers."</p>
<p>12658,"Erythromycin (500 mg t,i,d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil # mg in healthy volunteers."</p>
<p>12659,It is recommended not to exceed a single # mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin .</p>
<p>12660,Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.</p>
<p>12661,Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.</p>
<p>12662,A 5-mg Vardenafil dose should not be exceeded when used in combination with # mg once daily ketoconazole .</p>
<p>12663,"Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single # mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole # mg daily."</p>
<p>12664,"Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single # mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole # mg daily."</p>
<p>12665,"HIV_Protease_Inhibitors : Indinavir (800 mg t,i,d,) co-administered with Vardenafil # mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life."</p>
<p>12666,"HIV_Protease_Inhibitors : Indinavir (800 mg t,i,d,) co-administered with Vardenafil # mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life."</p>
<p>12667,"HIV_Protease_Inhibitors : Indinavir (800 mg t,i,d,) co-administered with Vardenafil # mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life."</p>
<p>12668,"HIV_Protease_Inhibitors : Indinavir (800 mg t,i,d,) co-administered with Vardenafil # mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life."</p>
<p>12669,It is recommended not to exceed a single # mg Vardenafil dose in a 24-hour period when used in combination with indinavir .</p>
<p>12670,"Ritonavir (600 mg b,i,d,) co-administered with Vardenafil # mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax."</p>
<p>12671,"Ritonavir (600 mg b,i,d,) co-administered with Vardenafil # mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax."</p>
<p>12672,"Ritonavir (600 mg b,i,d,) co-administered with Vardenafil # mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax."</p>
<p>12673,"The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir , a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9."</p>
<p>12674,Ritonavir significantly prolonged the half-life of vardenafil to # hours.</p>
<p>12675,"Consequently, it is recommended not to exceed a single # mg Vardenafil dose in a 72-hour period when used in combination with ritonavir ."</p>
<p>12676,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12677,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12678,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12679,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12680,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12681,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12682,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12683,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12684,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12685,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12686,"Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide , warfarin , digoxin , Maalox , and ranitidine ."</p>
<p>12687,"In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters."</p>
<p>12688,"In vivo studies: Nitrates : The blood pressure lowering effects of sublingual nitrates (# mg) taken # and # hours after vardenafil and increases in heart rate when taken at 1, # and # hours were potentiated by a # mg dose of Vardenafil in healthy middle-aged subjects."</p>
<p>12689,"In vivo studies: Nitrates : The blood pressure lowering effects of sublingual nitrates (# mg) taken # and # hours after vardenafil and increases in heart rate when taken at 1, # and # hours were potentiated by a # mg dose of Vardenafil in healthy middle-aged subjects."</p>
<p>12690,These effects were not observed when Vardenafil # mg was taken # hours before the NTG .</p>
<p>12691,"Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated."</p>
<p>12692,"Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated."</p>
<p>12693,"Nifedipine : Vardenafil # mg, when co-administered with slow-release nifedipine # mg or # mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine , a drug that is metabolized via CYP3A4."</p>
<p>12694,"Nifedipine : Vardenafil # mg, when co-administered with slow-release nifedipine # mg or # mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine , a drug that is metabolized via CYP3A4."</p>
<p>12695,"Nifedipine : Vardenafil # mg, when co-administered with slow-release nifedipine # mg or # mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine , a drug that is metabolized via CYP3A4."</p>
<p>12696,Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.</p>
<p>12697,"In these patients whose hypertension was controlled with nifedipine , Vardenafil # mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo."</p>
<p>12698,"Alpha-blockers : When Vardenafil # or # mg was given to healthy volunteers either simultaneously or # hours after a # mg dose of terazosin , significant hypotension developed in a substantial number of subjects."</p>
<p>12699,"With simultaneous dosing of Vardenafil # mg and terazosin # mg, # of # subjects experienced a standing systolic blood pressure of less than # mm Hg."</p>
<p>12700,"With simultaneous dosing of Vardenafil # mg and terazosin # mg, # of # subjects experienced a standing systolic blood pressure of less than # mm Hg."</p>
<p>12701,"When Vardenafil dosing was separated from terazosin # mg by # hours, # of # subjects who received # mg of Vardenafil experienced a decrease in standing systolic blood pressure below # mm Hg."</p>
<p>12702,"When Vardenafil dosing was separated from terazosin # mg by # hours, # of # subjects who received # mg of Vardenafil experienced a decrease in standing systolic blood pressure below # mm Hg."</p>
<p>12703,"In a similar study with tamsulosin in healthy volunteers, # of # subjects dosed with Vardenafil # mg and tamsulosin # mg separated by # hours experienced a standing systolic blood pressure below # mm Hg."</p>
<p>12704,"In a similar study with tamsulosin in healthy volunteers, # of # subjects dosed with Vardenafil # mg and tamsulosin # mg separated by # hours experienced a standing systolic blood pressure below # mm Hg."</p>
<p>12705,Two of # subjects dosed simultaneously with Vardenafil # mg and tamsulosin # mg experienced a standing systolic blood pressure below # mm Hg.</p>
<p>12706,The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.</p>
<p>12707,"Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy."</p>
<p>12708,"Ritonavir and indinavir : Upon concomitant administration of # mg of Vardenafil with # mg BID ritonavir , the Cmax and AUC of ritonavir were reduced by approximately 20%."</p>
<p>12709,"Ritonavir and indinavir : Upon concomitant administration of # mg of Vardenafil with # mg BID ritonavir , the Cmax and AUC of ritonavir were reduced by approximately 20%."</p>
<p>12710,"Ritonavir and indinavir : Upon concomitant administration of # mg of Vardenafil with # mg BID ritonavir , the Cmax and AUC of ritonavir were reduced by approximately 20%."</p>
<p>12711,"Upon administration of # mg of Vardenafil with # mg TID indinavir , the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively."</p>
<p>12712,"Upon administration of # mg of Vardenafil with # mg TID indinavir , the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively."</p>
<p>12713,Alcohol : Alcohol (# g/kg body weight: approximately # mL of absolute alcohol in a # kg person) and vardenafil plasma levels were not altered when dosed simultaneously.</p>
<p>12714,Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (# g/kg body weight).</p>
<p>12715,Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (# g/kg body weight).</p>
<p>12716,Aspirin : Vardenafil (10 mg and # mg) did not potentiate the increase in bleeding time caused by aspirin (two # mg tablets).</p>
<p>12717,Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).</p>
<p>12718,Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).</p>
<p>12719,Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).</p>
<p>12720,Zidovudine : There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.</p>
<p>12721,"Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV , as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4)."</p>
<p>12722,In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.</p>
<p>12723,In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.</p>
<p>12724,In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.</p>
<p>12725,"Lamivudine : In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner."</p>
<p>12726,Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);</p>
<p>12727,"however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine ."</p>
<p>12728,"however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine ."</p>
<p>12729,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine ."</p>
<p>12730,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine ."</p>
<p>12731,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine ."</p>
<p>12732,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine ."</p>
<p>12733,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine ."</p>
<p>12734,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine ."</p>
<p>12735,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine ."</p>
<p>12736,Concomitant use of zalcitabine and lamivudine is not recommended.</p>
<p>12737,"Saquinavir : The combination of HIVID , saquinavir , and ZDV has been studied (as triple combination) in adults."</p>
<p>12738,"Saquinavir : The combination of HIVID , saquinavir , and ZDV has been studied (as triple combination) in adults."</p>
<p>12739,Concomitant use of HIVID with didanosine is not recommended.</p>
<p>12740,Intravenous Pentamidine : Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.</p>
<p>12741,Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.</p>
<p>12742,"If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted."</p>
<p>12743,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12744,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12745,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12746,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12747,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12748,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12749,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12750,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12751,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12752,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12753,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12754,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12755,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12756,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12757,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12758,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12759,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12760,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12761,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12762,"Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure)."</p>
<p>12763,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12764,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12765,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12766,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12767,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12768,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12769,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12770,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12771,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12772,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12773,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12774,"Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine ."</p>
<p>12775,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12776,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12777,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12778,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12779,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12780,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12781,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12782,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12783,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12784,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12785,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12786,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12787,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12788,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12789,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12790,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12791,Magnesium / Aluminum -containing Antacid_Products : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium / aluminum -containing antacid_products .</p>
<p>12792,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium / aluminum -containing antacids ."</p>
<p>12793,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium / aluminum -containing antacids ."</p>
<p>12794,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium / aluminum -containing antacids ."</p>
<p>12795,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium / aluminum -containing antacids ."</p>
<p>12796,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium / aluminum -containing antacids ."</p>
<p>12797,Metoclopramide : Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.</p>
<p>12798,Doxorubicin : Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt # cells.</p>
<p>12799,"CNS-Active Drugs Ethanol : Sonata # mg potentiated the CNS-impairing effects of ethanol # g/kg on balance testing and reaction time for # hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for # hours after ethanol administration."</p>
<p>12800,"CNS-Active Drugs Ethanol : Sonata # mg potentiated the CNS-impairing effects of ethanol # g/kg on balance testing and reaction time for # hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for # hours after ethanol administration."</p>
<p>12801,"CNS-Active Drugs Ethanol : Sonata # mg potentiated the CNS-impairing effects of ethanol # g/kg on balance testing and reaction time for # hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for # hours after ethanol administration."</p>
<p>12802,zaleplon did not affect the pharmacokinetics of ethanol .</p>
<p>12803,Imipramine : Coadministration of single doses of Sonata # mg and imipramine # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration.</p>
<p>12804,Imipramine : Coadministration of single doses of Sonata # mg and imipramine # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration.</p>
<p>12805,Paroxetine : Coadministration of a single dose of Sonata # mg and paroxetine # mg daily for # days did not produce any interaction on psychomotor performance.</p>
<p>12806,Paroxetine : Coadministration of a single dose of Sonata # mg and paroxetine # mg daily for # days did not produce any interaction on psychomotor performance.</p>
<p>12807,"Additionally, paroxetine did not alter the pharmacokinetics of Sonata , reflecting the absence of a role of CYP2D6 in zaleplon s metabolism."</p>
<p>12808,"Additionally, paroxetine did not alter the pharmacokinetics of Sonata , reflecting the absence of a role of CYP2D6 in zaleplon s metabolism."</p>
<p>12809,"Additionally, paroxetine did not alter the pharmacokinetics of Sonata , reflecting the absence of a role of CYP2D6 in zaleplon s metabolism."</p>
<p>12810,Thioridazine : Coadministration of single doses of Sonata # mg and thioridazine # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration.</p>
<p>12811,Thioridazine : Coadministration of single doses of Sonata # mg and thioridazine # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration.</p>
<p>12812,Venlafaxine : Coadministration of a single dose of zaleplon # mg and multiple doses of venlafaxine ER (extended release) # mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine .</p>
<p>12813,Venlafaxine : Coadministration of a single dose of zaleplon # mg and multiple doses of venlafaxine ER (extended release) # mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine .</p>
<p>12814,Venlafaxine : Coadministration of a single dose of zaleplon # mg and multiple doses of venlafaxine ER (extended release) # mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine .</p>
<p>12815,Venlafaxine : Coadministration of a single dose of zaleplon # mg and multiple doses of venlafaxine ER (extended release) # mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine .</p>
<p>12816,Venlafaxine : Coadministration of a single dose of zaleplon # mg and multiple doses of venlafaxine ER (extended release) # mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine .</p>
<p>12817,Venlafaxine : Coadministration of a single dose of zaleplon # mg and multiple doses of venlafaxine ER (extended release) # mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine .</p>
<p>12818,"In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER."</p>
<p>12819,"Promethazine : Coadministration of a single dose of zaleplon and promethazine (10 and # mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon , but no change in the area under the plasma concentration-time curve."</p>
<p>12820,"Promethazine : Coadministration of a single dose of zaleplon and promethazine (10 and # mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon , but no change in the area under the plasma concentration-time curve."</p>
<p>12821,"Promethazine : Coadministration of a single dose of zaleplon and promethazine (10 and # mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon , but no change in the area under the plasma concentration-time curve."</p>
<p>12822,"Promethazine : Coadministration of a single dose of zaleplon and promethazine (10 and # mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon , but no change in the area under the plasma concentration-time curve."</p>
<p>12823,"However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated."</p>
<p>12824,"Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every # hours, q24h, for # days), however, reduced zaleplon Cmax and AUC by approximately 80%."</p>
<p>12825,"An alternative non-CYP3A4 substrate hypnotic_agent may be considered in patients taking CYP3A4 inducers such as rifampin , phenytoin , carbamazepine , and phenobarbital ."</p>
<p>12826,"An alternative non-CYP3A4 substrate hypnotic_agent may be considered in patients taking CYP3A4 inducers such as rifampin , phenytoin , carbamazepine , and phenobarbital ."</p>
<p>12827,"An alternative non-CYP3A4 substrate hypnotic_agent may be considered in patients taking CYP3A4 inducers such as rifampin , phenytoin , carbamazepine , and phenobarbital ."</p>
<p>12828,"An alternative non-CYP3A4 substrate hypnotic_agent may be considered in patients taking CYP3A4 inducers such as rifampin , phenytoin , carbamazepine , and phenobarbital ."</p>
<p>12829,"Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and # mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplon s maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve."</p>
<p>12830,"Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and # mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplon s maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve."</p>
<p>12831,Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon .</p>
<p>12832,"There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and # mg, respectively) of each drug."</p>
<p>12833,"Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine : Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism."</p>
<p>12834,Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon .</p>
<p>12835,Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon .</p>
<p>12836,Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon .</p>
<p>12837,Drugs with a Narrow Therapeutic Index Digoxin : Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (# mg q24h for # days).</p>
<p>12838,Warfarin : Multiple oral doses of Sonata (20 mg q24h for # days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin .</p>
<p>12839,Warfarin : Multiple oral doses of Sonata (20 mg q24h for # days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin .</p>
<p>12840,"There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and # mg, respectively) of each drug."</p>
